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                                             Abstract 
Malaria remains a serious human health problem and the disease is particularly 
prevalent in developing countries. Malaria is caused by a parasite of the genus Plasmodium. 
Diagnosis of malaria is required before any treatment or intervention. The gold standard for 
malaria diagnosis is microscopy. Rapid diagnostic tests (RDT) have been used at point-of-
care because of their relative ease of use. Correct and accurate diagnosis of malaria is a 
prerequisite as a point-of-care intervention aimed at eradication, detection of an 
asymptomatic reservoir, quantification of parasite load and tracking of drug resistance to 
malaria. Therefore, RDTs that have high sensitivity and specificity are required.  
Plasmodium LDH (PLDH) is one of the three proteins in current use as antibody 
targets in RDTs to detect human malaria. The other two proteins are Plasmodium falciparum 
histidine rich protein II (PfHRPII) and aldolase. Of the three proteins, HRPII is the most 
widely used protein in RDTs in sub-Saharan Africa. One of the requirements in improving the 
current RDTs is to improve specificity and sensitivity. Plasmodium falciparum heat shock 
protein 70-1 (PfHSP70-1) has been found to be immunogenic in infected humans, 
abundantly expressed in the asexual stages and thought to be a potential diagnostic target 
for malaria. Conditions were optimized for the recombinant expression of PfLDH and 
PfHSP70-1 in different growth media, temperatures, concentrations of IPTG, times of 
induction, stages at which IPTG is introduced, use of a single colony as starting material or a 
dilution of an overnight culture to inoculate fresh media. Terrific Broth was found to be a 
better growth medium than Lysogeny Broth and does not require induction with IPTG. Use of 
a single starting colony was found to be better than dilution of an overnight culture as it 
saves time. Inducing at the stationary phase of bacterial growth yields more soluble protein 
than at mid-log phase. Expressing at lower temperatures lower than 37°C produces more 
soluble protein than growth at 37°C. 
Methods of lysing the host bacterial cells expressing PfLDH and PfHSP70-1 by 
freezing and thawing, sonication, lysozyme digestion and a combination of these methods 
were compared and optimized. The combination of freeze and thaw followed by repeated 
sonication was found to be optimal for lysing the E. coli host cells. 
Both proteins were affinity purified using an affinity Talon® resin and proteins were 
eluted with 150 mM imidazole. The purification protocol was monitored by separating the 
proteins on a 12.5% sodium dodecyl sulphate polyacrylamide electrophoresis gel. Purifying 
recombinant protein at 4°C produced higher yields of recombinant protein. The identity of the 
recombinant protein was confirmed by probing a western blot with anti-His-tag antibodies 
against each protein. The anti-His-tag antibodies detected both PfLDH and PfHSP70-1. 
v 
 
Preliminary experiments on PfLDH enzyme found that the recombinant enzyme was 
active. In silico studies were done on PfLDH and PfHSP70-1 to identify potential 
immunogenic peptides to be used in the production of antibodies in chickens using a 
prediction program Predict7™. Potential post-translational modifications that may affect the 
activity of the native protein were evaluated. There is evidence that some post-translational 
modifications may affect the activity of proteins such as PfLDH and PfHSP70-1. Potential 
lysine acetylation, phosphorylation, glycosylation and proteolytic sites were identified on both 
PfLDH and PfHSP70-1.  
This research generated soluble PfLDH which can be used to produce antibodies in 
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                                                              Chapter 1 
                           Introduction and literature review 
 
1.1 History of malaria 
 
Malaria is an ancient disease infecting mankind. Symptoms of malaria have been described 
in an Egyptian papyri from 1570 BC, a Chinese document from 2700 BC and clay tablets 
from Mesopotamia from 200 BC (Cox, 2010). For over 2500 years the idea that malaria 
fevers were caused by unpleasant vapour rising from swamps persisted, and thus probably 
led to the naming of the disease as malaria, which in Italian translates as bad air (mal - bad, 
aria - air). Intensive studies into malaria were observed in the 19th century (Cox, 2010). 
Marchiafava and Bignami using eosin-based staining and an oil immersion microscope, 
observed amoeboid movement of blood in patients suspected of malaria, as these 
organisms invaded red blood cells, grew within the cells and produced daughter cells 
(Marchiafava and Bignami, 1894). Camillo Golgi between 1885-56, observed erythrocytic 
stages of the malaria parasite, and differentiated between the tertian (48 hrs periodicity) and 
quartan (72 hr periodicity) malaria (Golgi, 1886). Marchiafava and Golgi further described 
mild spring malaria (benign tertian) and severe summer-autumn (malignant tertian) malaria. 
The French scientist, Charles Louis Alphonse Laveran, observed that the symptoms 
characteristic of malaria coincided with the presence of infected red blood cells (Laveran, 
1893).  
In 1897, Ronald Ross discovered that avian malaria parasite Plasmodium relictum was 
transmitted by Culicine mosquitoes and suggested that human malaria parasites may also 
be transmitted by mosquitoes. In 1889 while in Sierra Leone, he demonstrated that human 
malaria parasites were indeed transmitted by anopheline mosquitoes (Bynum and Ovary, 
1998). Ross later discovered spores in the salivary glands of the anopheline mosquito and 
found the developmental stages of human malaria parasites in anopheline mosquitoes 
(Ross, 1923; Bynum and Ovary, 1998). After working with avian malaria, Ross concluded 
that mosquitoes fed on infected birds and took up male and female gametocytes which 
fertilized in the mosquito’s gut. In the mosquito gut rod-like structures were produced that 
invaded the mosquito’s salivary glands and these rod like structures were then injected into 
the new host, as the infected mosquito is feeding (Ross, 1898; Manson, 1898). Bignami and 
Grassi produced evidence that female anopheles mosquitoes would transmit malaria and 
described the whole-blood mosquito life cycle of P. vivax, P. falciparum and P. malariae 






1.2 Overview of malaria 
Malaria is a disease caused by a eukaryotic parasite of the genus Plasmodium (Cox, 2010; 
Miller et al., 1994; Bannister et al., 2000). Malaria transmission occurs globally and an 
estimated 3.3 billion people are at risk of being infected with malaria and 1.2 billion are at 
high risk (WHO, 2014). An estimated 198 million cases of malaria occurred globally in 2013 
and 584 000 deaths were recorded. About 90% of the deaths occurred in the African region 
and mostly in children under the age of five years (WHO, 2014; Black et al., 2003). The 
number of malaria cases seems to be on the increase due to increased transmission risks in 
areas where malaria control has declined, increases in the prevalence of drug resistant 
strains of parasites, and in a few cases, international travel to endemic regions and migration 
of people from endemic regions (Tangpukdee et al., 2009; Pasvol et al., 2005; Cui et al., 
2015; Sinha et al., 2014). Adults in endemic regions develop natural immunity against 
malaria. Though they may be prone to infection, they do not show symptoms of malaria but 
they are reservoirs of malaria (Miller et al., 1994; Hafalla et al., 2011). 
Though slow, the development of a vaccine against malaria has reached an advanced stage 
(Schwartz et al., 2012; Mordmüller et al., 2017). The strategies in vaccine development 
include multi-peptide vaccines such as RTS,S/AS02 ( Bojang et al., 2001; Snounou et al., 
2005; Alonso et al., 2005; Aponte et al., 2007), multi-stage vaccines using chimeric proteins 
(Thiesen et al., 2014), erythrocyte stage vaccine that uses Merozoite surface protein-1  
(Moss et al., 2012; Cavangh et al., 2014; Fong et al., 2015; De Silva et al., 2016) and 
another that uses Plasmodium falciparum Recticulocyte Binding Protein homologue 5 
(PfRH5)  (Wright et al., 2014). Other vaccines being developed include subunit protein and 
sporozoite vaccines (Nuussenzweig et al., 1967; Nussenzweig et al., 1989; Friesen et al., 
2010; Calvo-Calle et al., 2005), anti cyto-adhesion vaccines (Magowan et al., 1988; Bull et 
al., 1998) and placental malaria vaccines (Salanti et al., 2003; Salanti et al., 2004; Viebig et 
al., 2005). Even when a vaccine for malaria has been discovered, the accurate diagnosis 
and treatment with anti-malarials still remain an important part of malaria treatment and 
eradication of the disease (Moody 2002; Mouatcho and Goldring, 2013). 
 
1.3 The life cycle of malaria parasite 
The life cycle of malaria in the human host begins when the infected female anopheles 
mosquito injects sporozoites in the skin of the host during a blood meal (Baldacci and 
Menard, 2004) and during feeding the female anopheles mosquitoes releases the 
sporozoites along with their saliva anti-coagulants as part of their feeding process (Miller et 
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al., 1994). Only a fraction of the sporozoites released in the host survive the hostile 
environment in the blood, skin and lymphatic system (Kebaier et al., 2009), and successfully 
invade the hepatocytes. The sporozoites possess an apical complex machinery involved in 
host cell invasion (Florens et al., 2002). Approximately 10-100 sporozoites are injected per 
mosquito bite (Kappe et al., 2010; Baldacci and Menard, 2004) in the exoerythrocytic or liver 
stage. The sporozoites in the lymphatic system move by gliding motion and finally invade the 
hepatocyte within 60 minutes (Frischknecht et al., 2004; Amino et al., 2007; Kebaier et al., 
2009). However, in P. vivax and P. ovale the sporozoites can be transformed into a dormant 
form known as hypnozoite for up to six months (Krotoski et al., 1985; Fujioka and Aikiwa, 
2002). The schizonts, with time, divide to occupy the entire cytoplasm of hepatocytes 
causing them to rapture and release the thousands of merozoites in the blood stream of the 




Figure 1. 1 The life cycle of a malaria parasite in the mosquito and human host. The liver stage or 
exoerythrocytic, erythrocytic or blood stage and the mosquito stages are shown here. The stage at which the 
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diagnostic targets (d triangles) are found and the infective stage (I triangles) are shown. Taken from CDC 2016 
(https://www.cdc.gov/malaria/about/biology/). 
 
The erythrocytic or blood stage begins when the released merozoites invade uninfected red 
blood cells. Within a few minutes of their release from the hepatocytes or host RBCs the 
merozoites recognise new target RBCs and parasite entry begins which lasts about 27.6 s 
after primary contact (Gilson and Crabb, 2008). The entry phase can be divided into two 
distinct phases. After invasion, an echinocytosis phases commences where a dramatic 
dehydration-type morphology is adopted by the infected RBC every 36 seconds. The 
infected RBC recover after a 5-11 minute period. At this time, the merozoites would have 
assumed the amoeboid-like state and is apparently free in the cytoplasm (Gilson and Crabb, 
2008). The infected RBCs, now in the ring stage, then develop into the trophozoite stage at 
which point haemozoin begins to appear and finally they develop into the schizont stage 
after which the infected RBCs rapture and reinfection of new target RBCs occurs as shown 
in Figure 1.1, section B6 and 5. The erythrocytic stage has a cycle that ranges from 28-72 
hrs depending on the infecting species of the malaria parasite (Cowman and Crabb, 2006; 
Aikawa et al., 1978; Lee et al., 2013; Murray et al., 2008). This stage is responsible for the 
symptoms associated with malaria and is targeted for diagnosis as shown in Figure 1.1 blue 
triangle with the letter ”d” (Antia et al., 2008; Murray et al., 2008; Fong et al., 2015; Stansic et 
al., 2015; Piper et al.,1999; Lee et al., 2014; Sessions et al., 1997). The period of time from 
infection to appearance of symptoms is known as the incubation period and ranges from 12-
40 days for other species and 6-12 months in P. vivax. The erythrocytic cycle repeats 
several times, after 3-10 cycles of red blood cycle reinfection, male and female gametocytes 
are formed at which point female anopheles mosquitoes can ingest the gametocytes.  
 
Table 1.1 The approximate number of parasites per stage that are used to infect or are 
ingested by the host and vector, respectively. 
Infection stage         Approximate number of parasites 
Per stage 
 
Infected mosquito bite 
 
10 - 100 
Schizont liver stage 
rupture 
 
10 000 - 30 000 
Merozoite formed per infecting 
merozoite 
 
14 - 32 
Gametocyte ingested per blood   
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meal of mosiquito 10 - 1000 
 
The data was taken from Antia et al., 2008; Smith and Craig, 2005; Fujioka and Aikowa, 2002; Baldacci and 
Menard, 2004; Kappe et al., 2010; Miller et al., 1994. 
 
The gametocytes mature into gametes in the gut of mosquitoes (Fujioka and Aikowa, 
2002).The parasite densities associated with each stage are shown Table 1.1. 
During a blood meal, female anopheles mosquitoes ingest the gametocytes (MacCallum, 
1898) into the mid-gut lumen of mosquitoes where the male gamete, which is flagellated 
(Microgamete), fuses with the female gamete which is non-motile (Macrogamete) to form a 
zygote (Kappe et al., 2010). The zygote develops into an Ookinete that traverses the mid-gut 
epithelial cells. The Ookinete then becomes sessile and transforms into Oocysts. The 
Oocysts are the only parasitic developmental stage that grows extracellulary and the 
Ookinete nucleus inside the Oocyst divides (sporogony) resulting in the formation of 
sporozoites. The sporozoites are then released into the mosquito body cavity and invades 
the salivary glands (Hillyer et al., 2007).  
 
1.4 Species of malaria that infect humans 
There are five species of malaria parasites that infect humans: Plasmodium falciparum, 
Plasmodium vivax, Plasmodium ovale, Plasmodium malariae and the recently discovered 
and formerly thought to only infect macaques Plasmodium knowlesi (Moutaucho and 
Goldring, 2013; Van den Eede et al., 2009; Van den Eede et al., 2010; Lee et al., 2009; 
Singh & Daneshvar, 2010; Suh et   al., 2004; Tangpukdee et al., 2009). A summary of the 
life cycles in the exoerythrocytic (liver) and erythrocytic (blood) stages are shown in Table 
1.2. 
 
1.5 Malaria endemic regions 
All forms of human malaria are transmitted by female anopheles mosquitoes (Ross, 1923; 
Bynum, 1998; Baldacci and Menard, 2004; Kiszewski et al., 2004), and malaria endemic 
region encompass all the areas in which these species of mosquitoes are prevalent.  
The areas most affected are the tropical regions that include sub-Saharan Africa, East Asia 
and part of South America. Most of the developed North American and European countries 
have managed to eradicate the infectious species of mosquitoes and are thus regarded as 
non-transmitting regions. Figure 1.2 shows the regional distribution of anopheles mosquitoes 
and the prevalent species. 
 
1.6 Vector control of malaria 
6 
 
In the mid-20th century, North America and most of Europe eliminated the malaria vector by 
spraying agricultural crops with an insecticide dichloro-diphenyl-trichloroethane (DDT) (Shiff, 
2002). DDT was initially developed as a public insecticide prior to its widespread agricultural 
use and recognition as an environmental pollutant (Curtis & Lines, 2000)  
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Table 1.2 The data of the life cycle of the five human infecting species  
 Plasmodium species 
 
 P. falciparum 
 

























































































































































The table is summary of the life cycles in the exo-erythrocytic stage (liver) and erythrocytic stage (blood) of the 
five human infecting species. The data of the life cycle of the five human infecting species was collected from: 






Figure 1. 2 Regional distribution of anopheles mosquito vector. The information was taken from the 
following sources: White, 1974; Fanello et al., 2002; Choi et al., 2013; Soleimani-Ahmadi et al., 2015; Hay et al., 
2010, Daneshvar et al., 2010; Abdoon & Alshahran, 2003; Kiszewski et al., 2004; Sinka et al., 2012. The key to 
the colours of regions is shown in the left bottom panel.  
 
Insecticide classes include organochloride (DDT, hexachlorocyclohexane (HCH), dieldrin) 
(Goodman et al., 1999, Goodman et al., 2001), organophosphates (malathion, temephose), 
carbamites (proposur, carbaryl), pyrethroids (synthetic compounds that resemble active 
constituents of flowers), insect regulator (diflubenzuron, methoprene, pyripoxyfen). Most of 
these classes have a serious impact on the environment (Arrow et al., 2003). Around 1966 
the emergence of resistance by anopheles mosquitoes to DDT became evident as 15 
species were found to be resistant (WHO expert committee on insecticide, 1974). Also the 
environmental pollution of DDT was known, and as such, activists forced most governments 
in developed countries to discontinue its use (Shiff, 2002). Other methods included draining 
of the marshes, so that mosquitoes would have less breeding places. 
Indoor residual spraying (IRS) was introduced to destroy the mosquito vectors that entered 
homes and it reduced mortality rates (Pluess et al., 2010). Insect-treated mosquito nets were 
An darling, An albitarsis s.i, An 
albimanus, An aquasalis, An 
pseudopunctipennis
An gambiae, An arabiensis, An 
melas, An funestus, An coluzzii
An stephensi, An culicifacies, An fluviatilis
An sergenti, An Arabianses, An dthali, 
An labranchise, An superpictus
An koliensis, An lesteri, An sinensis, An 
farauti s.i, An balabacensis s.i, An 
punctulatus s.i
An flavirostris, An punctulatus
s.i, An lesteri, An sundaicus
High malaria transmission region
Moderate malaria transmission region
Low malaria transmission region
No transmission in the region
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also introduced and reduced the malaria mortality rate by about 55% in children under five 
years of age in sub-Saharan Africa, and reduced childhood death from other causes that are 
exacerbated by malaria (Lengeler et al., 2004). In Gambia, Alonso et al, (1991) reported an 
overall childhood mortality reduction by 60% when the use of insecticide-treated mosquito 
nets was combined with malaria chemoprophylaxis. But, to be effective, insecticide-treated 
mosquito nets need to be used properly and must contain insecticides that are effective 
against killing mosquitoes. With the prevalence of insecticide-resistant mosquitoes, this 
method may become ineffective and thereby increase the re-emergence of malaria. 
Other vector control measures introduced include House Siting and construction, by building 
houses far from mosquito breeding sites was demonstrated. There was a reduction of 
malaria cases (Trape et al., 1992). Zooprophylaxis was used, where animals were used to 
divert mosquitoes from biting humans, however in some cases the opposite happened 
(Hewitt et al., 1994; Booma and Rowland, 1995; Mouche, 1998). The introduction of 
repellants, aerosols and fumigation reduced mosquito bites (Snow et al., 1987; Lindsay et 
al., 1998). Environmental and biological management of breeding areas, such as the use of 
petroleum oil for larvicide, draining of pools, salinating of coastal marshes reduced breeding 
of mosquitoes (Romi et al., 1993; Karch et al., 1993).  
 
1.7 Treatment of malaria and the development of drug resistance  
The earliest recorded treatment of malaria came from the use of the Cinchona tree by Native 
Americans around 1934, which contains quinine. In China, the Chinese herb Quinghaosu 
(Artemisinin) was used to reduce fevers associated with malaria as early as 340 AD as 
recorded in the Zhou Hou Bei-ji Fang handbook (Klayman, 1985). In 1934, a German, Hans 
Andersag discovered Resochin, which later was named chloroquine. Because of World War 
II, chloroquine was not recognised until 1946. During the 1960s and 1970s chloroquine 
began losing its effectiveness against P. falciparum malaria in Asia, and later in Africa 
around the 1980s. This was caused by genetically-mediated chloroquine resistance 
appearing in the parasite. Because of poor diagnostic techniques that existed in that era, 
symptoms similar to malaria were treated as malaria, until proven otherwise (Perkins and 
Bell, 2008; Okiro and Snow, 2010), which lead to the overuse of chloroquine by many 
clinicians. Pyrimethamine, doxycycline, quinine and primaquine have been used to treat 
malaria.  
Malaria treatment is dependent on the geographical location of the infection and the type of 
infecting species. Species of importance such as P. vivax and P. ovale have hypnozoites 







Table 1.3 Antimalarial drugs used and their targeted stages, mutation positions in 
corresponding resistant allele’s and the regions where resistance in the drugs has 
been reported.  












P. vivax,  
P. ovale,  
P. marlariae 












Schizont in blood 
stage 
 
Halofantrine P. falciparum DHFR, 
Cytochrome b 
Blood stage  
Lumefantrine P. falciparum DHFR, 
Cytochrome b 
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 A summary of antimalarial drugs used and their targeted species, the targeted stage, mutation positions in 
corresponding resistant allele’s and the regions where resistance in the drugs has been reported. Chloroquine 
resistance transporter, Multidrug resistance p-glycoprotein pump, Dihydrofolate reductase, Dihydropteroate 
synthase. Data was adapted from Bruce-Chwatt, 1981; Kappe et al., 2010; Lallo et al., 2007; Suh et al., 2004; 
Peterson et al., 1998; Kublin et al., 2003; D’Alessandro et al., 2013. 
 
Drug resistance in malaria has been associated with protein transporters such as the 
Chloroquine resistance transporter (CDR), Multidrug resistance p-glycoprotein pump (MDR), 
dihydrofolate reductase (DHFR), dihydropteroate synthase (DHPS), cytochrome b of 
different species against different antimalarials as shown in Table 1.3 (Bruce-Chwatt, 1981; 
Kappe et al., 2010; Lallo et al., 2007; Suh et al., 2004; Peterson et al., 1998; Kublin et al., 
2003; D’Alessandro et al., 2013). Table 1.3 shows the different types of drugs used to treat 
malaria, the type of Plasmodium species they target, the stage targeted and resistance that 




Figure 1.3 A time course of merozoite invasion of the erythrocyte.  A cellular overview is given with 
associated timing of organelle secretion and key mechanistic or signalling steps listed below. After apical 
reorientation, the merozoite establishes a tight junction that is marked by RON4 and AMA1. The tight junction is 
ultimately connected to the actomyosin motor, although the exact nature of this has yet to be established. As the 
tight junction moves across the merozoite surface, proteins are shed into the supernatant through the activity of 
proteases such as ROM4, ROM1, SUB1, and SUB2. The parasitophorous vacuole and membrane are formed 
primarily from the rhoptries, although some red blood cell membrane components are included, which expel their 
contents, forming the space into which the parasite can move under the action of the actomyosin motor. Once the 
tight junction reaches the posterior end of the parasite, the membranes seal by an as yet unknown mechanism. 
Adapted from Cowman et al, 2012. 
 
To combat widespread resistance against malaria drugs, the WHO recommended the use of 
Artemisinin-based combination treatment (ACT). ACT has reduced the incidence of P. 
falciparum (Nosten et al., 2000).  
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As a result of high prevalence of malaria drug resistance to antimalarial treatment, there is a 
great need for diagnostic testing that is fast, accurate, reliable and that can be used to 
monitor treatment (Gupta et al., 2015). 
 
1.8 Diagnosis of malaria in the   human host  
Malaria diagnosis mostly targets the erythrocytic (blood) stage of parasite growth (Bannister 
el al., 2000; Parra et al., 1991; Calderwood et al., 2007; Beere & Green, 2001; Desakorn et 
al., 2005; Howard et al., 1986). The erythrocytic stage begins with the merozoites either from 
the exoerythrocytic stage or from another erythrocytic stage infecting fresh red blood cells as 
shown in Figure 1. 3. 
This stage has high levels of parasitaemia (Table 1.2) and is associated with the symptoms 
of malaria (Miller et al., 2002; Antia et al., 2008; Miller et al., 1994). The parasite changes its 
morphology as it changes from one stage to another as depicted in Figure 1.4.  These 
stages can be identified using a microscope and appropriate stain (Moody, 2002). As the 
ring stage develops and grow asexually, haemozoin begins to appear. The gametocytes of 
the parasite are found in the peripheral blood for several days after their release (Fujioka 
and Aikowa, 2002). Other methods of diagnosis make use of the presence of specific 
proteins released during the erythrocytic stage, associated with the parasite as described 
later. 
 
1.9 How to measure the performance of diagnostic tests 
Most malaria endemic countries are poor. In these countries the choice of the diagnostic 
method used is often based on the available skilled labour, presence or absence of 
electricity, easy use and interpretation of results (Wongsrhrichanalai et al., 2007). A criterion 
was developed to compare the performance of different tests. The Gold standard being 
microscopy (WHO, 1999; Mouatcho and Goldring, 2013, Murray et al., 2008). The criteria 
use specificity, sensitivity and limit of detection (Bharti et al., 2008, Murray et al., 2008). 
Specificity is how accurate a method is in identifying the infecting specie of Plasmodium. 
Sensitivity refers to the ability by the test method to detect infection out of a total number of 
positive and negative samples. Limit of detection (LOD) refers to minimum number of 
parasites per microliter that can be detected by the test (Bharti et al., 2008, Murray et al., 
2008). 
 
1.10 Methods of malaria diagnosis 
Diagnosis of malaria in the blood of patients involves identification of Plasmodial DNA, 
proteins and/or antigens and antigen products in the blood (Conroy et al., 2009). Some 
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methods were developed in which malaria infections were identified in the urine and saliva of 




Figure 1.4 Erythrocytic stages of malaria parasite development. The data was described by Cowman et al., 
2012; Bannister et al., 2003; Bannister et al., 2000.The ring stage lasts about 0-5 hr, early trophozoite 10-20 hr, 
late trophozoite 10-20 hr, schizont > 40 hr. After several cycles of erythrocytic development male and female 
gametocytes are formed. The rupture of schizonts releases new merozoites and haemozoin. 
 
1.10.1 Clinical diagnosis 
  During the erythrocytic stage of malaria, patients develop clinical symptoms of 
malaria such as fever, headaches, chills and sweating that are associated with the rupture of 
the schizonts (Miller et al., 1994; Antia et al., 2008). The parasitaemia, erythrocytic cycle and 
the incubation time of each infecting species has been detailed in Table 1.2. Other 
symptoms manifested during malaria include acute respiratory distress, jaundice, renal 
failure, coma and vomiting (Das, 2008; Wilairatana et al., 2013). Most tropical diseases, 
especially the mosquito vector borne diseases such as dengue share common symptoms 
like fever (Kallander et al., 2004) which leads to mis-diagnosis of malaria (Perkins and Bell, 
2008; Gwer et al., 2007). Presumptive diagnosis is reported to have reduced mortality 
(Kidane and Morrow, 2000), but can also lead to development of drug resistant strains of 
parasite due to overuse of antimalarials (Murray et al., 2008). 
 





In 1880, Charles Laveran visualised the protozoan parasite that causes malaria in a blood 
smear under a microscope (Sutherland and Hallet, 2009; Cox, 2010; Laveran, 1881). In 
1891, Dimitri Romanowsky accidentally discovered that methylene blue eosin stains the 
parasite nucleus red and cytoplasm blue (Garnham, 1966) which became the basis of 
staining blood of infected patients in thin and thick films of patient blood (Sutherland and 
Hallet, 2009). Microscopy makes use of the fact that the mature RBCs do not contain a 
nucleus (Moody, 2002; Suh et al., 2004). The eosin dye, therefore, stains the parasite DNA 
making the parasite visible. Thin blood films of parasitised blood are fixed by methanol and 
stained with diluted Giemsa or Wright’s stain (Moody, 2002). Because the parasite is fixed in 
a monolayer of peripheral blood cells, identification of parasite morphology is possible, and 
parasites can be enumerated and the species of malaria identified. Thick blood films have 
many layers of RBC on a small surface stained with Field’s or Wrights stain without fixation. 
This method has greater sensitivity than a thin film, and can detect 50 parasites/µl of blood. 
It is used for detecting low numbers of parasites and the reappearance of circulating 
parasites during recrudescence or relapse as observed in P. vivax and P. ovale infections 
(Moody et al., 2002). 
 
1.10.3 Detecting malaria with fluorescence microscopy 
Fluorescence microscopy uses fluorescent dyes that have an affinity for nucleic acid 
molecules in the parasite nucleus. Commonly used dyes include acridine orange (AO) (Gaye 
et al., 1999; Kawamoto et al., 1991a, Kawamoto et al., 1991b; Lowe et al., 1996) and AO in 
the quantitative buffy coat system (QBC) (Baird et al., 1992; Clendeman et al., 1995, Craig 
and Sharp, 1997), Benzothiocarboxypurine (BCP) (Makler et al., 1991; Cooke et al., 1992) 
and Rhodamine-123 (Srinavasan et al., 2000). When stained with dyes, the nucleus 





Figure1.5 Trophozoites of P. falciparum stained with AO in the QBC fluorescence method. The figure was 




Rodamine123 is used to access the viability state of parasites, because it is taken up only by 
membranes of living cells (Srinavasan et al., 2000; Makler et al., 1991). Another fluorescent 
method is the QBC which uses acridine orange after white blood cells (WBC) and platelets 
have been separated (Baird et al., 1992), leaving the parasite to settle below the layer of 
cells as shown in Figure 1.5. Alternatively BCP is applied directly to lysed blood suspension 
or to unfixed dry blood film and stains the nucleic acid of living P. falciparum parasite as 
shown in Figure 1.6. A gold nanoparticle-based fluorescence immunoassay for malaria 
antigen detection has been developed (Guirgis et al., 2011) and a method based on 
fluorescence spectra of a set of blood plasma biomolecules such as tyrosine, tryptophan, 
nicotinamide adenine dinucleotide (NAD), flavin adenine dinucleotide (FAD) and red blood 




Figure 1.6 Trophozoites of P. falciparum stained with benzothiocarboxypurine (BCP) in the fluorescence 
method. The figure was taken from Moody, 2002. 
 
1.10.4 Colorimetric detection of malaria in patients using immunomagnetic or nano-
particle capture 
 Antibodies against a biomarker for malaria such as parasite LDH have been couple to 
magnetic beads and used to measure enzyme activity, (Markwalter et al., 2015) or HRPII 
interacton with gold nan-particles (Gulka et al., 2015). In the reaction, PLDH in the infected 
lysed blood sample oxidises lactate to pyruvate, while reducing the cofactor acetylpyridine 
adenine dinucleotide (APAD+) to acetylpyridine adenine dinucleotide hydrogenate (APADH). 
The APADH in turn reduces a yellow tetrazolium dye nitro-blue tetrazolium (NBT), to a blue 
compound (diformazan) with the assistance of phenazine ethosulfate (PES). The reaction is 
measured at 650 nm (Makler et al., 2004; Makler and Hinrichs, 1993; Makler et al., 1998). 
Limit of detection (LOD) is as low as 21 parasites/µl. Advantages of PLDH is that PLDH is 
conserved across all five species of Plasmodium known to infect humans (Makler et al., 
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2004), PLDH activity is lost within 24 hrs post treatment and, therefore, can be used in the 
management of malaria and measuring drug susceptibility (Markwalter et al., 2015). Another 
magneto-colorimetric method uses the detection of malaria pigment hemozoin in the 
intraerythrocytic stage (Orban et al., 2016). Malaria parasites break down haemoglobin in 
the food vacuole as a source of amino acids. This releases free haematin a toxic substance 
which inhibits parasite enzyme activity and releases free radicals (Bannister et al., 2000; 
Olszewsk et al., 2011). The parasite, therefore, polymerises haematin to haemozoin, which 
begins to appear in the late ring stage as a brown pigment (Dossert et al., 2009). The LOD 
of 50 parasites/µl was obtained which exceeded that of RDTs and competes with the 
threshold achievable by light microscopic observation of blood smears. Another potential 
colorimetric method uses Cu2+ peroxidase-catalytic activity, which can catalyse H2O2-
mediated oxidation of peroxidase substrate and obtain the oxidation product colour change 
(Zheng et al., 2016; Xianyu et al., 2013). This method has the potential to detect many 
malarial proteins that interact with Cu2+, such as HRPII proteins. 
 
1.10.5 Detecting malaria with the polymerase chain reaction (PCR)  
The polymerase chain reaction (PCR) amplifies and detects specific sequences of malaria 
parasite nucleic acid (DNA or RNA) in whole blood lysates. A number of PCR assays have 
been developed. Some methods use sequences coding for small subunit ribosomal RNA 
(ssrRNA) (Snounou et al., 1993), 18S rRNA (Echeverry et al., 2016; Kawamoto et al., 1996; 
Gunderson et al., 1987; Water, 1994), sequences coding for specific genes such as 
dihydrofolate reductase-thymidylate synthase (DHFR-TS) (Wataya et al., 1993; Wataya et 
al., 1991), direct PCR combined with a rapid readout system, nucleic acid lateral flow 
immunoassay (Mens et al., 2012), amplified Plasmodium DNA probed with a specific DNA 
probe (Barket et al., 1992). A single-step direct-PCR uses the cytochrome oxidase III gene 
(COX-III) to detect microscopic and submicroscopic malaria infections in humans (Echeverry 
et al., 2016). Some methods use species-specific fluorescein such as 4',6-diamidino-2-
phenylindole (DAPI) or radio labelled probes for detection of P. vivax DNA on a microscope 
that uses a rechargeable battery (Sethabutr et al., 1992). PCR has high sensitivity with a 
LOD of < 5 parasites/µl of blood and is species specific (Snounou et al., 1993). However, 
PCR requires highly skilled labour, electricity, very expensive equipment and reagents. 
Investigations showed that disappearance of parasite P. falciparum using PCR was 
achieved for a median 144 hrs compared to 66 hrs for microscopy (Kain et al., 1994) and 
that the DNA of non-viable parasites may be detected from circulating blood (Srinavasan et 




1.10.6 Diagnosis of malaria with loop-mediated isothermal amplification (LAMP)  
Loop-mediated isothermal amplification (LAMP) was described as a novel DNA amplification 
method by Notomi et al, 2000.LAMP is an isothermic nucleic acid amplification using four 
different primers and a polymerase to identify six distinct regions on the target gene. 
Intensive amplification leads to accumulation of magnesium pyrophosphate, which turns the 
solution turbid, and this turbidity is visible to the naked eye or can be measured using a 
turbidity meter (Notomi et al., 2000). Poon et al, (2006) first reported the use of LAMP for the 
diagnosis of clinical malaria caused by P. falciparum.Han et al., (2007) designed primers that 
target 18S rRNA gene in a genus- and species-specific LAMP method that detected four 
Plasmodium species. Goto et al, 2009 introduced the concept of pre-addition of 
hydroxylnaphthol blue (HNB) as a cheap and easily visible dye in the reaction mixture that 
does not inhibit the amplification of target nucleic acid. The use of 18S rRNA as a target of 
P. falciparum in whole blood samples for the diagnosis of clinical malaria has been used 
recently (Mohon et al., 2014; Gupta et al., 2016). This method has also been used to detect 
other parasitic diseases such as visceral leishmaniasis (Khan et al., 2012). LAMP has been 
reported to have detected low-density malaria parasites in Zanzibar (Cooke et al., 2015). 
Two LAMP assays have been developed for use in detecting P. knowlesi which is difficult to 
identify with a microscope and RDTs (Jeremiah et al., 2014). One of the problems 
associated with LAMP is DNA contamination (Cooke et al., 2015). 
 
1.10.7 DNA aptamers used to diagnose malaria 
DNA aptamers are specific oligonucleotides, peptides or chemical molecules that bind 
specifically to target DNA. DNA aptamers specific for a malaria biomarker can be used to 
diagnose malaria (Godonoga et al., 2016). Some DNA aptamers can be tethered with a 
capture enzyme where the product can be measured colorimetrically (Dirkzwager et al., 
2015). . Jain et al., (2016a) used a novel ssDNA developed through systematic evolution of 
ligands by exponential enrichment (SELEX) to detect PfLDH. Aptamers have several 
advantages over antibodies such as, ease of chemical synthesis, thermal stability and 
reduced cost (Cho et al., 2009). Jain et al., (2016b) developed a 90 mer ssDNA aptamer 
against PfLDH.  
 
1.10.8 Antibody based diagnosis of malaria 
Enzyme-linked immunosorbent assay (ELISA) is based on the use of specific antibodies to 
capture target antigens in solution that is accompanied by a colour change. Antigens specific 
for malaria parasites have been used in ELISA (Wongsrhrichanalai et al., 2007; Spencer et 
al., 1979; Inoue et al., 2013; D’Allessandro et al., 2013; Sousa et al., 2014; Piper et al., 
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1999). ELISA can also be used to detect gametocytes in the asexual blood stage 
(D’Allessandro et al., 2013). Antibodies can be used to detect malaria antigens using an 
indirect immunofluorescence antibody assay (IFA) (Sulzer et al., 1969; Wongsrhrichanali et 
al., 2007). Another test, the Latex agglutination assay is based on specific agglutination of 
sensitive polystyrene particles that contain carboxylic acid with antigen or antibody 
molecules in the presence of corresponding antibody or antigen, respectively, in human 
plasma (Polpanich et al., 2007). 
Malaria antigens can be detected in the serum of infected blood using ELISA or IFA based 
on the presence of antibodies against malaria proteins like MSP-1 (She et al., 2007; Doderer 
et al., 2007). These antibodies in serum may persist in blood for longer periods (Makler et 
al., 1998) and as such may not detect a current infection. 
 
1.10.9 Flow cytometry 
Flow cytometry uses fluorescent dyes such as Hoechst 33258 to detect malaria parasites 
and monitor antimalarial drug sensitivity (Woodrow et al., 2015; Van-Vianen et al, 1993; 
Hanscheid, 1999). A laser flow cytometry system may detect the malaria pigment hemozoin 
in monocytes (Grobusch et al., 2003; Wongchotigul et al., 2004; Shapiro & Mandy, 2007) or 
detect stained P. falciparum DNA at different stages using SYBR Green I    (Izumiyama et 
al., 2009). Hemozoin within the phagocytes can be detected by depolarisation of laser light 
as cells pass through a flow cytometer (Padial et al., 2005). Though flow cytometry offers 
automated counts of parasitaemias, this is offset by low sensitivity due to background noise 
(Janse & Van-Vianen, 1994). 
 
1.11 Rapid diagnostic tests 
The WHO recognised the urgent need for a new, simple, quick, accurate and cost effective 
diagnostic test for the detection of malaria parasites to overcome the deficiencies of using 
microscopy (WHO, 2000). This led to the increase in the use of RDTs for malaria detection, 
as affected regions lack electricity and skilled manpower required to do microscopic 
examinations (Bell et al., 2006; Tangpukdee et al., 2009). The use of RDT is quick, requires 
basic skills and does not require electricity. Although most RDTs target P. falciparum specific 
proteins such as histidine rich protein II (HRPII) (Leow et al., 2014; Verma et al., 2014; 
Laurent et al., 2010; Ho et al., 2014), other RDTs target lactate dehydrogenase (LDH) (Shin 
et al., 2013; Otsuki et al., 2015; Miao et al., 2013; Brown et al., 2004) or both HRPII and LDH 
(Bharti et al., 2008). Other proteins targeted as antigens include aldolase 
(Wongsrhrichanalai et al., 2007), phosphoethanolamine N-methyltransferase (PMT) (Pessi 
et al., 2004) and heat shock protein 70-1. Recently a new RDT for detecting P. knowlesi has 
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been developed (McCutchan et al., 2008). Many RDTs on the market are used to diagnose 




1.11.1 How RDTs work 
RDTs use a chromatographic nitrocellulose membrane strip as a solid phase upon which a 
lysed infected blood sample moves by capillary action. This strip is fixed with antibodies at a 
capture point coupled to colloidal gold-nanoparticles against a Plasmodium antigen epitope. 
To capture the antigen in the infected blood, the antibodies on strip bind to the antigen and 
produce a colour change as shown in Figure 1.7. 
A second capture point with non-specific antibodies conjugated with colloidal gold nan-
particles against a protein such as human serum albumin (HSA) are fixed at a point further 
than the capture point to act as a control that shows the test works (Makler et al., 1998; 






Figure 1.7 Sample test line configurations on commercial RDTs that detect malaria and their result 
interpretation. Taken from Wongsrhrichanalai et al., 2007. 
 
There are more than 86 commercially available RDTs for malaria (Tangpukdee et al., 2009). 
Figure 1.7 also shows how blood with mixed infection samples are electrophoresed and 
interpreted on an HRPII/aldolase RDT (Wongsrhrichanalai et al., 2007). 
 
1.11.2 Why RDTs need to be improved 
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Rapid diagnostic tests have shown problems that relate to the device itself and problems 
associated with the antigen/antibody targeted for detection. In order to improve performance 
of RDTs, problems associated with transport, storage and durability of antibodies used in 
RDT have to be understood. 
 
1.11.3 False negative or invalid results caused by high temperature and humidity 
RDTs can be damaged by extreme temperatures of over 40°C and humidity (Jorgenesen et 
al., 2006; Chiodini et al., 2007). Most RDTs are used in tropical regions where temperatures 
are over 40°C (Jorgensen et al., 2006). LDH based RDT were found to be more thermal 
stable than HRPII based RDTs (Chiodini et al., 2007). This may lead to the test showing a 
positive result without a confirmatory test line, making the result a false negative or invalid 
test (Wongsrhrichanalai et al., 2007). The need to transport RDTs to field clinics using 
refrigerated transport was recommended (Wongsrhrichanalai et al., 2007). 
 
1.11.4 False positive test due to device 
Approved buffers sometimes runout or are lost in the field. Therefore, use of distilled water 
or tap water as a substitute of approved buffers has shown to yield false positive results 
(Gillet et al., 2010). Now RDTs supply buffers in each box containing RDTs. 
 
1.11.5 Antigen based diagnostic problems 
A RDT may give false results if there are factors that interfere with antibodies to detect 
corresponding epitopes in the antigen. 
 
1.11.6 False negative results 
Gene deletion and single nucleotide polymorphism (SNP) in the DNA of P. falciparum HRPII 
has been reported in Peru and caused false negative results in HRPII-based RDT tests 
(Gamboa et al., 2010; Baker et al., 2010; Lee et al., 2006a, Solano et al., 2015; Okoth et al., 
2015). LDH has also shown to have SNPs in some isolates of P. vivax (Shin et al., 2013; 
Cicek et al., 2013), though no false negative has been reported as a result. Low parasite 
densities can also cause a false negative result (Palmer et al., 1998; Lee et al., 2007). 
The prozone effect caused by excessive HRPII antigen concentration has resulted in false 
negative tests in P. falciparum infected blood samples (Gillet et al., 2009; Ho et al., 2014; Ho 
et al., 2015). LDH RDTs were not affected by the prozone effect.  
 
1.11.7 False positive results 
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HRPII persists in blood for upto 28 days after parasite clearance. Therefore HRPII-based 
RDTs may test positive in the absence of viable parasites (Iqbal et al., 2004; Tjitra et al., 
2001; Vakharia 1997; Kodisinghe et al., 1997; Humar et al., 1997). LDH and aldolase 
antigens persist less than 2-7days (Iqbal et al., 2004; Ashley et al., 2009; Murray et al., 
2008; Markwalter et al., 2015) and can, therefore, be used to monitor the treatment of 
malaria. LDH and aldolase are produced during gametocyte stages of the asexual 
erythrocytic stage and, as such, low levels of these antigens may be present if the 
gametocytes are not cleared in the blood of infected humans (Vakharia et al., 1997; Farcas 
et al., 2003; Tjitra et al., 2001; Murray et al., 2008). 
 
1.11.8 Rheumatoid factor 
Rheumatoid factor can react with the antibodies employed in RDTs and give false positive 
results for RDT (Mishra et al., 1999; Jelinek et al., 2001; Karbwang et al., 1996, Sing et al., 
2000, Iqbal et al., 2000; WHO, 2000). Rheumatoid factors are autoantibodies against the Fc 
region of IgG and were found to react with the mouse IgG isotype monoclonal antibodies 
often used in RDTs (Iqbal et al., 2000). The Fc portion of lgG molecules is made of a heavy 
chain at the carboxyl termini involved in the activation of complement by binding effector 
molecules or immune Fc receptors (Delves et al., 2006). Producing antibodies in chicken 
can circumvent this problem as chicken antibodies are in form of lgY. 
Other cross reaction were observed in LDH and aldolase based-RDTs in which P. vivax-
specific LDH based RDT cross reacted with and detected P. knowlesi (Kawai et al., 2009; 
McCutchan et al., 2008).  
 
1.12 Quality assurance of RDTs 
In 2008, the WHO recommended a series of tests for RDTs to improve the quality of RDTs 
and delivery of quality product (Wongsrhrichanalai et al., 2007). Among the initiatives 
outlined were guidelines for testing RDTs, standardising manufacturing process and 
distribution (Wongsrhrichanalai et al., 2007) and evidence of good manufacturing practise 
(Bell et al., 2006). The WHO, working together with Foundation for Innovated New 
Diagnostics (FIND), has established and offers a testing program to evaluate performance of 
RDTs (WHO, 2009, 2010, 2011b; Mouatcho & Goldring, 2013). Positive controls have been 
developed (Murray et al., 2008; Lon et al., 2005) to ensure RDT sensitivity is maintained 
after delivery to the field (Lon et al., 2005; McMorrow et al., 2008). 
 
1.13 Why improve malaria RDT? 
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The limit of detection (LOD) of current RDTs is about 50-100 parasites/µl (Tangpedkee et 
al., 2009). Therefore, there is a possible need to look at alternative proteins so that detection 
of malaria can be improved. This requires RDTs to detect <100 parasites/µl that act as 
reservoirs (Hans et al., 2010; Miller et al., 1994; Hafalla et al., 2011). Identifying other 
parasite antigens can be an added advantage. If these alternative antigen can be used to 
detect viable parasite, clear in peripheral blood within a short period and are present in 
higher concentration in the intraerythrocytic stage they, therefore, can be potential diagnostic 
targets.  
 
1.13.1 PfLDH as target antigen in malaria RDTs 
Plasmodium LDH (PLDH) is a metabolic protein and is associated with a viable parasite 
(Lang-Unnasch and Murphy, 1998; Vaidya and Mather, 2009; Brown et al., 2004). PLDH-
based RDTs reverted back to negative within 2-7 days after clearance of infection (Iqbal et 
al., 2004; Murray et al., 2008; Markwalter et al., 2015). The presence of PLDH can be used 
to measure a current infection.  PLDH was found not to produce the prozone (Gillet et al., 
2009; Martin et al., 2009). Aldolashas little antigenic variation and single nucleotide 
polymorphism, and has been found to show no false negative results (Lee et al., 2006b).  
PLDH has a conserved catalytic residue involved in enzyme activity and shares > 90% 
amino acid identity among Plasmodia species (Brown et al., 2004; Turgut-Balik et al., 2004). 
Because PLDH is a conserved enzyme across all species and all malarial PLDH sequences 
share common epitopes (Hurdayal et al., 2010) it can, therefore, be used to detect pan-
specific malaria (Makler and Hinrichin, 1993; Piper et al., 1999; Brown et al., 2004). 
Differences in the P. falciparum, P. knwolesi and P. vivax LDH amino acid sequences are 
present that can allowto differentiate between the among thesespecies (Hurdayal et al., 
2010; McCutchan et al., 2008; Piper et al., 2011). PLDH-based RDTs does not detect low 
parasitaemias (Ashley et al., 2009, Abba et al., 2011, Kattenburg et al., 2011, Hendrisken et 
al., 2011; Hopkins et al., 2008; Heutmekers et al., 2012).  
 
1.13.2 PfHSP70-1 as target antigen in malaria RDTs 
PfHSP70-1, a member of the heat shock protein family (HSPs), is induced in cells exposed 
to sublethal heat shock. In 1984 Hugh Pelham suggested that the ability of HSP70 to 
enhance the recovery of stressed cells was mediated by its ability to catalyse the assembly 
of damaged ribosomal proteins (Pelham et al., 1984). Subsequently, research revealed that 
such chaperoning function was characteristic of HSP70 proteins and that it was essential for 
HSP70 mediated protection against stress (Sharma, 1992; Josh et al., 1992) that cause 
protein denaturation as well as many of the newly discovered house-keeping roles of 
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constitutively expressed HSP70 in non-stressed cells. Heat shock is not the only stimulus 
that can induce and alter the synthesis of HSPs. Exposure of cells to amino acid analogues 
(Kelly and Schlesinger, 1978; Li and Laszlo, 1985), glucose analogues (Pouyssegur et al., 
1977), heavy metals (Levison et al., 1980), protein kinase C stimulator (Ding et al., 1996), 
Ca2+ increasing agents (Ding et al., 1986), ischemia, sodium arsenate (Johnson et al., 1980), 
microbial infections, nitric oxide, hormones and antibiotics induce the expression of HSPs. 
HSPs in malaria parasites play important roles in parasite growth, development and survival 
and are, therefore, important targets for diagnosis, anti-malarial vaccines and drug targets 
(Archaya et al., 2007; Guirgis et al., 2012; Dat et al., 2000; Shonai et al., 2007; Calderwood 
et al., 2007; Kumar et al., 1990). PfHsp70-1 was found to be abundantly expressed in the 
asexual stages at 37oC and is also induced and translocated to the nucleus upon heat shock 
at 41oC (Beere and Green, 2001; Calderwood et al., 2007; Bindu et al., 1992; Singh, 2004). 
Studies have shown the effect of various body temperatures (close to malaria fever) on the 
P. falciparum viability, growth and expression of the PfHSP70-1 gene (Bindu et al., 1992). 
PfHSP70-1 is abundantly available as soluble cytosolic proteins during the intra-erythrocytic 
stage of parasite development after fever   (Bindu et al., 1992; Bottger et al., 2012; Beere 
and Green, 2001, Ardeshir et al., 1987; Calderwood et al., 2007; Pavithra et al., 2004) and, 
therefore, can be used as an alternative to HRPII, PLDH and aldolase in RDTs. Previously, 
PfHSP70-1 was detected by antibodies in infected blood during the intra-erythrocytic stage  
(Ardeshir et al., 1987; Zhang et al., 2001). Other studies have shown that PfHSP70-1 is a 
good target for detection in blood samples during the intra-erythrocytic stage (Kumar et al., 
1990; Tatu et al., 2007; Dat et al., 2000; Haldar et al., 2007). The P. falciparum heat shock 
protein is well conserved across all plasmodia species and was found to be immunogenic in 
infected humans (Mattei et al., 1989) and experimentally infected monkeys (Gysin et al., 
1982). Patients’ sera and T-cells collected from malaria endemic areas showed increased 
activity to PfHSP70-1 in individuals already exposed to malaria (Duboi et al., 1987). PfHSP 
70-1 is produced by sporozoite (Tsuji et al., 1994), hepatic (Renia et al., 1990) and 
gametocyte stages. 
 
1.14 Aims and objectives of the current study 
RDTs currently in use have shortcomings. These shortcomings include the lack of thermal 
stability, lower sensitivity caused by high limit of detection and cross reactivity with 
rheumatoid factor (Mishra et al., 1999; Jelinek et al., 2001; Karbwang et al., 1996; Sing et 
al., 2000; Iqbal et al., 2000; WHO, 2000).  
The first aim of this study was to optimise the expression and purification of PfLDH and 
PfHSP70-1 to produce soluble proteins for use in producing polyclonal and peptide-specific 
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antibodies in chicken and test the antibodies in detecting the expressed protein and the 
native protein in ELISA, western blots and dip stick format. The antibodies produced in 
chicken do not cross react with rheumatoid factors as they lack the Fc portion to which 
rheumatoid factors bind. 
PfHSP70-1 was reported in literature as being expressed in higher amounts during the   
intraerythrocytic stage. The second aim was, therefore, to assess whether the use of 
PfHSP70-1 would improve the LOD below 50 parasites/µl and compare it with that of PfLDH. 
The objectives were: 
1) To optimise the recombinant expression and purification of PfLDH and PfHSP70-1. 
2) To identify immunogenic peptides with higher surface probability in order to produce 
anti-peptide antibodies in chicken. 
3) To identify possible post-translation modifications that may affect the activity of 



































                                                         Chapter 2 
 
                            Materials and Methods 
 
 This chapter describes the techniques used in this study. The techniques include 
biological, biochemical, bioinformatical and immunochemical methods. The chapter also lists 
the reagents used in the experiments and the source of the reagents. 
 
2.1        Materials 
 
2.1.1     Equipment 
 Beckman CoulterTM AllegraTM X-22R centrifuge, Beckman CoulterTM AvantiTM J-26XPI 
centrifuge were purchased from Beckman Coulter (California, USA). Labnet SpectrafugeTM 
16M Brushless Laboratory Microcentrifuge was purchased from Labnet International Inc 
(New Jersey, USA). Shimadzu UV-1800 UV spectrophometer, Shimadzu CPS- Controller 
were purchased from (Japan). MRC Benchtop shaker incubator 300 x 400 mm, 250 rpm, 
70°C and MRC Refrigerated shaker incubator 960 x 600 mm, 250 rpm, 0-60°C were 
purchased from MRC (London, UK). Another orbital shaking incubator was purchased from 
New Brunswick Scientific (New Jersey, USA). Small volume shaker LabnetTM Pro 30 
Laboratory reciprocal shaker was purchased from Labnet (New Jersey, USA). A VirosonicTM 
cell disruptor using a rod was purchased from VirTis (New York, USA) and a Shalom 
Laboratory Supplies c.c Utrasonic cell disruptor that uses water was purchased from 
advanced Labs (Durban, South Africa). Mini Protean IITM vertical SDS-PAGE unit, Poly 
Prep® system for electrophoresing polyacrylamide gels. DNR Bio-imaging system MiniBis 
Pro was purchased from Bio-Imaging Systems (USA) for gel imaging and the Vacutec G-
BOX Syngene system was purchased from Syngene (Maryland, USA) for western and 
chemiluminescence imaging. The pH meter microprocessor was purchased from Hanna 
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Instruments (Durban, South Africa). Magnetic stirrer Veep was purchased from Fisher 
Scientific (USA) and the Corning hot plate stirrer PC-351 was purchased from Sigma-Aldrich 
(Steinheim, Germany). An Edward 5A.C. pump was purchased from GEC Machines Ltd. 
(Newcastle, UK) and Micro tube peristaltic pump MP-3 was purchased from Rikakikai Co. 
Ltd (Tokyo, Japan), NanoDrop 2000 spectrophotometer (Thermo Scientific, USA). 
 
2.1.2   Reagents 
 Unstained molecular weight marker with sizes ranging from: 116-14.4 kDa, 
dithiothreitol (DTT) molecular biology grade, restriction enzymes, 10 mM dNTP mix, DNA 
MassRulerTM were all purchased from Fermentas (Vilinius, Lithuania). Tween-20, yeast 
extract, Rabbit albumin, kanamycin, penicillin, Ponceau S, Coomassie Brilliant Blue R-250, 
Coomassie Brilliant Blue G-250, bisacrylamide, acrylamide, N,N,N’,N’- 
tetramethylethylenediamine (TEMED), bromophenol blue, 4-chloro-naphthol, ethidium 
bromide (EtBr), triton X-100, β-mercaptoethanol, isopropyl β-D-1- thiogalactopyranoside 
(IPTG), tryptone, Freud’s complete adjuvant (FCA), Freud’s incomplete adjuvant (FIA), 
sodium azide, ammonium persulphate, kanamycin sulphate analytical grade, ampicillin 
analytical grade, were all  purchased from Sigma- Aldrich  Fluka (Steinheim, Germany). 
Sodium chloride, potassium dihydrogen orthophosphate, dipotassium hydrogen 
orthophosphate, potassium chloride, agar bacteriological, D+ glucose, sodium dihydrogen 
orthophosphate, hydrogen peroxide, sucrose, all types of polyethylene glycol, glycine, were 
all purchased from Merck (Germany). Agarose for DNA gel electrophoresis, agarose for 
protein gel electrophoresis were purchased from Whiteman Scientific (Rockland, USA). 
Dimethyl sulfoxide (DMSO) was purchased from Capital Laboratory supplies (New Germany, 
RSA). Ninety-six well culture plates and immunotubes were from NUNC (Roskilde, 
Denmark). The anti-M13 monoclonal antibody was from Thermo Scientific (Waltham, MA, 
USA) and the goat anti-mouse-HRPO secondary antibody was from Jackson 
Immunochemicals (Pennsylvania, USA).   
  
2.2     Molecular biology techniques 
 These are the methods that were used to clone, transform, express and isolate the 
recombinant proteins used in this study. The expression vector expressing recombinant 
Plasmodium falciparum lactate dehydrogenase (rPfLDH) was a kind gift from Professor R.L. 
Brady, University of Bristol, UK. Recombinant Plasmodium falciparum heat shock protein 70-
1 (rPfHsp70-1) was kindly provided by Professor A. Shonhai, University of Venda, SA. 
 




2.2.1.1 The pKK233-3 plasmid 
 The vector map shows the cleavage sites for inserting the desired coding gene 
sequences and the ampicillin resistance marker in Figure 2.1. PfLDH sequence was inserted 
between the PstI and EcoRI restriction sites. The size of the vector without an insert is 4.6 
kb. 
 
 2.2.1.2 The pQE30 plasmid  
 The plasmid used for the expression of His6 recombinant Plasmodium falciparum Heat 
shock protein 70-1 (His6-rPfHsp70-1) was pQE30 which was used to transform the 
Escherichia coli BL21 (DE3) expression host. The pQE30 plasmid was co-transformed with 
the RIG plasmid. The RIG plasmid codes tRNA for rare codons during protein synthesis in E. 
coli namely: Arg, Ile and Gly and thus the name RIG (Baca and Hol, 2000).  The plasmid 








Figure 2.1 pKK233-3 vector map expressing PfLDH. 
The pKK233-3 plasmid used for the expression of His6 recombinant Plasmodium falciparum lactate 
dehydrogenase (His6-rPfLDH) which was transformed into an Escherichia coli BL21 (DE3) expression host. 





Figure 2.2 Map of the pQE30/PfHSP70-1 plasmid. Restriction maps of pQE30/PfHSP70-1 indicating 
the BamHI and HindIII restriction sites and the PfHSP70-1 gene insert.  
PfHSP70-1 was inserted between BamHI and HindIII sites in pQE30 plasmid as shown in 
Figure 2.2.The size of the plasmid vector without insert is 5459 base pairs. 
 
2.2.1.3 Agarose gel electrophoresis 
 A 1% (w/v) agarose gel (0.3 g agarose was dissolved in 30 ml TAE buffer (2 M Tris, 
0.95 M glacial acetic acid, 50 mM EDTA, pH 8.0)) was prepared and heated in a microwave 
until the agarose was melted. 2 μl of ethidium bromide (1% (w/v)) was added. The solution 
was poured into a casting tray with a dimension of (7 x 6.5 cm) and left to solidify at RT. A 
volume of 5 μl sample was mixed with 1 μl of loading dye (0.25% (w/v) bromophenol blue 
and 40% (w/v) sucrose in TAE buffer). A volume of 3 μl of DNA ladder and 12 μl of sample 
were used to load the lanes. The gels were electrophoresed at 70V for about 45 min in TAE 
buffer containing ethidium bromide. Gels were visualised under UV light and images of gels 
were taken using VersaDocTM imaging system. Sizes of the unknown bands were calculated 
from the log of relative distance travelled from start point to the band of DNA and compared 
to the molecular mass standards. 
 
2.2.1.4 Plasmid isolation  
 A volume of 5 ml of an overnight culture (16 hrs) grown in LB media supplemented 
with 10 μl of 100 μg/ml ampicillin with 200 rpm shaking at 37°C was centrifuged at 6800xg, 
4°C, 5 min and the supernatant was discarded. The plasmid was isolated from the pellet 





2.2.1.5 Restriction digestion 
 Restriction digestion was performed on plasmid DNA. A single restriction and double 
restriction digestion was done. The A280/A230 ratio was determined to establish the purity of 
DNA.  
 A single restriction digest of plasmid DNA was used. The reaction mixture of 0.5μl of 
restriction endonuclease, 2 μl of 10 x digestion buffer and milliQ water to a final volume of     
50 μl.  For double digestion using BamHI and HindIII, the following reaction mixture was 
used;    1 μg of plasmid DNA, the amount of restriction enzyme was chosen according to the 
selected buffer chosen using the Fermentas restriction endonuclease buffers and the 
mixture was made up to 50 μl using milliQ water. The reaction was done at 37°C for 2 hrs.  
 
2.2.2 Expression of recombinant proteins in various growth media 
 From a glycerol stock a 3-way streak on an LB agar plate [1% (w/v) tryptone, 0.5% 
(w/v) yeast extract, 0.5% NaCl, 0.2% (w/v) glucose, and 1.5% (w/v) bacto-agar] was done 
and incubated overnight at 37°C. A single colony was picked and inoculated into  5 ml of 
either fresh LB [1% (w/v) tryptone, 0.5% (w/v) yeast extract, 0.5% (w/v) NaCl, and 0.2% 
(w/v) glucose] or TB [1.2% (w/v) tryptone, 2.4% (w/v) yeast extract, 0.4% (v/v) glycerol, 
0.23% (w/v) KH2PO4, 1.25% (w/v) K2HPO4] broth supplemented with 50 μg/ml ampicillin for 
PfLDH and 100 μg/ml ampicillin for PfHSP70-1 or 34 μg/ml kanamycin for PfHSP70-1 and 
left to incubate overnight at 37°C, with shaking at 200 rpm. These cultures were used to 
inoculate large volumes of either LB or TB growth media at 1:10 or 1:100 dilutions of 
overnight cultures or using a single starting colony supplemented with the appropriate 
antibiotic. Cultures were left to incubate at 37°C or 25°C, with shaking at 200 rpm until OD600 
of 0.5-0.6 for mid-log phase induction or 0.7 for induction after stationary phase. A 
concentration of 0.3 mM IPTG was used for PfLDH and 1 mM for PfHSP70-1. IPTG Induced 
expression was allowed to continue for 4 hrs after addition of IPTG. TB media was not 
induced because it is self-inducing. Cultures grown in TB were left to incubate for 8 hrs. The 
cultures were then centrifuged at 4000xg, 4°C, 10 min and the pellet was resuspended in 4% 
original volume with appropriate buffer PBS pH 8.0  [0.8% (w/v) NaCl, 0.02% (w/v) KCl, 
1.02% (w/v) Na2HPO4, 0.02% (w/v) KH2PO4] or 10 mM imidazole lysing buffer [0.6% (w/v) 
NaH2PO4, 1.753% (w/v) NaCl, 0.068% (w/v) imidazole, and 0.02% NaN3] as required.  
 
2.2.3 Lysis of bacterial cells 
 Lysis of the bacterial cells was accomplished through freeze and thaw, lysozyme 
digestion, sonication or a combination of these methods. For freezing and thawing, liquid 
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nitrogen was used to freeze the bacterial pellet and cells were thawed at 37°C. The steps 
were repeated three times. Lysozyme samples were prepared by addition of STET buffer [10 
mM Tris-HCl, pH 8.0, 100 mM NaCl, 1 mM EDTA, 5% (v/v) Triton X-100] to the freshly 
prepared lysozyme solution (10 mg of lysozyme dissolved in 1 ml in dH2O). The mixture was 
vortexed and put in a water bath at 37°C for 30 min. Samples for small volumes were lysed 4 
x 30 s with resting on ice using a box sonicator. Large sample volumes were lysed 4 x 30 s 
on ice at 80 watts, 6 rms using a rod sonicator.  
 
2.2.4 Affinity purification of PfLDH and PfHSP70-1 on Talon® (Co2+) resin 
 The insert in pKK233-3/PfLDH and pQE30/PfHSP70-1 plasmids are expressed 
 as proteins with an N-terminal poly-histidine (His6) tag. Poly-histidine has a high affinity for 
Co2+ immobilised on resin. The polyhistidine-tagged recombinant proteins selectively bind to 
the column during purification and are eluted with a high concentration of imidazole in the 
elution buffer in a step wise method. Low concentrations of imidazole were incorporated in 
the wash buffer to reduce the binding of contaminating proteins with low affinity for the Talon 
resin.  
 A 10 ml of the clarified sample (from section 2. 2. 3) was added to the Talon® resin. 
The resin was rocked gently at RT (25°C) or at 4°C overnight to allow the protein to bind to 
the resin. The resin was centrifuge at 700xg for 5 min and the supernatant was carefully 
removed. The resin was washed with 10 bed volumes of 10 mM imidazole wash buffer [10 
mM imidazole, 50 mM NaH2PO4, 300 mM NaCl, 0.02% NaN3], centrifuged at 700xg for 5 min 
and the supernatant discarded. The resin was resupended in one column volume of 10 mM 
imidazole wash buffer and added to a column. The column was washed with 10 mM 
imidazole until A280 of <0.02 was reached.  The polyhistidine-tagged proteins were eluted by 
adding 5 ml of 150 mM imidazole buffer (150 mM imidazole, 50 mM NaH2PO4, and 300 mM 
NaCl, 0.02% NaN3), 250 mM imidazole buffer (250 mM imidazole, 50 mM NaH2PO4, 300 mM 
NaCl, 0.02% NaN3) or gradient of 10 mM to 250 mM imidazole. Eluents were analysed by 
absorbance at A280 nm. Samples from each step of the purification protocol were evaluated 
by a 12.5% SDS-PAGE gel and a western blot. The Talon® resin was regenerated according 
to manufacturer’s instruction. 
 
2.2.5 Concentrating proteins by dialysis against polyethylene glycol 20 000 (PEG20000)  
 A dialysis bag (snake skin) with a molecular weight cut-off of 3, 500 Da was briefly 
soaked in distilled water. Excess water and bubbles were squeezed out, and one end was 
clamped. The protein sample solution was poured into the bag and the other end clamped. 
The sample was surrounded by PEG20000 (Mr 20 000) at 4°C. Wet PEG20000 was changed 
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from time to time until the proteins reached the desired concentration. High concentration of 
imidazole were removed from the protein by dialysis against dialysis buffer [PBS, 10% (v/v) 
glycerol, 5 mM EDTA, 10 mM imidazole, 10 mm DTT, and pH 8.0]. The buffer was changed 
after 2 hr twice and was left overnight at 4°C with a magnetic stirrer. 
 
2.2.6 Concentrating protein using SDS/KCl precipitation 
 5% SDS (10 μl) was added to the sample (100 μl) in 1.5 ml tube. The solution was 
mixed by inverting the tube and 3 M KCl (10 μl) was added. The mixture was inverted again 
and centrifuged at 12,000xg, 2 min, RT, the supernatant was discarded and the precipitate 
resuspended in stacking gel buffer and reducing treatment buffer (Hejazi et al., 2013; 
Reynolds and Tanford, 1970; Laemmli, 1970). 
 
2.3 Biochemical methods 
 Biochemical methods were used to analyse and characterise the recombinant and 
native proteins. 
 
2.3.1 Bradford method to measure protein concentration 
 This method was performed according to (Bradford, 1976) without modifications. A 
standard curve was obtained by preparing BSA standards from 0-80 µg. Each standard was 
made up in triplicate with dH2O up to 100 µl and 900 μl of Bradford (0.09 mg/ml) reagent was 
added and incubated in the dark for 15 minutes. Absorbance was measured at 595 nm (A595) 
and a graph plotted. The samples whose concentration was not known were prepared the 
same way as the standard and protein concentration determined from the standard curve in 

















Figure 2. 3 Bradford standard curve to measure protein concentration. All values are the average of 





2.3.2 A280 determination of protein concentration 
 Samples were prepared to appropriate dilutions before measuring absorbance at         
280 nm using a quartz cuvette in a Shimadzu UV-1800 spectrophotometer. 
 
2.3.3 Measuring A280/A260 and A260/A230 using a Nano-drop spectrophotometer 
 Samples were measured according to the manufacturer’s instructions of the NanoDrop 
2000 spectrophotometer. The measurements were done at 280, 260 and 230 nm to 
determine the purity of proteins and the amount of contaminating nucleic acids. 
 
2.3.4 Sodium dodecyl sulphate polyacrylamide gel electrophoresis  
 Sodium dodecyl sulphate polyacrylamide gel (SDS-PAGE) was used as described by 
(Laemmli, 1970). The gel consists of a lattice made by cross linking of acrylamide with N, N’- 
methylenebisacrylamide (bisacrylamide). The cross linking creates a sieve that separates 
proteins according to size as smaller proteins are less impeded through the lattice. 
According to Chart (1994) the size of the sieve can be altered by changing the ratio of 
acrylamide to biscacrylamide to make different percentage gels. The proteins that contain 
disulphide bonds are reduced by β-mercaptoethanol in the reducing buffer (Walker and 
Rapley, 2002). Sodium dodecyl sulphate (SDS), an anionic detergent, is used to further 
denature the proteins and covers the protein in an overall negative charge so that in an 
electric field proteins are separated only based on size and not charge as they migrate 
towards a positive electrode. The samples are also boiled for 5 minutes to denature the 
proteins. 
The appropriate separating and stacking gels were prepared according to Table 2.1. 
Solution A [30% (w/v) acrylamide, 2.7% (w/v) bis-acrylamide]; Solution B [1.5 M Tris-HCl, pH 
8.8]; Solution C [500 mM Tris-HCl, pH 6.8]; Solution D [10% (w/v) SDS); Solution E [10% 
(m/v) ammonium persulfate]. Gels were set in a Bio-Rad Mini PROTEAN II® vertical slab 
apparatus. Samples were prepared in 2 x reducing treatment buffer [125 mM Tris-HCl, 4% 
(m/v) SDS, 20% (v/v) glycerol, 10% (v/v) 2-mercaptoethanol, 0.1% bromophenol blue, pH 
6.8] in a ratio of 1:1, boiled for 5 min and loaded in the lanes. The gel was then placed in an 
electrophoresis tank filled with tank buffer [250 mM Tris-HCl, 192 mM glycine, 0.1% (m/v) 
SDS, pH 8.3] and electrophoresed at 20 mA per gel until the bromophenol blue was 0.5 cm 
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from the bottom of the gel. The gel was stained in coomassie brilliant blue R-250 [125% 
(m/v) Coomassie Brilliant Blue R-250, 50% (v/v) methanol, 10% (v/v) acetic acid] for at least 
4 hr and destained in destain solution I [50% (v/v) methanol, 10% (v/v) acetic acid] until 
bands were clearly seen. The gels were left in destain solution II [7% (v/v) acetic acid, 5% 
(v/v) methanol] to swell back to the original size. The size of the protein bands were 
determined by extrapolation from a graph of log molecular weight of the molecular weight 
standards electrophoresed on the same gel against relative distance travelled by the protein 




Table 2. 1 The ingredients to make different percentage acrylamide electrophoresis 
gels.  
       Running gel % Stacking gel % 
  15* 12.5* 10* 7.5* 5** 4* 3** 
A 0.5 0.42 0.33 0.25 0.17 0.13 0.1 
B 0.25 0.25 0.25 0.25 0.25 0 0 
C 0 0 0 0 0 0.25 0.25 
D 0.01 0.01 0.01 0.01 0.01 0.01 0.01 
E 0.005 0.005 0.005 0.005 0.005 0.005 0.005 
dH2O 0.23 0.32 0.4 0.48 0.57 0.6 0.64 
TEMED 0.0005 0.0005 0.0005 0.0005 0.0005 0.002 0.002 
*refers to % gel to be prepared 
 
% Acrylamide Separation range (kDa) 
6 60 - 300 
8 40 - 100 
10 20 - 70 
12 20 - 60 
14 10 - 40 
 
2.3.5 Western blot 
 Western blot is done after completion of SDS-PAGE technique described in section 2. 
3. 4. The SDS-PAGE gel was soaked in blotting buffer [0.6% (w/v) Tris, 1.44% (w/v) glycine, 
20% (v/v) methanol]. Electrophoretic transfer to nitrocellulose was carried out overnight at      
40 mA. The nitrocellulose membrane was stained with Ponceau S [0.1% (m/v) Ponceau S, 
1% (v/v) glacial acetic acid] to mark the molecular weight markers and removed with distilled 
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water containing a little NaOH. The gel was stained with Coomassie Brilliant Blue R-250 to 
determine the efficiency of the blotting. The nitrocellulose membrane was rinsed with TBST 
[0.24% (w/v) Tris, 1.17% (w/v) NaCl, and 0.05% (v/v) Tween-20] for 5 minutes. The 
membrane was blocked with 5% (m/v) Elite low fat milk in TBST for 1 hr. The membrane 
was washed in TBST 3 x 5 minutes and incubated with primary antibody 1:2000 in 0.5% 
BSA-TBST for 2 hrs. The membrane was washed in TBST 3 x 5 minutes. Secondary 
antibodies were prepared in 0.5% BSA-TBST at a dilution of 1:6000 and was incubated for 1 
hr followed by 3 x 5 min washes in TBST. The nitrocellulose membrane was then immersed 
in substrate solution (4-chloro-1-naphthol (2 ml), TBS (8 ml) and 30% H2O2 (4 μl)) and the 
colour was allowed to develop in the dark for 10 - 30 minutes. The membrane was allowed 
to dry before the picture was taken using a Vacutec G-Box Syngene system. 
 
2.4 Bioinformatics 
 Algorithms were used in silico to predict the peptide epitopes for recombinant 
PfHSP70-1 and the effect of certain post-translational modifications on the activity of the 
native proteins as described in the section below. 
 
2.4.1 Predict7TM 
 Predict7TM was used to predict immunogenic and soluble peptides in the primary 
structure of proteins in order to raise antibodies against these peptides in chickens 
(Carmenes et al., 1989). Graphs were generated based on four parameters; antigenicity 
(Kolaskar and Tongaona, 1990), surface probability (Emini et al., 1985), flexibility (Karplus 
and Shulz, 1985) and hydrophilicity (Parker et al., 1986). Peptides with potential 
immunogenicity should be soluble and situated on the surface of proteins for easy interaction 
with antibodies. However, not all predicted peptides are necessarily immunogenic. 
The National Centre for Biotechnology Information (NCBI) (www.ncbi.org/) or plasmoDB 
(www.plasmodb.org/) were used to obtain protein sequences.  
 
2.4.2 Sequence alignments 
 The alignment of the primary structure of proteins and coding DNA were done using 
ClustalW2 (www.ebi.ac.uk/Tools/msa/clustalW/). The protein sequences were either 
obtained from PlasmoDB (www.plasmodb.org/) or the national centre for biotechnology 
information (NCBI) (www.ncbi.org/). 
 
2.4.3 The 3D crystal structure of PfLDH 
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 The 3D structure of PfLDH was viewed using SwisPDB viewer software at spdv.vital-
it.ch/disclaim.html#.  
 
2.4.4 Prediction of acetylation, phosphorylation, glycosylation and proteolytic sites 
 The prediction of potential acetylation of PfLDH and PfHSP70-1 were done using PAIL 
(bdmpail.biocuckoo.org/predicitions.php/) and NetAcet (www.cbs.dtu.dk/services/NetAcet/). 
The prediction of potential phosphorylation sites on PfLDH and PfHSP70-1 was done using 
Kinasephos (www.kinasephos.mbc.nctu.edu.tw/predict.php/). 
The prediction of potential ‘O’ glycosylation sites on PfLDH and PfHSP70-1 was done using 
DictyOGlyc (www.cbs.dtu.dk/services/DictyOGlyc/) and ‘N’ glycosylation sites were done 
using (www.cbs.dtu.dk/services/NetNGlyc/). 
The prediction of potential proteolytic sites on PfLDH and PfHSP70-1 was done using 
































                                             Chapter 3 
Recombinant expression of PfLDH and PfHSP70-1 
 
3.1 Introduction 
In order to study and characterise a protein of interest, the protein has to be available 
in sufficient quantities. Proteins can be recombinantly expressed in different expression 
systems including prokaryotic Escherichia coli (Baneyx, 1999) and the Bacillus genus, 
eukaryotic (Saccharomyces cerevisiae, Pichia pastoris), human (HeLa) and insect cell 
(Luciferase vectors) systems and cell free systems (Yin et al., 2007). The most commonly 
used expression system is gram negative E. coli bacteria (Baneyx, 1999). Malaria rapid 
diagnostic tests (RDTs) in current use are based on three soluble malaria parasite proteins. 
The Plasmodium falciparum histidine rich protein II (PfHRP-II), and the metabolic parasite 
proteins Plasmodium lactate dehydrogenase (PLDH), and aldolase (Murray et al., 2008). 
Malaria infecting humans is caused by five malaria species namely: P. malariae, P. 
ovale, P. vivax, P. falciparum and a monkey parasite P. knowlesi has emerged causing 
zoonotic malaria in humans in South East Asia (Anderios, 2009; Daneshvar et al., 2009; Lee 
et al., 2009; Sabbatani et al., 2010; Van den Eede et al., 2010; Van Hellemond et al., 2009; 
Collin, 2012). Most RDTs currently use PfHRPII as the antigen but this protein is only 
expressed by P. falciparum and can only be used to detect Plasmodium falciparum malaria. 
Problems that stem from the use of PfHRPII as the antigen include patients testing positive 
for malaria even after parasite clearance. This is because the protein persists in blood after 
parasite clearance (Murray et al., 2008; Iqbal et al., 2004; Tjitra et al., 2001; Kodisinghe et 
al., 1997; Bell et al., 2005). False positive RDTs for malaria may be due to the presence of 
rheumatoid factor in patients (Iqbal et al., 2000). Another problem is false negatives which 
can be due to deletion of the PfHRPII gene as reported by Gamboa et al., in 2010 in Peru 
and other parts of the world (Koita et al., 2012). Single nucleotide polymorphisms (SNPs) in 
parasite DNA have been reported to affect the detection of P. falciparum malaria infections 
(Baker et al., 2010; Lee et al., 2006a). 
Because of possible co-infection of P. falciparum with other species of malaria, there 
is a need for RDTs that can detect other forms of malaria, so that drugs can be prescribed 
39 
 
that target each infecting species to avoid relapses (Murray et al., 2008; Chuangchaiya et 
al., 2009) and the development of drug resistant strains (Price et al., 2001; Price et al., 2006; 
Van Vugt et al., 1998; Van Vugt et al., 1999; Van Vugt et al., 2000). Plasmodium LDH and 
Plasmodium aldolase enzymes are found in all Plasmodium species (Murray et al., 2008). 
PLDH and aldolase are involved in metabolism, and are, therefore, associated with living 
parasites (Murray et al., 2008; Iqba et al., 2004). The proteins have a short half-life and can 
be used to detect current infection and monitor the progress of treatment. Ashley et al, 2009 
reported that some PLDH-based RDTs revert back to negative within 2-7 days post drug 
clearance thus confirming the rapid clearance of PfLDH from blood. All the RDTs developed 
to date have limited specificity, sensitivity and limits of detection (Moody, 2002; Moutacho 
and Goldring, 2007). 
Malaria has similar symptoms to other tropical diseases such as Dengue and, 
therefore, incorrect treatment can be administered (Gwer et al., 2007; Kallander et al., 2004). 
The most vulnerable to malaria are children (Black et al., 2003; WHO 2014). Often children 
with malaria-like symptoms who end up testing negative for malaria still get treated for 
malaria. This led the CDC to outline a requirement for diagnosis before treatment (Lallo et 
al., 2007). Confidence in malaria RDTs is still low among clinicians who still prescribe 
presumptive treatment of malaria when the RDT test is negative (Bisoffi et al., 2009). The 
WHO, together with the Foundation for Innovated New Diagnostics (FIND), has established 
and offers a testing programme to evaluate the performance of RDTs in order to improve 
confidence in their use among clinicians (WHO, 2008; WHO, 2009; WHO, 2010; WHO, 
2010b). Other measures taken include the buying of RDTs from manufacturers with 
evidence of good manufacturing practice as well as “in field testing” of RDTs. As a method of 
testing RDTs in the field a positive control was included. This would entail the use of 
recombinant antigens or peptides reconstituted in uninfected blood (Murray et al., 2008; Lon 
et al., 2005) or dried blood spots (Versteeg and Men, 2009). This format was found to work 
better for PfHRPII-based tests than PLDH-based and aldolase-based tests and this was 
thought to be due to the stability of the PfHRPII antigen.  
PfHSP70-1, a member of the heat shock protein family (HSPs), is induced in malaria 
parasite exposed to sublethal heat shock. In 1984 Hugh Pelham suggested that the ability of 
HSP70 to enhance the recovery of stressed cells was mediated by its ability to catalyse the 
assembly of damaged ribosomal proteins (Pelham et al., 1984). Subsequently, research 
revealed that chaperoning was characteristic of HSP70 proteins and that it was essential for 
the HSP70-mediated protection against stresses that cause protein denaturation and other 
newly discovered house-keeping roles of constitutively expressed HSP70 in non-stressed 
cells. Heat shock is not the only stimulus that can induce and change the synthesis of HSPs. 
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Exposure of cells to amino acid analogues (Kelly and Schlesinger, 1978; Li and Laszlo, 
1985), glucose analogues (Pouyssengur et al., 1977), heavy metals (Levison et al., 1980), 
protein kinase C stimulator (Ding et al., 1986), Ca2+ increasing agents (Ding et al., 1986), 
Ischemia, sodium arsenate (Johnston et al., 1980), microbial infections, nitric oxide, 
hormones and antibiotics induce the expression of HSPs. HSPs in malarial parasites play 
important roles in growth, development and survival and HSPs are, therefore, potential 
targets for anti-malarial vaccines and drugs. PfHsp70-1 has been found to be abundantly 
expressed in the asexual stages and is induced and translocated to the nucleus upon heat 
shock at 41°C. Studies have shown the effect of various body temperatures (close to malaria 
fever) on the P. falciparum viability, growth and expression of PfHSP70-1 proteins (Bindu et 
al., 1994). PfHSP70-1 is abundantly available as a soluble cytosolic protein during the intra-
erythrocytic stage of parasite development that is induced by heat shock in the form of 
febrile episodes and has potential as a malaria diagnostic target. 
For this study, two parasite proteins were selected for study. The first protein 
Plasmodium falciparum lactate dehydrogenase (PfLDH) is in use as a RDT target and the 
second protein is Plasmodium falciparum heat shock protein 70-1 (PfHSP70-1). PfLDH is a 
conserved glycolytic metabolic enzyme, making it a good target to detect and measure 
current infection (Lee et al., 2006b; Murray, 2008). PfHSP70-1 is also highly conserved 
across all Plasmodial species and was found to be immunogenic in infected humans (Mattei 
et al., 1989) and experimentally infected monkeys (Gysin et al., 1982). PfHS70-1 is 
abundantly expressed during fever and has diagnostic potential. These proteins were 
recombinantly expressed in E. coli BL21 (DE3) host cells and were characterised using 





Figure 3.1 Expression of PfLDH in Lysogeny Broth and Terrific Broth media at (A) 30°C and (B) 37°C. 
Recombinant PfLDH was expressed at 30°C and 37°C in LB (panel A) and TB (panel B). The samples were 
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analysed on 12.5% reducing SDS-PAGE gels, stained with Coomassie Brilliant Blue R-250. Panel A lane 1: 
molecular weight marker, non-induced PfLDH lane 2 and 3 at 30°C, lane 4 and 5 , at 37°C; induced PfLDH lane 6 
and 7 at 30°C, lane 8 and 9 at 37
°
C. Panel B lane 1: molecular weight markers, lane 2, 3 and 4:  samples of 
PfLDH incubated at 30°C, lane 5, 6 and 7: samples of PfLDH incubated at 37
°
C. The experiment was repeated 
three times, an example experiment is shown. The arrow shows the expected size of PfLDH. 
 
3.2.1 Comparison of media used to express PfLDH 
Recombinant protein expression was evaluated in different growth media to 
determine which media promoted high amounts of soluble recombinant protein.   
The media compared were Terrific Broth (TB) and Lysogeny Broth (LB). Terrific broth 
contains glycerol and phosphates and is said to be self-inducing (Li et al., 2011). 
The expression of PfLDH appeared to be higher in TB than LB media. The expression was 
marginally better at 37°C compared to 30°C in TB as shown by the intensity of a 36 kDa 
band on the gels above shown by the arrow (figure 3.1). Lower expression was observed in 
LB media.  
 
3.2.2 Growth of E. coli host cells in Terrific and Lysogeny Broth media 
Figure 3. 2 shows that E. coli host cells initially grow faster in TB media than in LB 
media. All cells reach stationary phase at approximately 4 hrs after inoculation. The growth 
of E .coli host cells was also observed after inoculation with a single colony. Figure 3.3 
shows similar growth patterns for cells from a single starting colony grown in TB and LB 
media. All cells reach stationary phase at approximately 4 hrs after inoculation at an OD600 of 
0.6. It is suggested that a single colony can be used to inoculate media for expression of 



















Figure 3.2 Growth of E. coli host cells grown in Terrifc Broth and Lysogeny Broth inoculated from 
overnight cultures at 1: 100 dilution. E. coli host cells growing in TB and LB media at 37°C. LB media and 

















Figure 3.3  Growth of E. coli host cells grown in Terrifc and Lysogeny Broth media from a single starting 
colony. E. coli host cells growing in TB and LB media at 37°C.  Triplicate cultures are shown. 
 
 
Figure 3.4 Expression of PfLDH comparing inoculating with a single starting colony and from an 
overnight culture. Expression of  recombinant PfLDH in TB media was monitored on a reducing 12.5% SDS-
PAGE gel stained with Coomassie Brilliant Blue R-250. Panel A are individual colonies taken from the same LB 
agar plate, lane 1: Molecular weight marker, Lane 2, 3, 4, 5, 6, 7, 8 and 9: are different colonies containing 
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6XHisrPfLDH insert grown on the same agar plate. B is a 1:100 dilution of an overnight culture. Lane 1: 
Molecular weight maker, lane 2, 3, 4, 5, 6, 7, 8 and 9: are PfLDH samples of different 1:100 dilution. The 
experiment was repeated three times, an example experiment is shown. The arrow indicates the 36 kDa PfLDH 
band. 
 
Cells in TB appear to grow faster and do not require induction, and constant checking of 
ODs that may contaminate the cell culture (Li et al., 2011). So growing cells in TB media was 
chosen. 
Result in Figure 3.4 suggests the use of single starting colony appears to express more 
PLDH  than an overnight starting culture. It should be noted that the protein profile for each 
colony with the same plasmid insert does not always yield the same amount of protein as 
shown by the variation in the intensity of the PfLDH protein band of individual samples grown 
in TB media. The cells were normalised in each lane. 
 
3.2.3 Comparison of methods for lysing PfLDH E. coli cells 
The methods of lysing bacterial host cells were compared to determine which 
methods released more proteins. Lysozyme digestion, freezing and thawing, sonication, 
freezing and thawing followed by sonication and a combination of all the methods were 
compared. Results in Figure 3.5 shows that similar amounts of the 36 kDa PfLDH protein 
were observed in the sample from freezing and thawing followed by sonication Figure 3.5 
lane 2 and 3 in A and B. There were more protein bands and  a larger concentration of the 
36 kDa PfLDH protein in the supernatant of the combination of freeze and thaw followed by 
sonication and the combination of all three methods.   
Figure 3.6 shows that after the first round of freeze and thaw followed by sonication, 
there is more protein in the pellet than in the supernatant. To see if more protein could be 
released after the first round of freezing and thawing followed by sonication, freezing and 




Figure 3.5 Comparing methods of lysing E. coli cells. The effectiveness of the lysing methods was evaluated 
on a reducing 12.5% SDS-PAGE gel stained with Coomassie Brilliant Blue R-250. Panel A is the supernatant 
and B is the pellet: lane 1: molecular weight maker, lane 2 and 3: samples from lysozyme digestion, lane 4 and 5: 
samples from freezing and thawing, lane 6 and 7: samples from sonication, lane 8 and 9: samples from freeze 
and thaw followed by  sonication, lane 10: samples from all methods combined. The experiment was repeated 











Figure 3.6 Evaluating the amount of recombinant PfLDH in the soluble fraction after lysing using a 
combination of freeze and thaw followed by sonication. The recombinant PfLDH was frozen and thawed four 
times and sonicated four times. The amount of protein in the supernatant and pellet was evaluated using a 
reducing 12.5% SDS-PAGE gel stained with Coomassie Brilliant Blue R-250. Lane 1: Molecular weight marker, 
lane 2, 3, 4 and 5: supernatants (soluble fraction) after lysis, lane 6, 7, 8 and 9: pellets that remained after 
removing each supernatant respectively. The experiment was repeated three times, a sample experiment is 











Figure 3.7 Evaluating the amount of recombinant PfLDH which remains in the insoluble fraction after two 
rounds of lysis using a combination of freeze and thawing followed by sonication. The recombinant PfLDH 
was frozen and thawed X4 followed by sonication, the first supernatant was collected. The processes was 
repeated and the second supernatant collected. The amount of supernatant and pellet that was obtained was 
evaluated using a reducing 12.5% SDS-PAGE gel, stained with Coomassie Brilliant Blue R-250. Lane 1: 
Molecular weight marker, lane 2, 3 and 4: supernatant obtained after the first round of freeze and thaw followed 
by sonication, lane 5, 6 and 7: the supernatant obtained after the second round of freeze and thaw followed by 
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sonication, lane 8, 9 and 10: pellet that remained after removal of supernatants. The experiment was repeated 
three times, a sample experiment is shown. The arrow indicates the 36 kDa band of PfLDH.  
 
The results are shown in Figure 3.7 and shows that proteins were present in the soluble 
fraction after the second round of freeze and thaw followed by sonication. There was less 
protein in the supernatant of the second round of freeze and thaw followed by sonication 
compared to the first round. This data suggests that there is still more protein present in the 
pellet.  
 
3.2.4 Comparison of phase of induction 
The effect of inducing protein expression at mid-log phase and stationary phase in 
LB media was evaluated to see which phase of induction produces more soluble proteins. 
There was an overall higher expression of the PfLDH protein in cultures induced at 
stationary phase than at mid-log phase, as seen by the intensity of the 36 kDa bands (Figure 
3.8) in the supernatant and the pellet on the SDS page gel. More of the PfLDH was seen in 
the supernatant of cell cultures induced at the stationary phase in all the samples tested. 
This result is similar to those found by Flick et al, (2004). E. coli host cells with the same 
plasmid insert did not always yield the same amount of PfLDH as seen by the intensity of the 





Figure 3.8 Expression of PfLDH in LB broth after induction at mid-log and stationary phases. Recombinant 
PfLDH was expressed at 37°C in LB media and induced with 0.3 mM IPTG at mid-log (OD600 of 0.5-0.6) and 
stationary phases (OD600 of 0.65-0.68). The expression was evaluated using reducing 12.5% SDS-PAGE gel 
stained with Coomassie Brilliant Blue R-250. Lane 1: molecular weight marker, lane 2, 3 and 4: PfLDH samples 
induced at mid-log phase, lane 5, 6 and 7: PfLDH samples induced in the stationary phase. (A) is the pellet and 
46 
 
(B) is the supernatant from the pellet in A. The experiment was repeated three times, an example experiment is 
shown. The arrows indicate the 36 kDa PfLDH band. 
 
3.2.5 Comparison of 25°C and 37°C growth temperatures on the expression of PfLDH 
induced at stationary phase. 
One of methods to improve the expression of soluble proteins is to change the 
growth temperature of cultures. At lower temperatures, bacteria grow slowly and, typically 
exhibit a low rate of protein synthesis. When bacteria grow slowly there is a low probability of 
misfolding and aggregation of proteins to form inclusion bodies, favouring a relatively high 
yield of expressed protein (Vasina and Baneyx, 1997). Results in Figure 3.9 shows higher 
amounts of PfLDH at 37°C and 25°C in the pellet sample. There were higher amounts of 
PfLDH in the soluble fraction (supernatant) at 25°C than at 37°C. The amounts of PfLDH in 
the supernatant at 25°C are high compared to other protein bands in each lane, whereas at 
37°C all the protein bands are more intense. This suggests that relatively the expression of 
PfLDH compared to other proteins is higher at 25°C than at 37°C. This result is similar to 
what Tsai et al., 2016 found.   
 
 
Figure 3.9 Comparing the expression of PfLDH in LB media induced at stationary phase grown at 25°C or 
37°C. Bacteria were grown at 25°C and 37°C.The expression was evaluated using 12.5% reducing DSD-PAGE 
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gel stained with Coomassie Brilliant Blue R-250.   Panels A and B E. coli host cells incubated at 25°C, panels C 
and D E. coli host cells incubated at 37°C. Lane 1: molecular weight marker, lane 2, 3, 4, 5 and 6: PfLDH pellet 
samples induced in the stationary phase in panel A and C. Panels B and D are supernatants from the same 
pellets. The experiment was repeated three times, a sample experiment is shown. The arrow indicates the 36 
kDa PfLDH. 
 
3.2.6 Affinity purification of PfLDH on Talon® (Co2+) resin 
After cell lysis, as described above, the clarified soluble protein fraction was passed 
over a Talon® (Co2+) resin and incubated overnight at either 4°C, or room temperature on a 
platform shaker. When purifying at 4°C, more recombinant PfLDH compared to room 
temperature was obtained (Figure 3.10). A doublet was observed with one band at about 36 
kDa and a second band at 33 kDa (Figure 3.10 A. lanes 6, 7, 8 and figure 3.10 B. lanes 11, 
12, 13).  
 
 
Figure 3.10 Comparison of affinity purification of PfLDH at room temperature and at 4°C. Expression and 




) resin at RT (A) and 4°C (B) monitored on a reducing 
12.5% SDS-PAGE stained with Coomassie Brilliant Blue R-250. Panel A: Lane 1: Molecular weight marker, lane 
2: supernatant whole cell lysate, lane 3: unbound protein to the column, lane 4: wash samples from the column, 
lane 5-8: elutions of PfLDH. Panel B: Lane 1: Molecular weight marker, lane 2: supernatant from the mid-log 
phase, lane 3: supernatant from the stationary phase, lane 4: supernatant from the stationary phase induced with 
IPTG, lane 5: pellet after removal of supernatant at mid-log phase, lane 6: pellet after removal of supernatant at 
stationary phase, lane 7: pellet after removal of supernatant at stationary phase induced with IPTG, lane 8: wash 
samples from of the column, lane 9: wash one, lane 10-14: elutions of PfLDH. The experiment was repeated 





Figure 3.11 Affinity purification of PfLDH at 4°C. Panel A is a 12.5% reducing SDS-PAGE gel stained with 
Coomassie Brilliant Blue R-250. Lane 1: Molecular weight marker, lane 2: supernatant of cell lysate, lane 3: 
unbound protein to the column, lane 4: wash sample from the column, lane 5-8: elutions of PfLDH. Panel B is an 
elution profile of PfLDH taken by measuring absorbance at 280 nm of elution 1 to elution 10. Arrows shows the 
monomer (36 kDa) and dimer (75 kDa) of PfLDH. The experiment was repeated three times, a sample 
experiment is shown. 
 
The bands in Figure 3.10 B lanes 11, 12 and 13 are sharper compared to Figure 3.10 A 
lanes 6, 7, and 8. A faint band was seen in Figure 3.10 A at about 75 kDa and was thought 
to be a dimer of PfLDH similar to the observation by Zocher et al., (2012) with P. falciparum 
glutamate dehydrogenase. The 33 kDa band was suggested to be a truncated form of 
PfLDH (Turgut-Balik et al., 2004; Berwal et al., 2008; Hurdayal et al., 2010) due to an 
internal Shine Dalgarno sequence (GGAGGA) between base 45 and 51 in the coding 
sequence of recombinant PfLDH (Cicek et al., 2012).  
A 50 ml bacterial culture was grown and used for the purification PfLDH in Figure 3.11. An 
elution profile of the purification shows a high yield of recombinant protein was obtained.  
  
3.2.7 Western blot of recombinant PfLDH 
Western blot of each of the steps in the purification protocol of PfLDH showed high 
yields of recombinant protein as shown by the intensity of bands in Figure 3.12. The total 
protein obtained as determined by the Bradford method section 2.3.1 from a 200 ml culture 
yielded 144.77 mg of recombinant PfLDH.  The proteins in different fractions were pooled 
together and concentrated using PEG20000 (section 2.2.5). The yield obtained was higher 
than obtained by others (Berwal et al., 2008; Hurdayal et al., 2010). 
 
 
Figure 3.12 Expression, purification and detection of PfLDH using anti-His-tag primary antibodies. Panel 
A is a 12.5% SDS-PAGE reducing gel of recombinant PfLDH stained with Coomassie Brilliant Blue R-250 and 
panel  B is a western blot of an identical gel as in A of recombinant PfLDH probed with anti- His-tag monoclonal 
antibodies at dilution 1 : 1000 and goat anti-mouse HRPO conjugated secondary antibodies at 1: 6000 dilution. 
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Lane 1: Molecular weight marker, lane 2: supernatant whole cell lysate, lane 3: unbound protein to the column, 
lane 4: wash sample from the column, lane 5-9: elution of PfLDH. Arrows show the monomer (36kDa) and dimer 
(75 kDa) of PfLDH. The experiment was repeated three times. A sample experiment is shown. 
 
3.2.8 Enzyme activity of recombinant PfLDH 
Preliminary studies of the activity of the recombinant protein were done to see if an 
active enzyme was expressed. An assay in which the amount of cofactor NAD+ and 
substrate L-lactate were kept constant. An increase in the concentration of PfLDH resulted in 
an increase in activity as indicated by an increase in the absorbance at 345 nm (Figure 
3.13). The noise seen at 50 s was when the spectrophotometer was opened to add the 
substrate to the reaction. 
                                                    LDH                                




Figure 3.13 Enzyme activity at various amounts of PfLDH are shown. The substrate, lactic acid, and cofactor 
NAD
+ 
was kept constant and the enzyme concentration was increased. The experiment was repeated three 
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3.2.9 Comparison of induced and uninduced cultures in the expression of 
recombinant PfHSP70-1 
Induced E. coli cell cultures produced high amounts of recombinant PfHSP70-1 and 
basal expression of PfHSP70-1 was observed in uninduced E. coli cells. Even in the 
absence of IPTG, basal expression levels of target protein known as ‘leaky’ expression can 
occur, as shown in Figure 3.14 lanes 2, 3 and 4. Expression of PfHSP70-1 protein increased 
after induction with 1 mM IPTG as seen in lanes 5, 6 and 7 (Figure 3.14). The experiment 
shows that there can be different amounts of protein expressed by each sample of three 















Figure 3.14 Expression of recombinant PfHSP70-1 in LB media at 37°C. Expression of recombinant 
PfHSP70-1 E. coli cell culture induced at mid-log phase (OD600 of 0.5-0.6) with 1 mM IPTG in LB media 
monitored on a 12.5% reducing SDS-PAGE gel stained with Coomassie Brilliant Blue R-250. Lane 1: Molecular 
weight marker, lane 2, 3 and 4: uninduced E. coli culture, lane 5, 6 and 7 induced E. coli culture. Arrow shows the 
72 kDa band of PfHSP70-1. 
 
Induction of E. coli cultures in LB media at 37°C, at OD600 of 0.5 (mid-log phase) showed a 
minor difference compared to induction at OD600 of 0.2 as shown in Figure 3.15 panel A and 
B, respectively. There was overall poor growth of E. coli cells. 
The growth of E. coli host cells showed earlier increase in cell number after 1 hr and 
subsequently reached stationary phase earlier when induced at OD600 of 0.5 compared at 
0.2 (at 2 hr) as seen in Figure 3.16. The difference is not very significant, suggesting poor 
growth of E. coli host cells as observed in Figure 3.15. The E. coli host cells reached 
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stationary phase after approximately 5 hrs and the optical density at stationary phase was 
about 1.8.  
 
           
 
 
Figure 3.15 Comparison of PfHSP70-1 expression after induction at OD600 of 0.2 with that of OD600 of 0.5 
in LB media at 37°C. The induction of the recombinant protein with 1 mM IPTG at OD600 of 0.2 in panel A and 
0.5 in panel B was monitored using a 12.5% SDS-PAGE reducing gel stained with Coomassie Brilliant Blue R-
250. Lane 1: Molecular weight marker, lane 2 and 3: uninduced E. coli culture 1, lane 4 and 5: induced E. coli 



















Figure 3.16 E. coli host cell growth in cultures induced at OD600 0.2 and 0.5. The E. coli host cell were grown 
in LB media and monitored at OD 600 nm over a 6 hrs period. The experiment was done in triplicate. 
 
3.2.10 Comparison of growth media on the expression of recombinant PfHSP70-1 
The effect of TB and LB media on the expression of PfHSP70-1 was evaluated. TB is 
a self-inducing medium and, therefore, the addition of IPTG is not required. The cultures 
grown in LB media were induced with 1 mM IPTG at mid-log phase at an OD600 of 0.5-0.6. 
The results in Figure 3.17 shows a difference in the expression of recombinant PfHSP70-1 in 
TB compared to LB media. Expression of recombinant PfHSP70-1 was higher in TB than LB 
media. The expression of PfHSP70-1 protein in the E. coli lysate was higher relative to other 
proteins in the TB media. 
The effect of inoculating fresh LB broth with overnight cultures at different dilutions was 
evaluated. A dilution of 1:10 was compared with that of 1:100. The cultures were induced at 
OD600 of 0.5-0.6 with 1 mM IPTG. The results in Figure 3.18 suggest that a dilution of 1:100 
is marginally better than that of 1:10. 
The expression of PfHSP70-1 using different individual starting colonies of host E. 
coli cells was evaluated and Figure 3.19 shows that the protein profiles in all lanes were 
different. Lanes 3, 6, 7 and 9 had similar amounts of recombinant PfHSP70-1, lane 11 had 
the highest amount of recombinant PfHSP70-1 and lane 2 had the least amount of 
recombinant PfHSP70-1.  Inoculating fresh broth with a single colony to express 
recombinant protein has an advantage over overnight culture dilutions. It involves less steps 
and can save time.  
   
 
Figure 3.17 Expression of recombinant PfHSP70-1 E. coli cell culture in TB and LB media. The expression 
of PfHSP70-1 E. coli cell culture in TB and LB was monitored using a reducing 12.5% SDS-PAGE gel stained 
with Coomassie Brilliant Blue R-250. Panel A is recombinant PfHSP70-1 E. coli cell culture grown in TB media. 
Lane 1: molecular weight marker, lane 2, 3 and 4: lysate of E. coli cells. Panel B is recombinant PfHSP70-1 E. 
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coli cells grown in LB media. Lane 1: Molecular weight marker, lane 2 and 3: un-induced PfHSP70-1 E. coli cells, 











Figure 3.18 Comparing different dilutions of overnight cultures on the growth of E. coli host cells. The 
effect of diluting an overnight culture into fresh LB broth induced at OD600 of 0.5-0.6 was tested and monitored 
using a reducing 12.5% SDS-PAGE gel stained with Coomassie Brilliant Blue R-250. Lane 1: Molecular weight 
marker, lane 2, 3 and 4: induced E. coli culture diluted at 1:10 from an overnight culture, lane 5, 6 and 7: induced 










Figure 3.19 Expression of recombinant PfHSP70-1 from different starting colonies in TB media. The 
expression profile of 10 different E. coli colonies containing a 6XHis PfHSP70-1 was analysed on a 12.5% SDS-
PAGE reducing gel stained with Coomassie Brilliant Blue R-250. Lane 1: molecular weight marker, lanes 2-11: 
contain lysate prepared from different individual colonies on the same petri dish. The arrow shows the 72 kDa 
PfHSP70-1 band. 
 
The data above suggests that TB is a better choice of media to use for expressing 
recombinant PfHSP70-1 as TB does not require use of IPTG for induction recombinant 
protein and frequent checking of the optical density during expression. The use of a single 
colony can be easier. The data indicated that triplicate samples are necessary when looking 
to optimise bacterial growth and recombinant protein expression. 
  
3.2.11 Comparison of methods for lysing PfHSP70-1 E. coli cells 
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Methods of lysing bacterial cells includes lysozyme digestion, freezing and thawing, 
sonication, and a combination of all three methods. Combining all three methods yielded the 
most proteins as seen by intensity of the bands in Figure 3.20. The sample obtained after 
lysing of E. coli host cells containing PfHSP70-1 were always viscous. The samples were 
prepared and lysed as in section 2.2.4 above were run on 1% agarose gel to determine if 
these samples contained high amounts of nucleic acids. The agarose gels showed high 











Figure 3.20 Methods used to lyse bacterial cells. The bacterial cells were lysed using lysozyme, freezing and 
thawing, sonication and a combination of all the methods. The amount of protein released by each method was 
evaluated on a reducing 12.5% SDS-PAGE stained with Coomassie Brilliant Blue R-250. Lane 1: molecular 
weight marker, lane 2 and 3: supernatant of lysozyme digested samples, lane 4 and 5: supernatant of freeze and 
thaw samples, lane 6 and 7: supernatant of sonication samples, lane 8 and 9: supernatant of freeze and thaw 
then sonication samples, lane 10 and 11: supernatant of all three methods combined. The experiment was 













Figure 3.21 A 1% (w/v) agarose gel of E. coli host cells containing a PfHSP70-1 insert. The E. coli cells 
were frozen and thawed, then sonicated. A 1% (w/v) agarose gel of expressed PfHSP70-1. Panel A: Lane 1: 
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DNA ladder, lane 2: supernatant of un-induced culture, lane 3 and 4: supernatant of induced culture. The 
experiment was repeated three times, a sample experiment is shown. 
The use of freeze and thaw, followed by sonication was chosen as it was a less viscous 
solution and contained less contaminants.  
 
3.2.12 Affinity purification of recombinant PfHSP70-1 on Talon® (Co2+) resin and 
detection of the protein on a western blot 
After cell lysis, the clarified soluble protein fraction was poured over a Talon® (Co2+) 
resin. The expressed and affinity purified recombinant PfHSP70-1 protein were run on an 
SDS-PAGE gel and transferred to a nitrocellulose membrane and probed with anti-His-tag 
monoclonal antibodies.  
 




) resin. The expression and 




) resin was evaluated using a reducing 12.5% SDS-PAGE gel 
stained with Comassie Brilliant Blue R-250 in panel A and western blot probed with anti- His-tag primary 
antibodies at a dilution of 1:2000 as shown in panel B. Lane 1: molecular weight marker, lane 2. proteins that did 
not bind to resin, lane 3 and 4: 2 washes of the resin, lane 5-12: elution of PfHSP70-1 from resin. The arrows 
show the 72 kDa PfHSP70-1 bands.  
 
There was a low yield of purified protein as shown by low intensity of the bands in 
panel A and the western blot in panel B of Figure 3.22. The expression and purification steps 
were repeated to establish the cause of the low yields of the purified protein. Bacteria from 
different stocks were compared to see if source of material may make a difference. Low 
yields were obtained from all sample (Figure 3.23). Each expression round of PfHSP70-1 
yielded less and less protein until no protein was detected on western blots. The lower 







Figure 3.23 Samples of PfHSP70-1 E. coli host cells from two different glycerol stocks. 12.5% SDS-PAGE 
(A and C) and western blots probed with anti-His-tag (B and D) of recombinant PfHSP70-1 from bacterial 
colonies streaked from different glycerol stocks. Lane 1: molecular weight marker, lane 2 and 3 un-induced 
culture of colonies taken from stock 1 petri dish, lane 4 and 5: un-induced culture of colonies taken from stock 2 
petri dish, lane 6 and 7: induced culture of colonies from stock 1 petri dish, lane 8 and 9: induced culture of 
colonies from stock 2 petri dish. The 30 KDa is the truncated form of PfHSP70-1. The experiments were repeated 
three times. A sample experiments are shown. The arrows show the 72 kDa PfHSP70-1 bands. 
 
3.2.13 Isolation of pQE30/His6PfHSP70-1 plasmid and restriction digestion 
Due to the poor expression of the PfHSP70-1, the original plasmid was obtained as 
described in section 2.2.1.4 and digested with BamHI. 
As a positive control, E. coli containing the human HSP70 whose insert is known to 
be present was used. The PfHSP70-1 insert appeared to have been lost, as there was no 
restriction digestion with BamHI in lane 4. This explains why very low concentrations of 
recombinant protein in the western blots (Figures 3.22 panel B, Figure 3.23 panel B and D) 






















Figure 3.24 Restriction digestion of pQE30/His6PfHSP70-1 and pET/hHSP70 by BamHI. A 1% (w/v) agarose 
gel showing plasmid DNA of PfHSP70-1 and human HSP70-1 (hHSP70-1). Lane 1: DNA ladder, lane 2: 
pQE30/PfHSP70-1 plasmid, lane 3: a 1:10 dilution of pQE30/PfHSP70-1 plasmid, lane 4: pQE30/PfHSP70-1 
plasmid digested with BamHI, lane 5: pET/hHSP70 plasmid digested with BamHI. 
 
3. 3 Discussion 
 
The conditions that were evaluated for the expression of two recombinant proteins 
included comparisons of the type of media used, the growth of E. coli host cells in TB and LB 
media, starting bacterial growth from a single colony or an overnight culture, the time during 
growth when protein expression is induced, two temperatures on the expression of 
recombinant protein induced at stationary or mid-log phase of growth, methods for lysing E. 
coli cells and conditions for affinity purification of the recombinant proteins. 
 
 3.3.1 Media used to express recombinant PfLDH and PfHSP70-1 
PfLDH showed better expression in TB than LB media. TB media contains tryptone, 
yeast extract, glycerol and dibasic phosphates. Tryptone, a pancreatic digest of casein 
provides source of amino acids. Yeast extract provides a source of amino acids and trace 
elements to the medium. The extra addition of tryptone and yeast extract in TB medium 
allows bacteria to produce higher plasmid yield per volume. Glycerol is both a source of 
carbon and carbohydrates in the medium and unlike glucose, glycerol is not fermented to 
acetic acid, as such, it prevents the drop of pH during the growth of E. coli cell culture. 
Dibasic potassium phosphates are added to provide potassium for cellular systems and to 
maintain the pH during growth of the E. coli cell culture.  TB media is self-induced and does 
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not require measuring ODs, and as such does not require to be monitored for the correct 
time of induction (Li et al., 2011). In Figure 3.3.2 the OD600 was measured to compare 
growth in TB and LB medium. Expression of PfHSP70-1 in TB was better than in LB 
medium. Previously, the amount of IPTG in the expression of PfLDH was determined to 0.3 
mM and 1 mM for PfHSP70-1 when expressed in LB media.  
 
3.3.2 Growth of E. coli host cells in TB and LB media 
The E.coli host cells grow faster in TB media than LB media. This may be due to the 
presence of extra tryptone, yeast extract and glycerol in TB media. The use of a single 
colony to inoculate media also showed faster growth of E. coli host cells in TB media than in 
LB media. The time it takes to reach stationary phase for PfLDH and PfHSP70-1 was 
approximately 4 hrs at an optical density measured at 600 nm of about 0.68 and 5 hrs at 
optical density measured at 600 nm of about 1.8 respectively to monitor the growth of E. coli 
host cells. 
 
3.3.3 Initiating bacterial growth from a single colony or an overnight bacterial culture 
Starting with an overnight culture to evaluate recombinant protein expression was 
compared to starting with a single starting colony. There appeared to be more intense bands 
of recombinant proteins seen for both  PfLDH and PfHSP70-1 from E. coli cell cultures 
grown using a single colony than a dilution of 1:100 as shown in Figure 3.4 (section 3.2.2) 
and Figure 3.18-19 (section 3.2.10), respectively. Use of a single colony to inoculate fresh 
media would save a lot of time as there is no requirement to grow an overnight culture for 16 
hrs prior to protein expression. Each individual colony and dilution of an overnight culture did 
not produce the same amount of protein in the lanes examined. 
 
 
3.3.4 Time of induction of protein expression  
The induction of the expression of protein in the culture after the stationary phase 
OD600 of 0.68 for PfLDH yielded higher amounts of PfLDH compared to induction at mid-log 
phase OD600 of 0.5-0.6 with        0.3 mM ITPG, which was similar to results obtained by 
Flick et al, (2004). Among the reasons suggested for this observation are that proteins 
expressed at post-log phase tend to be less truncated (Flick et al., 2004). Induction of E. coli 
host cells containing PfHSP70-1 at mid-log phase and early log phase did not show a 





3.3.5 Two temperatures (25°C and 37°C) on the expression of PfLDH induced at 
stationary phase 
Expression of PfLDH at 25°C produced more PfLDH protein than at 37°C. The result 
is similar to what Flick et al, (2004) and Tsai et al, (2016) found when expressing 
Plasmodium falciparum erythrocyte membrane protein I (PfEMP I) at temperatures as low as 
16°C. Schein and Noteborn (1988) also found that expression at 30°C produced more 
recombinant interferon α2 (IFN-α2) and interferon ɣ (IFN-ɣ) proteins than at 37°C. Berwal et 
al., (2008) also noted the same observation with recombinant Plasmodium falciparum LDH 
at 15°C compared to 37°C. 
Expression in E. coli BL21 (DE3) has some advantages. The strain is deficient in the 
outer membrane protease (OmpT) and Lon protease which can digest recombinant proteins 
as they are expressed (Lee, 2009). BL21 DE3 E. coli cells require the T7 RNA polymerase 
gene to be lysogenised into the host E. coli BL21 genome (Sorensen and Mortensen, 2005). 
The T7 RNA polymerase, which is under control of the lacUV5 promoter, remains 
suppressed by LacI until IPTG is added to media to induce transcription of the target protein 
(Divan and Royds, 2013).  
 
3.3.6 Optimising the method of lysis of E. coli cells 
Bacterial cells are often lysed using three methods: lysozyme digestion, freezing and 
thawing and sonication. Lysozyme digestion released most proteins in the supernatant after 
lysing of E. coli cells as an individual method compared to sonication and, freezing and 
thawing. The only drawback in using lysozyme digestion was that the resulting supernatant 
was viscous and was contaminated with nucleic acids (Figure 3.7 & Figure 3.20). Freezing 
and thawing released more protein in the supernatant than sonication as an individual 
method after lysing of E. coli cells and contained less contaminants (Figure 3.7 & Figure 
3.20). Sonication released the least amount of proteins in the supernatant after lysing E. coli 
cells as an individual method and contained the least contaminants (Figure 3.7 & Figure 
3.20).The combination of freezing and thawing followed by sonication and then the two 
methods repeated yielded high amounts of recombinant PfLDH and PfHSP70-1 compared to 
lysozyme digestion alone, freeze and thaw alone and sonication alone. The problems of 
using all three methods is that it produces high contamination of nucleic acids in the samples 
and the samples were viscous (Figure 3.21). The combination of freeze and thaw followed 






3.3.7 Affinity purification of recombinant PfLDH and PfHSP70-1 
His-tagged proteins contain a histidine whose imidazole side chain has a pKa of 6.04 
(Voet and Voet, 2004). The solubility of a protein is dependent on the overall charge which is 
negative if the pH is above the protein’s pI and positive if the pH is below the protein’s pI 
(Bondansky and Latner, 1975, Voet and Voet, 2004). The pI of PfLDH is around 8.5 
(Nirmalan et al., 2004). The buffers used for the purification of PfLDH was 8.0 suggesting 
that PfLDH will have an overall positive charge and is likely to be soluble. Imidazole binds to 
cobalt ion (Co2+) in the Talon® (Co2+) resin. At pH 8.0, the recombinant protein will bind with 
high affinity to the Co2+ ions on the Talon® (Co2+) resin. Nguyen et al., (2014) showed that 
His-tag provides good yields of tagged proteins from inexpensive, high capacity resins. 
Purification of PfLDH at room temperature was compared to purification at 4°C. Improved 
purification was observed at 4°C compared to RT (Tsai et al., 2016 and Goto et al., 2016). A 
doublet was clearly observed at around 33 kDa and 36 kDa and a single band was observed 
at around 75 kDa when purified at 4°C and a blurred doublet and 75 kDa were observed 
when purified at 37°C. Hurdayal et al., (2010) expressed a 2X His6-PfLDH with His tags at 
both the N- and C- terminal ends of PfLDH and found the size to be approximately 39 kDa 
and Berwal et al., (2008) expressed a His6-PfLDH and found the size to be around 36.3 kDa. 
Purification of PfHSP 70-1 yielded low amounts compared to what was observed by 
Matambo et al., (2004). The size observed was about     72 kDa. 
 
3.3.8 Western blots detecting PfLDH and PfHSP70-1 
Anti-His-tagged antibodies were used to detect PfLDH band on a western blot. A 
36kDa band and another band at about 75 kDa were detected. The 75 kDa may be due to 
dimer formation a result similar to Zocher et al., (2012) with recombinant Plasmodium 
falciparum glutamate dehydrogenase 1 on reducing SDS-PAGE gel which was detected by 
western blots, and was determined to be a dimer of PfLDH. This could be confirmed by 
molecular exclusion chromatography. Another small band just below the 36 kDa of about 33 
kDa was observed in the western blot which is similar to results found by others (Berwal et 
al., 2008; Hurdayal et al., 2010 and Turgurt-Balik et al., 2004). This was due to the presence 
of an internal Shine-Dalgarno like sequence (GGAGGA) between bases 46 to 61 in the 
coding sequence for recombinant PfLDH (Cicek et al., 2013). Berwal et al., (2008) with His6-
rPfLDH and Goto et al., (2016) with swine LDH found both the recombinant proteins form 
tetramers and had enzyme activity. Probing western blots of PfHSP70-1 with anti-His-tag 
antibodies showed low concentration of PfHSP70-1. The size of the recombinant protein was 
approximately 72 kDa, similar to what was observed by Matambo et al., (2004) who found a 
monomer of 73.5 kDa and a dimer of 199.5 kDa using SE-HPLC analysis. The 199.5 kDa 
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was too large to be a dimer and too small to be a trimer. Therefore the dimer may have been 
formed as an intermediated complex between a dimer and trimer. It was also noted that 
PfHSP70-1 exists mainly in the monomer form. 
 
3.3.9 Determination of the cause of poor expression of PfHSP70-1 
To determine the cause of poor expression of PfHSP70-1, the plasmid was isolated 
according to manufacturer’s instructions in section 2.2.1.4. The plasmid was then subjected 
to restriction digestion by BamHI to determine if the insert was still present. As a positive 
control, the plasmid containing human HSP70 whose insert was known to be present in 
plasmid was isolated and digested with BamHI and electrophoresed on the same 1% 
agarose gel. The DNA samples were resolved on 1% agarose gel and viewed under UV 
radiation. The results showed PfHSP70-1 the insert appeared to have been lost. More 
sensitive methods such as PCR may be used to confirm the loss of the plasmid containing 
His6-PfHSP70-1 insert.  
 
Summary 
These results suggest that for the recombinant expression of PfLDH in TB media at 
low temperature and purifying the protein at 4°C ensures production of more soluble 
recombinant proteins. The use of a single colony as starting material yields a larger amount 
of recombinant protein compared to dilution of an overnight culture. Therefore, use of a 
single colony was preferred as it was time saving.  Freezing and thawing followed by 
sonication twice appeared to release more protein in the supernatant and was sufficient for 
lysing E. coli cells. The evidence as shown by poor expression and purification of PfHSP70-
1 coupled with results of plasmid digestion of pQE30/PfHSP70-1 as shown on agarose gel 





















Most of the antibodies used in current malarial RDTs are monoclonal antibodies. These 
monoclonal antibodies are selected against one of three peptides as opposed to identifying them 
from a unique epitope. Epitope mapping can be done to determine an epitope target (Saravanan 
and Kumar, 2009). Identifying a target epitope is important because antigenic variations 
sometimes affects the detection of certain antigens as in the case of a commonly used RDT 
target HRPII in malaria (Lee et al., 2006; Baker et al., 2010). HRPII undergoes antigenic variation 
leading to false negative results with antibodies in particular test kits (Gamboa et al., 2010). In 
this study, polyclonal and anti-peptide specific antibodies against the target epitopes are 
intended to be raised as an alternative to monoclonal antibodies. The peptides used to raise anti-
peptide antibodies are usually 12-15 amino acid residues in length and cannot elicit an immune 
response by themselves. They are, therefore, coupled to a carrier protein usually rabbit albumin.  
The use of polyclonal antibodies raised against the peptides of target proteins for malaria 
diagnosis has been validated (Tomar et al., 2006). The use of anti-peptide antibodies raised 
against specific epitopes for diagnosis of malaria and differentiation between the malaria lactate 
dehydrogenase from different species has been demonstrated by Hurdayal et al., 2010.   
Many human proteins undergo post translational modifications which may reduce the 
interactions between antibodies raised against a recombinant protein or a peptide and its 
detection in the native protein (Glozak et al., 2005; Huang et al., 2007; Gupta et al., 1999; 
Nielsen et al., 2005). This chapter describes the ‘in silico’ work done to identify potential 
immunogenic peptides to be used in the production of antibodies in chicken using a prediction 
program Predict7™. The chapter describes the prediction of potential post translational 
modifications such as lysine acetylation, phosphorylation, glycosylation and protease digestion to 
see if these modifications have the potential to reduce antibody recognition. There is evidence 
that certain post translational modifications of each protein can affect the activity of native 
proteins (Zhao et al., 2013; Fan et al., 2011). 
 
4.2 Selection of immunogenic peptides 
The entire amino acid sequence of PfHSP70-1 was analysed using Predict7™ to identify 
which regions in the sequence had potential as immunogenic peptides as described by 
Carmenes et al., 1989. The structural features analysed were antigenicity (Welling et al., 1985), 
flexibility (Karplus and Schulz, 1985), hydrophilicity (Hoop and Woods, 1981) and surface 
probability (Janin et al., 1978; Emini, 1985). Other features of the program include hydropathy 
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(Kyte and Doolittle, 1982) and secondary structure (Garnier et al., 1978). The selected peptides 
need to be on the surface of the protein to increase the probability of recognition and binding by 
antibodies in solution (Saravanan and Kumar, 2009). Three peptides with high surface probability 
and hydrophilicity values were selected from the amino acid sequence of PfHSP70-1 and are 
shown in Figure 4.1. All the three amino acid sequences chosen are located in the α-helical-
subdomain (lid and hinge region) of PfHSP70-1, which closes in the ADP state and is open in the 
ATP state to allow substrate binding.  Analysis of PfLDH sequences with Predict7™ to identify 
immunogenic epitopes was previously done in our laboratory. Within the sequence of PfHSP70-1 
three peptides chosen had hydrophilicity and surface probability values above zero, and were, 















































Figure 4.1 Predict7™ analysis of three PfHSP70-1 peptides. Data from the Predict7™ program analysing the 
three chosen PfHSP70-1 epitopes based on antigenicity, hydrophilicity, surface probability and flexibility. Panel 
A; RNSLENYCYGVKSSLED, panel B; PAEIETCMKTIT and panel C; AGKDEYYAKQLEAESVC were the 
epitopes chosen. Surface probability and hydrophilicity were plotted on the primary axis while flexibility and 






PfHSP70-1    1 MASAKGSKPNLPESNIAIGIDLGTTYSCVGVWRNENVDIIANDQGNRTTPSYVAFTDTER 
cKHSP70-1    1 ----------MSGKGPAIGIDLGTTYSCVGVFQHGKVEIIANDQGNRTTPSYVAFTDTER 
hHSP70-1     1 -----------MAKAAAIGIDLGTTYSCVGVFQHGKVEIIANDQGNRTTPSYVAFTDTER 
                            .  ***************::: :*:********************** 
 
PfHSP70-1   61 LIGDAAKNQVARNPENTVFDAKRLIGRKFTESSVQSDMKHWPFTVKSGVDEKPMIEVTYQ 
cKHSP70-1   51 LIGDAAKNQVAMNPTNTIFDAKRLIGRKYDDPTVQSDMKHWPFRVVNE-GGKPKVQVEYK 
hHSP70-1    50 LIGDAAKNQVALNPQNTVFDAKRLIGRKFGDPVVQSDMKHWPFQVIND-GDKPKVQVSYK 








PfHSP70-1  121 GEKKLFHPEEISSMVLQKMKENAEAFLGKSIKNAVITVPAYFNDSQRQATKDAGTIAGLN 
cKHSP70-1  110 GEMKTFFPEEISSMVLTKMKEIAEAYLGKKVQNAVITVPAYFNDSQRQATKDAGTITGLN 
hHSP70-1   109 GDTKAFYPEEISSMVLTKMKEIAEAYLGYPVTNAVITVPAYFNDSQRQATKDAGVIAGLN 
               *: * *.********* **** ***:**  : **********************.*:*** 
 
 
PfHSP70-1  181 VMRIINEPTAAAIAYGLHKKG--KGEKNILIFDLGGGTFDVSLLTIEDGIFEVKATAGDT 
cKHSP70-1  170 VMRIINEPTAAAIAYGLDKKGTRAGEKNVLIFDLGGGTFDVSILTIEDGIFEVKSTAGDT 
hHSP70-1   169 VLRIINEPTAAAIAYGLDRTG--KGERNVLIFDLGGGTFDVSILTIDDGIFEVKATAGDT 
               *:***************.:.*   **:*:*************:***:*******:***** 
 
 
PfHSP70-1  239 HLGGEDFDNRLVNFCVEDFKRKNRGKDLSKNSRALRRLRTQCERAKRTLSSSTQATIEID 
cKHSP70-1  230 HLGGEDFDNRMVNHFVEEFKRKHK-RDIAGNKRAVRRLRTACERAKRTLSSSTQASIEID 
hHSP70-1   227 HLGGEDFDNRLVNHFVEEFKRKHK-KDISQNKRAVRRLRTACERAKRTLSSSTQASLEID 
               **********:**. **:****:: :*:: *.**:***** **************::*** 
 
 
PfHSP70-1  299 SLFEGIDYSVTVSRARFEELCIDYFRDTLIPVEKVLKDAMMDKKSVHEVVLVGGSTRIPK 
cKHSP70-1  289 SLFEGIDFYTSITRARFEELNADLFRGTLEPVEKALRDAKLDKGQIQEIVLVGGSTRIPK 
hHSP70-1   286 SLFEGIDFYTSITRARFEELCSDLFRSTLEPVEKALRDAKLDKAQIHDLVLVGGSTRIPK 
               *******: .:::*******  * **.** ****.*:** :** .::::*********** 
 
 
PfHSP70-1  359 IQTLIKEFFNGKEACRSINPDEAVAYGAAVQAAILSGDQSNAVQDLLLLDVCSLSLGLET 
cKHSP70-1  349 IQKLLQDFFNGKELNKSINPDEAVAYGAAVQAAILMGDKSENVQDLLLLDVTPLSLGIET 
hHSP70-1   346 VQKLLQDFFNGRDLNKSINPDEAVAYGAAVQAAILMGDKSENVQDLLLLDVAPLSLGLET 




PfHSP70-1  419 AGGVMTKLIERNTTIPAKKSQIFTTYADNQPGVLIQVYEGERALTKDNNLLGKFHLDGIP 
cKHSP70-1  409 AGGVMTALIKRNTTIPTKQTQTFTTYSDNQSSVLVQVYEGERAMTKDNNLLGKFDLTGIP 
hHSP70-1   406 AGGVMTALIKRNSTIPTKQTQIFTTYSDNQPGVLIQVYEGERAMTKDNNLLGRFELSGIP 
               ****** **:**:***:*::* ****:*** .**:********:********:*.* *** 
 
PfHSP70-1  479 PAPRKVPQIEVTFDIDANGILNVTAVEKSTGKQNHITITNDKGRLSQDEIDRMVNDAEKY 
cKHSP70-1  469 PAPRGVPQIEVTFDIDANGILNVSAVDKSTGKENKITITNDKGRLSKDDIDRMVQEAEKY 
hHSP70-1   466 PAPRGVPQIEVTFDIDANGILNVTATDKSTGKANKITITNDKGRLSKEEIERMVQEAEKY 
               **** ******************:*.:***** *:***********:::*:***::*** 
 
Connect 1 region 
PO4
-2 Binding domain 
Adenosine 
Binding region 
β-Subdomain (Peptide substrate binding) 
Connect 2 region 




PfHSP70-1  539 KAEDEENRKRIEARNSLENYCYGVKSSLEDQKIKEKLQPAEIETCMKTITTILEWLEKNQ 
cKHSP70-1  529 KAEDEANRDRVGAKNSLESYTYNMKQTVEDEKLKGKISDQDKQKVLDKCQEVISWLDRNQ 
hHSP70-1   526 KAEDEVQRERVSAKNALESYAFNMKSAVEDEGLKGKISEADKKKVLDKCQEVISWLDANT 
               ***** :*.*: *:*:**.* :.:*.::**: :* *:.  : :. :..   ::.**: *  
 
 
PfHSP70-1  599 LAGKDEYEAKQKEAESVCAPIMSKIYQDAAGAAGGMPGGMPGGMPGGMPSGMPGGMNFPG 
cKHSP70-1  589 MAEKEEYEHKQKELEKLCNPIVTKLYQGAGGAGAGGSG---------------------- 
hHSP70-1   586 LAEKDEFEHKRKELEQVCNPIISGLYQGAGGPGPGGFGAQ-------------------- 
               :* *:*:* *:** *.:* **:: :**.*.* . *  *                       
 
 
PfHSP70-1  659 GMPGAGMPGNAPAGSGPTVEEVD 
cKHSP70-1  626 ---------------GPTIEEVD 
hHSP70-1   625 -----G--PKGGSGSGPTIEEVD 
                              ***:**** 
                                                      
 
Figure 4.2 Alignment of amino acid sequences from P. falciparum, chicken and human HSP70-1 
showing the positions of the immunogenic peptides identified by the prediction program. A multiple 
sequence alignment of P. falciparum HSP70-1 (PlasmoDB ID: PF3D7_0818900), Gallus gallus HSP70 
(NCBI accession ID: NP_001006686 XP-421406) and Homosapien HSP70 (NCBI accession ID: PODMV8) 
amino acids. The annotation ‘*’ refers to identical amino acid residues, “:” refers to conserved amino acid 
residues, “.” refers to semi-conserved amino acid residues and a blank space represented no identity in 
amino acid residues in the sequences. The blue, green and pink colour show the positions of chosen 
peptides in the sequence of PfHSP70-1. The blue, green and red colour in the α-helical subdomain (lid and 
hinge region) in grey colour show RNSLENYCYGVKSSLED, PAEIETCMKTIT and AGKDEYEAKQKEAESVC 
immunogenic peptide sequences respectively chosen using Predict7™. The underlined regions are: 
phosphate 1 binding region (dark green), phosphate 2 binding region (red), connect 1 region (yellow), 
connect 2 region (light green), Adenosine binding region (light blue), β-subdomain for peptide substrate 
binding (purple), α-helical subdomain for hinge and lid region (grey) and the EEVD motif (greenish ). 
 
Multiple alignment (Figure 4.2) of the amino-acid sequence of PfHSP70-1 (PlasmoDB ID: 
PF3D7_0818900), chicken HSP70 (Gallus gallus) (NCBI accession ID: NP_001006686 XP-
421406) and human (Homosapien) HSP70 (PODMV8) using clustal W 
(www.ebi.ac.uk/Tools/msa/clustalo/) was done to ensure that the peptides chosen were 
unique to P. falciparum malaria, so that the antibodies produced in chicken will not cross 
react with the chicken and human HSP70-1 proteins. The positions of important domains in 
the sequence of the PfHSP70-1, ckHSP70-1 and hHSP70-1 proteins are also shown. The 
peptides selected by Predict7™ analysis are shown on the sequence as 
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RNSLENYCYGVKSSLED (blue), PAEIETCMKTIT (green) and AGKDEYYAKQLEAESVC 
(red). The alignment shows that RNSLENYCYGVKSSLED has six identical, six conserved 
and four semi-conserved amino acid residues. PAEIETCMKTIT has three conserved and 
three semi-conserved amino acid residues. AGKDEYYAKQLEAESVC has nine identical, 
four conserved and one semi-conserved amino acid residues. The three peptide sequences 
were aligned to predict if the anti-peptide raised against these peptides would cross react 
with the chicken and human HSP70-1 protein sequences. The data suggests that there 
would be no cross reactivity with chicken and human HSP70-1. 
 
 
Figure 4.3 An image of the crystal structure of PfHSP70-1 showing the location of the three selected 
peptides. All the selected peptides (blue, green and pink) were located on the surface of PfHSP70-1. The 
structure was developed using SwissPDB 4.1.0 (http://www.expasy.org.spdv/). The sequence was obtained from 
the SWISS-MODEL repository (www.spdv.vital-it.ch/disclaim.html#). 
 
A blast search (data not shown) in http://blast.ncbi.nlm.nih.gov/Blast.cgi showed that 
RNSLENYCYGVKSSLED and PAEIETCMKTIT are unique to the Plasmodium falciparum 
genome and AGKDEYEAKQKEAESVC was 100% identical in P. ovale and P. vivax genome and 
was, therefore, a common peptide. There was 63.58% (433 amino acid residues) identical, 
13.8% (94 amino acid residues) conserved, 4.26% (29 amino acid residues) semi-conserved and 
18.36% (125 amino acid residues) non-identical amino acid residues in the sequence of 
PfHSP70-1 that was compared with ckHSP70-1 and hHSP70-1. The phosphate, adenosine and 
β-subdomain are highly conserved. The α-helical subdomain is semi conserved. All the three 
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immunogenic peptides for PfHSP70-1 identified above were located on the surface of the 3D 
crystal structure model of PfHSP70-1 (spdbv.vital-it.ch/disclaim.html#) as shown in Figure 4.3. 
The chosen peptides ranged from 15 – 17 amino acid residues in length. The peptide 
AGKDEYEAKQKEAESVC has cysteine at the C-terminal end and the other two peptides 
required the addition of a cysteine at the C-terminus during synthesis of the peptides for coupling 
to carrier proteins. A common carrier is rabbit albumin, and coupling is done with 
maleimidobenzoyl-N-hydroxysuccinimide ester (MBS). MBS links with SH-group of a cysteine 
side chain to the ε-amino group of lysine on the carrier protein (Peeters et al., 1989). All selected 
peptides had predicted surface probability and hydrophilicity values. This prediction suggests the 
surface location of the peptides which ensures the interaction with and binding to antibodies 
raised against the epitopes on the native protein in solution (Saravanan et al., 2009). All the three 
immunogenic peptides for PfHSP70-1 identified above were located on the surface of the 3D 
crystal structure model of PfHSP70-1. This confirmed the data obtained using Predict7™ 
analysis of the amino-acid sequence of the PfHSP70-1. The peptides will be synthesized and 
used to produce antibodies in chickens. Peptides selected in the same manner for PfLDH were 
found to be on the surface of the 3D structure based on the published crystal model by Hurdayal 
et al., 2010 (Dunn et al., 1996). The antibodies will be tested in ELISA and dip-stick format to 
detect both recombinant and native PfHSP70-1.  
 
4.3 Prediction of post-translational modification 
Post translational modification of proteins in cells play an important role in biological 
functions such as cell signalling (Kiemer et al., 2005), transcription regulation (Faiola et al., 
2005), apoptosis (Subramanian et al, 2005), cytokine signalling (Yuan et al., 2005) and many 
other functions. The prediction of possible post translational modification was done to access if 
the potential post translational sites are close to or on the site of important catalytic amino acids. 
There is evidence that certain post translational modifications affect the activity of enzymes 
(Zhao et al., 2013; Fan et al., 2011). Antibodies produced against a recombinant protein may not 
interact with the native protein if the native protein is acetylated, phosphorylated, glycosylated or 




Acetylation is a widespread post translational modification of eukaryote proteins, in which 
an acetyl group from acetyl coenzyme A is transferred to either the α-amino group of the amino-
terminal residue or to the ε-amino group of internal lysines at specific sites (Glozak et al., 2005; 
Kouzarids, 2000; Polevoda et al., 2000; Yang, 2004). Acetylation alters the electrostatic 
properties of proteins as the positive charge of the lysine residue is neutralised. Also formation of 
hydrogen bonds on lysine side-chains are disrupted (Yang et al., 2004). This leads to loss of 
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function of the protein. In addition, lysine acetylation also creates a new interface for protein 
binding, this may results in a gain of function, such as in protein-protein interaction, enzymatic 
activity, stability and subcellular localization (Glozak et al., 2005; Polevoda et al., 2002; Yang 
2004; Faiola et al., 2005). 
The recombinant proteins used in this study are produced in E. coli cells and, therefore, 
they are not acetylated. This may result in recombinant proteins having less activity as a result of 
non-acetylation. Native PfLDH and PfHSP70-1 can be acetylated (Miao et al., 2013; Zhao et al., 
2010).  The antibodies produced from recombinant proteins may not recognise the epitopes in 
the native protein if the epitopes contain lysine residues that are acetylated. Two prediction 




Peptide Position Score Threshold 
***MAPKAKIVLV 4 11.04 0.20 
*MAPKAKIVLVGS 6 3.01 0.20 
ATLIVQKNLGDVV 26 0.23 0.20 
KNMPHGKALDTSH 44 0.57 0.20 
MAYSNCKVSGSNT 60 1.03 0.20 
VTAGFTKAPGKSD 84 1.27 0.20 
FTKAPGKSDKEWN 88 1.92 0.20 
APGKSDKEWNRDD 91 1.84 0.20 
EIGGHIKKNCPNA 114 0.96 0.20 
QHSGVPKNKIIGL 144 0.22 0.20 
SGVPKNKIIGLGG 146 0.51 0.20 
VGAHGNKMVLLKR 185 1.30 0.20 
MAESYLKDLKKVL 252 1.03 0.20 
SYLKDLKKVLICS 255 1.10 0.20 
QLNSEEKAKFDEA 299 0.48 0.20 
EAIAETKRMKALA 310 1.69 0.20 
AETKRMKALA*** 313 3.06 0.20 
B 
PfHsp70-1 
Peptide Position Score Threshold 
**MASAKGSKPNL 5 8.42 0.20 
ASAKGSKPNLPES 8 2.77 0.20 
LIGDAAKNQVARN 67 0.73 0.20 
KRLIGRKFTESSV 88 1.50 0.20 
VTYQGEKKLFHPE 123 0.91 0.20 
TYQGEKKLFHPEE 124 0.78 0.20 
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MVLQKMKENAEAF 140 0.33 0.20 
AEAFLGKSIKNAV 149 0.46 0.20 
IAYGLHKKGKGEK 199 0.58 0.20 
AYGLHKKGKGEKN 200 1.03 0.20 
GLHKKGKGEKNIL 202 1.63 0.20 
KKGKGEKNILIFD 205 1.30 0.20 
FCVEDFKRKNRGK 258 0.73 0.20 
VEDFKRKNRGKDL 260 0.88 0.20 
KRKNRGKDLSKNS 264 3.13 0.20 
RGKDLSKNSRALR 268 1.96 0.20 
TQCERAKRTLSSS 284 1.81 0.20 
PVEKVLKDAMMDK 335 0.76 0.20 
KIQTLIKEFFNGK 364 0.57 0.20 
AGGVMTKLIERNT 425 0.42 0.20 
TTIPAKKSQIFTT 437 1.12 0.20 
GERALTKDNNLLG 464 0.98 0.20 
DNNLLGKFHLDGI 471 0.41 0.20 
IPPAPRKVPQIEV 483 0.62 0.20 
NVTAVEKSTGKQN 506 1.19 0.20 
VEKSTGKQNHITI 510 1.93 0.20 
ITITNDKGRLSQD 520 0.59 0.20 
MVNDAEKYKAEDE 537 0.51 0.20 
NYCYGVKSSLEDQ 563 0.27 0.20 
DQKIKEKLQPAEI 574 0.40 0.20 
KNQLAGKDEYEAK 602 1.94 0.20 
CAPIMSKIYQDAA 622 1.07 0.20 
  
C 
  NetAcet 1.0 prediction results, 1 sequence 
#  
#  
# Sequence   #     Context   Score      Acetylation 
# ----------------------------------------------------------------- 









# Sequence   #     Context   Score      Acetylation 
# ----------------------------------------------------------------- 
PfHSP70-1                2 A   --MASAK   0.471           .  





























Figure 4.4 The predicted lysine acetylation sites on PfLDH and PfHSP70-1 using two programs. A and B 
show the lysine acetylation site using a program PAIL and C and D using a program NetAcet that uses N-
acetyltransferase A as a substrate. E and F shows the tables the numbers of sites for PAIL and NetAcet, 
respectively. 
  
PfLDH alignments showing position of acetylation acetylation 
 
PfLDH    1 -----------------MAPKAKIVLVGSGMIGGVMATLIVQKNLGD-VVLFDIVKNMPH 
mLDH     1 -ATLKDQLIYNLLK-EEQTPQNKITVVGVGAVGMACAISILMKDLADELALVDVIEDKLK 
ckLDH    1 MATLKEKLITPVAA-GSTVPSNKITVVGVGQVGMACAISILGKGLCDELALVDVLEDKLK 
htLDH    1 -ATLKEKLIAPVAEEEATVPNNKITVVGVGQVGMACAISILGKSLADELALVDVLEDKLK 
                             .*. **.:** * :* . *  *: *.* * :.*.*::::  : 
 
PfLDH   43 GKALDTSHTNVMAYSNCKVSGSNTYDDLAGADVVIVTAGFTKAPGKSDKEWNRDDLLPLN 
mLDH    59 GEMMDLQHGSLFLR-TPKIVSGKDYNVTANSKLVIITAGARQQEGESRLN-----LVQRN 
ckLDH   60 GEMMDLQHGSLFLQ-THKIVADKDYAVTANSKIVVVTAGVRQQEGESRLN-----LVQRN 
htLDH   60 GEMMDLQHGSLFLQ-TPKIVADKDYSVTANSKIVVVTAGVRQQEGESRLN-----LVQRN 
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           *: :* .* .::   . *: ..: *   *.:.:*::***  :  *:*  :     *:  * 
 
PfLDH  103 NKIMIEIGGHIKKNCPNAFIIVVTNPVDVMVQLLHQHSGVPKNKIIGLGGVLDTSRLKYY 
mLDH   113 VNIFKFIIPNVVKYSPNCKLLIVSNPVDILTYVAWKISGFPKNRVIGSGCNLDSARFRYL 
ckLDH  114 VNVFKFIIPQIVKYSPNCTILVVSNPVDILTYVTWKLSGLPKHRVIGSGCNLDTARFRYL 
htLDH  114 VNVFKFIIPQIVKYSPDCIIIVVSNPVDILTYVTWKLSGLPKHRVIGSGCNLDSARFRYL 
            :::  *  :: * .*:. :::*:****::. :  : **.**:::** *  **::*::*  
 
PfLDH  163 ISQKLNVCPRDVNAHIVGAHGNKMVLLKRYITVGGIPLQEFINNKLIS--DAELEAIFDR 
mLDH   173 MGERLGVHPLSCHGWVLGEHGDSSVPVWSGMNVAGVSLKTLHPDLGTDKDKEQWKEVHKQ 
ckLDH  174 MAERLGIHPTSCHGWILGEHGDSSVAVWSGVNVAGVSLQELNPAMGTDKDSENWKEVHKQ 
htLDH  174 MAEKLGIHPSSCHGWILGEHGDSSVAVWSGVNVAGVSLQELNPEMGTDNDSENWKEVHKM 
           :.::*.: * . :. ::* **:. * :   :.*.*: *: :      .  . : : :..  
 
PfLDH  221 TVNTALEIVNLHASPYVAPAAAIIEMAESYLKDLKKVLICSTLLEGQYGH-SDIFGGTPV 
mLDH   233 VVESAYEVIKLKGYTSWAIGLSVADLAESIMKNLRRVHPVSTMIKGLYGIKDDVFLSVPC 
ckLDH  234 VVESAYEVIRLKGYTNWAIGLSVAELCETMLKNLYRVHSVSTLVKGTYGIENDVFLSLPC 
htLDH  234 VVESAYEVIKLKGYTNWAIGLSVADLIESMLKNLSRIHPVSTMVKGMYGIENEVFLSLPC 
           .*::* *::.*:.    * . :: :: *: :*:* ::   **:::* **  .::* . *  
  
PfLDH  280 VLGANGVEQVIELQLNSEEKAKFDEAIAET----KRMKALA 
mLDH   293 ILGQNGISDLVKVTLTSEEEARLKKSADTLWGIQKELQF-- 
ckLDH  294 VLSASGLTSVINQKLKDDEVAQLKKSADTLWSIQKDLKDL- 
htLDH  294 ILNARGLTSVINQKLKDDEVAQLKKSADTLWDIQKDLKDL- 
           :*.  *: .:::  *..:* *::.::        * ::   
Figure 4.5 Predication of acetylation sites in the sequence of PfLDH aligned with chicken (Gallus gallus) 
cKLDH and human (Homo sapien) hLDH using PAIL. The dark red colour (with letter K) show the positions of 
predicted potential lysine acetylation sites by PAIL in the PfLDH sequence. Light blue conserved arginine 109 
and 171, Dark green conserved aspartic acid 168, Yellow conserved histidine 195 all conserved in the catalytic 
site of LDH sequence. The numbering of these conserved amino acids is based on the standard N numbering 
system (Evenlhoff et al., 1977). Dark blue threonine 246 and grey isoleucine 250 are residues in the cofactor 









PfHSP70-1    1 MASAKGSKPNLPESNIAIGIDLGTTYSCVGVWRNENVDIIANDQGNRTTPSYVAFTDTER 
cKHSP70-1    1 ----------MSGKGPAIGIDLGTTYSCVGVFQHGKVEIIANDQGNRTTPSYVAFTDTER 
PO4-1 Binding domain 
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hHSP70-1     1 -----------MAKAAAIGIDLGTTYSCVGVFQHGKVEIIANDQGNRTTPSYVAFTDTER 
                            .  ***************::: :*:********************** 
 
 
PfHSP70-1   61 LIGDAAKNQVARNPENTVFDAKRLIGRKFTESSVQSDMKHWPFTVKSGVDEKPMIEVTYQ 
cKHSP70-1   51 LIGDAAKNQVAMNPTNTIFDAKRLIGRKYDDPTVQSDMKHWPFRVVNE-GGKPKVQVEYK 
hHSP70-1    50 LIGDAAKNQVALNPQNTVFDAKRLIGRKFGDPVVQSDMKHWPFQVIND-GDKPKVQVSYK 
               *********** ** **:**********: :  ********** * .  . ** ::* *: 
 
PfHSP70-1  121 GEKKLFHPEEISSMVLQKMKENAEAFLGKSIKNAVITVPAYFNDSQRQATKDAGTIAGLN 
cKHSP70-1  110 GEMKTFFPEEISSMVLTKMKEIAEAYLGKKVQNAVITVPAYFNDSQRQATKDAGTITGLN 
hHSP70-1   109 GDTKAFYPEEISSMVLTKMKEIAEAYLGYPVTNAVITVPAYFNDSQRQATKDAGVIAGLN 
               *: * *.********* **** ***:**  : **********************.*:*** 
 
 
PfHSP70-1  181 VMRIINEPTAAAIAYGLHKKG--KGEKNILIFDLGGGTFDVSLLTIEDGIFEVKATAGDT 
cKHSP70-1  170 VMRIINEPTAAAIAYGLDKKGTRAGEKNVLIFDLGGGTFDVSILTIEDGIFEVKSTAGDT 
hHSP70-1   169 VLRIINEPTAAAIAYGLDRTG--KGERNVLIFDLGGGTFDVSILTIDDGIFEVKATAGDT 
               *:***************.:.*   **:*:*************:***:*******:***** 
 
PfHSP70-1  239 HLGGEDFDNRLVNFCVEDFKRKNRGKDLSKNSRALRRLRTQCERAKRTLSSSTQATIEID 
cKHSP70-1  230 HLGGEDFDNRMVNHFVEEFKRKHK-RDIAGNKRAVRRLRTACERAKRTLSSSTQASIEID 
hHSP70-1   227 HLGGEDFDNRLVNHFVEEFKRKHK-KDISQNKRAVRRLRTACERAKRTLSSSTQASLEID 
               **********:**. **:****:: :*:: *.**:***** **************::*** 
 
 
PfHSP70-1  299 SLFEGIDYSVTVSRARFEELCIDYFRDTLIPVEKVLKDAMMDKKSVHEVVLVGGSTRIPK 
cKHSP70-1  289 SLFEGIDFYTSITRARFEELNADLFRGTLEPVEKALRDAKLDKGQIQEIVLVGGSTRIPK 
hHSP70-1   286 SLFEGIDFYTSITRARFEELCSDLFRSTLEPVEKALRDAKLDKAQIHDLVLVGGSTRIPK 
               *******: .:::*******  * **.** ****.*:** :** .::::*********** 
 
 
PfHSP70-1  359 IQTLIKEFFNGKEACRSINPDEAVAYGAAVQAAILSGDQSNAVQDLLLLDVCSLSLGLET 
cKHSP70-1  349 IQKLLQDFFNGKELNKSINPDEAVAYGAAVQAAILMGDKSENVQDLLLLDVTPLSLGIET 
hHSP70-1   346 VQKLLQDFFNGRDLNKSINPDEAVAYGAAVQAAILMGDKSENVQDLLLLDVAPLSLGLET 




PfHSP70-1  419 AGGVMTKLIERNTTIPAKKSQIFTTYADNQPGVLIQVYEGERALTKDNNLLGKFHLDGIP 
cKHSP70-1  409 AGGVMTALIKRNTTIPTKQTQTFTTYSDNQSSVLVQVYEGERAMTKDNNLLGKFDLTGIP 
Connect 1 region PO4-2 Binding domain 
Adenosine 
Binding region 
β-Subdomain (Peptide substrate binding) 
Connect 2 region 
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hHSP70-1   406 AGGVMTALIKRNSTIPTKQTQIFTTYSDNQPGVLIQVYEGERAMTKDNNLLGRFELSGIP 
               ****** **:**:***:*::* ****:*** .**:********:********:*.* *** 
 
PfHSP70-1  479 PAPRKVPQIEVTFDIDANGILNVTAVEKSTGKQNHITITNDKGRLSQDEIDRMVNDAEKY 
cKHSP70-1  469 PAPRGVPQIEVTFDIDANGILNVSAVDKSTGKENKITITNDKGRLSKDDIDRMVQEAEKY 
hHSP70-1   466 PAPRGVPQIEVTFDIDANGILNVTATDKSTGKANKITITNDKGRLSKEEIERMVQEAEKY 
               **** ******************:*.:***** *:***********:::*:***::**** 
 
 
PfHSP70-1  539 KAEDEENRKRIEARNSLENYCYGVKSSLEDQKIKEKLQPAEIETCMKTITTILEWLEKNQ 
cKHSP70-1  529 KAEDEANRDRVGAKNSLESYTYNMKQTVEDEKLKGKISDQDKQKVLDKCQEVISWLDRNQ 
hHSP70-1   526 KAEDEVQRERVSAKNALESYAFNMKSAVEDEGLKGKISEADKKKVLDKCQEVISWLDANT 
               ***** :*.*: *:*:**.* :.:*.::**: :* *:.  : :. :..   ::.**: *  
PfHSP70-1  599 LAGKDEYEAKQKEAESVCAPIMSKIYQDAAGAAGGMPGGMPGGMPGGMPSGMPGGMNFPG 
cKHSP70-1  589 MAEKEEYEHKQKELEKLCNPIVTKLYQGAGGAGAGGSG---------------------- 
hHSP70-1   586 LAEKDEFEHKRKELEQVCNPIISGLYQGAGGPGPGGFGAQ-------------------- 
               :* *:*:* *:** *.:* **:: :**.*.* . *  *                       
 
PfHSP70-1  661 GMPGAGMPGNAPAGSGPTVEEVD 
cKHSP70-1  626 ---------------GPTIEEVD 
hHSP70-1   625 -----G--PKGGSGSGPTIEEVD 
                              ***:****  
Figure 4.6 Predication of acetylation sites in the sequence of PfHSP70-1 aligned with chicken (Gallus 
gallus) cKHSP70-1 and human (Homo sapien) hHSP70-1 using PAIL. Dark red colour (with letter K) potential 
lysine acetylation sites by PAIL in the PfHSP70-1 sequence. Dark green phosphate 1 binding region, red 
phosphate 2 binding region, yellow connect 1 region, light green connect 2 region, light blue the adenosine 
binding region, purple β-subdomain for peptide substrate binding, grey α-helical subdomain for hinge and lid 
region, greenish is the EEVD mortif. Within the α-subdomain the blue, green and pink colours shows the position 
of the 3 immunogenic peptide sequences predicted by Predict7™. 
 
The program, “prediction of acetylation on internal lysine” (PAIL) 
(bdmpail.biocuckoo.org/predictions.php/) which was used to generate the data in Figure 4.4 (A, B 
and E), predicted 17 possible lysine acetylation sites for native PfLDH and 32 for native 
PfHSP70-1.  The position of the predicted acetylation sites are shown in Figure 4.5 and Figure 
4.6 on the aligned sequences of PfLDH and PfHSP70-1, respectively with chicken and human 
sequences for each protein. The position of the predicted potential lysine acetylation sites 
relative to the important amino acid residues in the active sites of each protein can be seen on 
Figure 4.5 and 4.6. Should lysine acetylation occur near or close to essential catalytic residues in 
the active site and this lysine acetylation is conserved in the species, this may alter activity of the 
native protein. Another program NetAcet (www.cbs.dtu.dk/services/NetAcet/) predicts substrates 
of N-acetyltransferase A (NatA) in acetylation (Kiemer et al., 2004). NetAcet predicted no 
α-Helical subdomain (Lid and hinge region) 
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acetylation site for PfLDH and one acetylation site for PfHSP70-1 as shown in Figure 4.4 (C, D 
and F). Another important factor is the surface probability of the acetylated lysine residue, 
because only the acetylated sites on the surface would interfere with the activity of the protein. 
Only acetylated lysine residues on the surface of the native protein can interact with antibodies. 
Crystal structure analysis is required to determine which lysines are on the surface. Miao et al., 
2013 and Zhao et al., 2010 showed that Plasmodium proteins like many parasitic proteins are 
acetylated. 
Zhao et al., (2013) demonstrated that human LDH-A in tumour cells is acetylated at 
lysine 5 (K5) and that acetylation inhibits LDH-A activity. Furthermore, the K5 acetylated LDH-A 
is recognised by the HSC70 chaperone and delivered to lysosomes for degradation (Zhao et al., 
2013). Neumann et al., (2008) showed that a genetically modified Nε-acetyllysine recombinant 
protein produced in E. coli that produces 100% acetylated LDH-A at K5 had less enzyme activity 
compared to un-acetylated LDH-A activity. In addition, K5 acetylation lead to a time-dependent 
reduction of LDH-A protein levels. The K5 of PfLDH is a conserved lysine in chicken, muscle and 
heart LDH, and may, therefore, be acetylated. If that is the case, then the activity of native PfLDH 
has the potential to alter enzyme activity. Because human LDH and PfLDH are conserved 
proteins, it would, therefore, be interesting to observe if K5 on PfLDH is acetylated in vivo and 
does this influence PfLDH activity in the parasite. Then it may be responsible for reduced 
sensitivity in the detection of parasitemia and drug sensitivity assay using PfLDH (Makler and 
Hinrichs, 1993; Makler et al., 1993). The numbering of amino acid residues in LDH is based on 
the standard N numbering system (Evenhoff et al., 1977; Gomez et al., 1997).  
Yang et al., 2013 demonstrated that cellular stresses could influence increase in 
intracellular levels of acetylated HSP70s (HSP72, HSP70-1, HSPAIA, GRP78), which bind to 
Beclin-I-Vps 34 complex and promote KAPI-dependent SUMOylation and activity of Vps34. 
These findings add to accumulating evidence that supports the role of HSP70 and HSP90 in 
stabilising and promoting the activity of the molecular effectors upstream in the AV formation, 
such as ULKI and downstream in the AV expansion and fusion with lysosome (Yang et al., 
2013). Most of the predicted potential lysine acetylation sites were far from key catalytic domain 
of PfHSP70-1.The interesting acetylation sites were K563, K574 and K602 which are found in the 
α-helical subdomain of PfHSP70-1 and conserved in chicken and humans HSP70 proteins. The 
K563, K574 and K602 acetylations may affect the activity of the native protein if they are 
acetylated as they have a higher possibility of being on the surface in P. falciparum, Chicken and 
Human HSP70-1. If poly-clonal antibodies against of the whole PfHSP70-1 were produced in 
chicken and tested on the native protein, there may be a possibility of reduced recognition due to 
acetylation of K563, K574 and K602. HSP70 proteins are highly conserved proteins and 
investigation will show if PfHSP70-1 acetylation has an effect on the interaction with antibodies 
raised against the recombinant proteins. 
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The results showed potential acetylation sites in both PfLDH and PfHSP70-1 and that similar 
proteins in humans are acetylated. Human LDH and HSP70 acetylation alter the activities of 
these proteins. It would be interesting to study the effect of acetylation of Plasmodial LDH and 
PfHSP70-1 in human blood with malaria. 
 
4.3.2 Phosphorylation 
Phosphorylation is a post-translational modification of proteins in which amino acid 
residues threonine, serine or tyrosine undergo the addition of a phosphate group covalently 
bonded by a protein kinase. Protein phosphorylation is the most fundamental molecular 
mechanism through which protein function is regulated in response to extracellular stimuli. 
Virtually all types of extracellular signals, including neurotransmitters, light, hormones, cytokines, 
neurotropic factors, energy management and cell regulation, produce their diverse physiological 
effects by regulating the phosphorylation of specific phosphoproteins in their target cells. 
Potential phosphorylation sites on PfLDH and PfHSP70-1 were predicted using a 
phosphorylation predicting algorithm Kinasephos (Huang et al., 2005a; Huang et al., 2005b; 
Hong et al., 2007) at www.kinasephos.mbc.nctu.edu.tw/predict.php/. Phosphorylation plays an 
important role in protein function modification by either activating or deactivating many enzyme, 
thereby regulating their function (Nestler et al., 1984). Peace et al., (2013) identified 2767 
proteins, 1337 phosphoproteins, and 6293 phosphrylation sites in P. falciparum. Post 
translational regulatory mechanisms have dominant roles in regulation of intraerythrocytic gene 
expression. Lasonder et al., (2015) identified merozoite proteasome revealing 1765 unique 
phosphorylation sites, including 785 phosphorylation sites previously identified in schizonts. 
These merozoite phosphorylation interaction network, a subnet of 119 proteins with potential 
roles in cellular movement and invasion. Wu et al., 2009 also showed that P. falciparum 






Predicted phosphorylated site 
Serine (S) Threonine (T) Tyrosine (Y) 
PfLDH 3 0 1 





 MAPKAKIVLV GSGMIGGVMA TLIVQKNLGD VVLFDIVKNM PHGKALDTSH TNVMAYSNCK 60  
 
VSGSNTYDDL AGADVVIVTA GFTKAPGKSD KEWNRDDLLP LNNKIMIEIG GHIKKNCPNA 120 
77 
 
------Y--- ---------- ---------- ---------- ---------- ---------- INSR 
------Y--- ---------- ---------- ---------- ---------- ---------- Syk 
 
FIIVVTNPVD VMVQLLHQHS GVPKNKIIGL GGVLDTSRLK YYISQKLNVC PRDVNAHIVG 180 
---------- ---------- ---------- ---------- ---S------ ---------- ATM 
 
AHGNKMVLLK RYITVGGIPL QEFINNKLIS DAELEAIFDR TVNTALEIVN LHASPYVAPA 240 
---------- ---------- ---------S ---------- ---------- ---------- CKII 
 
AAIIEMAESY LKDLKKVLIC STLLEGQYGH SDIFGGTPVV LGANGVEQVI ELQLNSEEKA 300 
--------S- ---------- ---------- ---------- ---------- ---------- PKG 
 
KFDEAIAETK RMKALA 316  
C 
PfHSP70-1 
MASAKGSKPN LPESNIAIGI DLGTTYSCVG VWRNENVDII ANDQGNRTTP SYVAFTDTER 60  
------S--- ---------- ---------- ---------- ---------- ---------- PKG 
---------- ---------- ---------- ---------- --------T- ---------- MAPK 
 
LIGDAAKNQV ARNPENTVFD AKRLIGRKFT ESSVQSDMKH WPFTVKSGVD EKPMIEVTYQ 120 
---------- ---------- ---------T ---------- ---------- ---------- PKC 
---------- ---------- ---------T ---------- ---------- ---------- PKA 
---------- ---------- ---------- --S------- ---------- ---------- CKII 
 
GEKKLFHPEE ISSMVLQKMK ENAEAFLGKS IKNAVITVPA YFNDSQRQAT KDAGTIAGLN 180 
---------- ---------- ---------- ---------- ---------T ---------- PKC 
---------- ---------- ---------- ---------- ---------T ---------- PKA 
 
VMRIINEPTA AAIAYGLHKK GKGEKNILIF DLGGGTFDVS LLTIEDGIFE VKATAGDTHL 240 
 
GGEDFDNRLV NFCVEDFKRK NRGKDLSKNS RALRRLRTQC ERAKRTLSSS TQATIEIDSL 300 
---------- ---------- ---------- ---------- -----T---- ---------- PKC 
---------- ---------- ---------- ---------- -----T---- ---------- PKA 
---------- ---------- ---------- ---------- -------S-- ---------- PKG 
---------- ---------- ---------- ---------- -------S-- ---------- CKI 
---------- ---------- ---------- ---------- -------S-- ---------- IKK 
 
FEGIDYSVTV SRARFEELCI DYFRDTLIPV EKVLKDAMMD KKSVHEVVLV GGSTRIPKIQ 360 
--------T- ---------- ---------- ---------- ---------- ---------- PKC 
 
TLIKEFFNGK EACRSINPDE AVAYGAAVQA AILSGDQSNA VQDLLLLDVC SLSLGLETAG 420 
 
GVMTKLIERN TTIPAKKSQI FTTYADNQPG VLIQVYEGER ALTKDNNLLG KFHLDGIPPA 480 
 
PRKVPQIEVT FDIDANGILN VTAVEKSTGK QNHITITNDK GRLSQDEIDR MVNDAEKYKA 540 
---------- ---------- ---------- ---------- ---S------ ---------- CKII 
---------- ---------- ---------- ---------- ---S------ ---------- PKG 
---------- ---------- ---------- ---------- ---S------ ---------- ATM 




EDEENRKRIE ARNSLENYCY GVKSSLEDQK IKEKLQPAEI ETCMKTITTI LEWLEKNQLA 600 
---------- ---S------ ---------- ---------- ---------- ---------- PKG 
---------- ---------- ----S----- ---------- ---------- ---------- PKG 
 
GKDEYEAKQK EAESVCAPIM SKIYQDAAGA AGGMPGGMPG GMPGGMPGGM NFPGGMPGAG 660 
----Y----- ---------- ---------- ---------- ---------- ---------- EGFR 
----Y----- ---------- ---------- ---------- ---------- ---------- INSR 
----Y----- ---------- ---------- ---------- ---------- ---------- Syk 
---------- ---S------ ---------- ---------- ---------- ---------- PKC 
---------- ---S------ ---------- ---------- ---------- ---------- CKII 
---------- ---S------ ---------- ---------- ---------- ---------- IKK 
 
MPGNAPAGSG PTVEEVD 677 
---------- -T----- PKC  
Figure 4.7 Predicted phosphorylation sites on the PfLDH and PfHSP70-1 amino acid sequences using 
Kinasephos. A is the table showing the number of predicted sites, and B and C the position of the predicted 




PfLDH    1 -----------------MAPKAKIVLVGSGMIGGVMATLIVQKNLGD-VVLFDIVKNMPH 
mLDH     1 -ATLKDQLIYNLLK-EEQTPQNKITVVGVGAVGMACAISILMKDLADELALVDVIEDKLK 
ckLDH    1 MATLKEKLITPVAA-GSTVPSNKITVVGVGQVGMACAISILGKGLCDELALVDVLEDKLK 
htLDH    1 -ATLKEKLIAPVAEEEATVPNNKITVVGVGQVGMACAISILGKSLADELALVDVLEDKLK 
                             .*. **.:** * :* . *  *: *.* * :.*.*::::  : 
 
 
PfLDH   43 GKALDTSHTNVMAYSNCKVSGSNTYDDLAGADVVIVTAGFTKAPGKSDKEWNRDDLLPLN 
mLDH    59 GEMMDLQHGSLFLR-TPKIVSGKDYNVTANSKLVIITAGARQQEGESRLN-----LVQRN 
ckLDH   60 GEMMDLQHGSLFLQ-THKIVADKDYAVTANSKIVVVTAGVRQQEGESRLN-----LVQRN 
htLDH   60 GEMMDLQHGSLFLQ-TPKIVADKDYSVTANSKIVVVTAGVRQQEGESRLN-----LVQRN 
           *: :* .* .::   . *: ..: *   *.:.:*::***  :  *:*  :     *:  * 
 
PfLDH  103 NKIMIEIGGHIKKNCPNAFIIVVTNPVDVMVQLLHQHSGVPKNKIIGLGGVLDTSRLKYY 
mLDH   113 VNIFKFIIPNVVKYSPNCKLLIVSNPVDILTYVAWKISGFPKNRVIGSGCNLDSARFRYL 
ckLDH  114 VNVFKFIIPQIVKYSPNCTILVVSNPVDILTYVTWKLSGLPKHRVIGSGCNLDTARFRYL 
htLDH  114 VNVFKFIIPQIVKYSPDCIIIVVSNPVDILTYVTWKLSGLPKHRVIGSGCNLDSARFRYL 
            :::  *  :: * .*:. :::*:****::. :  : **.**:::** *  **::*::*  
 
PfLDH  163 ISQKLNVCPRDVNAHIVGAHGNKMVLLKRYITVGGIPLQEFINNKLIS--DAELEAIFDR 
mLDH   173 MGERLGVHPLSCHGWVLGEHGDSSVPVWSGMNVAGVSLKTLHPDLGTDKDKEQWKEVHKQ 
ckLDH  174 MAERLGIHPTSCHGWILGEHGDSSVAVWSGVNVAGVSLQELNPAMGTDKDSENWKEVHKQ 
htLDH  174 MAEKLGIHPSSCHGWILGEHGDSSVAVWSGVNVAGVSLQELNPEMGTDNDSENWKEVHKM 




PfLDH  221 TVNTALEIVNLHASPYVAPAAAIIEMAESYLKDLKKVLICSTLLEGQYGH-SDIFGGTPV 
mLDH   233 VVESAYEVIKLKGYTSWAIGLSVADLAESIMKNLRRVHPVSTMIKGLYGIKDDVFLSVPC 
ckLDH  234 VVESAYEVIRLKGYTNWAIGLSVAELCETMLKNLYRVHSVSTLVKGTYGIENDVFLSLPC 
htLDH  234 VVESAYEVIKLKGYTNWAIGLSVADLIESMLKNLSRIHPVSTMVKGMYGIENEVFLSLPC 
           .*::* *::.*:.    * . :: :: *: :*:* ::   **:::* **  .::* . *  
 
PfLDH  280 VLGANGVEQVIELQLNSEEKAKFDEAIAET----KRMKALA 
mLDH   293 ILGQNGISDLVKVTLTSEEEARLKKSADTLWGIQKELQF-- 
ckLDH  294 VLSASGLTSVINQKLKDDEVAQLKKSADTLWSIQKDLKDL- 
htLDH  294 ILNARGLTSVINQKLKDDEVAQLKKSADTLWDIQKDLKDL- 
           :*.  *: .:::  *..:* *::.::        * :: 
Figure 4.8 Predicted phosphorylation sites on the PfLDH sequence with the key catalytic amino acids in 
the active site of PfLDH aligned with chicken (Gallus Gallus ) cKLDH and human (Homo sapien) mLDH 
using Kinasephos. The light green colour (with letter Y) show the positions of predicted potential tyrosine 
phosphorylation sites by Kinasephos in the PfLDH sequence. Light blue (with letter S) potential serine 
phosphorylation sites. Light red conserved arginine 109 and 171, purple conserved aspartic acid 168, yellow 
conserved histidine 195 are conserved amino-acid residues in the active site of LDH sequence. Dark blue 
threonine 246 and the greenish isoleucine 250 are residues in the cofactor binding site of LDH are substituted by 
proline residues in PfLDH. The numbering of these conserved essential catalytic amino acids is based on the 






PfHSP70-1    1 MASAKGSKPNLPESNIAIGIDLGTTYSCVGVWRNENVDIIANDQGNRTTPSYVAFTDTER 
cKHSP70-1    1 ----------MSGKGPAIGIDLGTTYSCVGVFQHGKVEIIANDQGNRTTPSYVAFTDTER 
hHSP70-1     1 -----------MAKAAAIGIDLGTTYSCVGVFQHGKVEIIANDQGNRTTPSYVAFTDTER 
                            .  ***************::: :*:********************** 
 
PfHSP70-1   61 LIGDAAKNQVARNPENTVFDAKRLIGRKFTESSVQSDMKHWPFTVKSGVDEKPMIEVTYQ 
cKHSP70-1   51 LIGDAAKNQVAMNPTNTIFDAKRLIGRKYDDPTVQSDMKHWPFRVVNE-GGKPKVQVEYK 
hHSP70-1    50 LIGDAAKNQVALNPQNTVFDAKRLIGRKFGDPVVQSDMKHWPFQVIND-GDKPKVQVSYK 
               *********** ** **:**********: :  ********** * .  . ** ::* *: 
 
PfHSP70-1  121 GEKKLFHPEEISSMVLQKMKENAEAFLGKSIKNAVITVPAYFNDSQRQATKDAGTIAGLN 
cKHSP70-1  110 GEMKTFFPEEISSMVLTKMKEIAEAYLGKKVQNAVITVPAYFNDSQRQATKDAGTITGLN 
hHSP70-1   109 GDTKAFYPEEISSMVLTKMKEIAEAYLGYPVTNAVITVPAYFNDSQRQATKDAGVIAGLN 




-1 Binding domain 
Connect 1 region 
PO4
-2 Binding domain 
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PfHSP70-1  181 VMRIINEPTAAAIAYGLHKKG--KGEKNILIFDLGGGTFDVSLLTIEDGIFEVKATAGDT 
cKHSP70-1  170 VMRIINEPTAAAIAYGLDKKGTRAGEKNVLIFDLGGGTFDVSILTIEDGIFEVKSTAGDT 
hHSP70-1   169 VLRIINEPTAAAIAYGLDRTG--KGERNVLIFDLGGGTFDVSILTIDDGIFEVKATAGDT 
               *:***************.:.*   **:*:*************:***:*******:***** 
 
PfHSP70-1  239 HLGGEDFDNRLVNFCVEDFKRKNRGKDLSKNSRALRRLRTQCERAKRTLSSSTQATIEID 
cKHSP70-1  230 HLGGEDFDNRMVNHFVEEFKRKHK-RDIAGNKRAVRRLRTACERAKRTLSSSTQASIEID 
hHSP70-1   227 HLGGEDFDNRLVNHFVEEFKRKHK-KDISQNKRAVRRLRTACERAKRTLSSSTQASLEID 
               **********:**. **:****:: :*:: *.**:***** **************::*** 
 
 
PfHSP70-1  299 SLFEGIDYSVTVSRARFEELCIDYFRDTLIPVEKVLKDAMMDKKSVHEVVLVGGSTRIPK 
cKHSP70-1  289 SLFEGIDFYTSITRARFEELNADLFRGTLEPVEKALRDAKLDKGQIQEIVLVGGSTRIPK 
hHSP70-1   286 SLFEGIDFYTSITRARFEELCSDLFRSTLEPVEKALRDAKLDKAQIHDLVLVGGSTRIPK 
               *******: .:::*******  * **.** ****.*:** :** .::::*********** 
 
 
PfHSP70-1  359 IQTLIKEFFNGKEACRSINPDEAVAYGAAVQAAILSGDQSNAVQDLLLLDVCSLSLGLET 
cKHSP70-1  349 IQKLLQDFFNGKELNKSINPDEAVAYGAAVQAAILMGDKSENVQDLLLLDVTPLSLGIET 
hHSP70-1   346 VQKLLQDFFNGRDLNKSINPDEAVAYGAAVQAAILMGDKSENVQDLLLLDVAPLSLGLET 




PfHSP70-1  419 AGGVMTKLIERNTTIPAKKSQIFTTYADNQPGVLIQVYEGERALTKDNNLLGKFHLDGIP 
cKHSP70-1  409 AGGVMTALIKRNTTIPTKQTQTFTTYSDNQSSVLVQVYEGERAMTKDNNLLGKFDLTGIP 
hHSP70-1   406 AGGVMTALIKRNSTIPTKQTQIFTTYSDNQPGVLIQVYEGERAMTKDNNLLGRFELSGIP 
               ****** **:**:***:*::* ****:*** .**:********:********:*.* *** 
 
PfHSP70-1  479 PAPRKVPQIEVTFDIDANGILNVTAVEKSTGKQNHITITNDKGRLSQDEIDRMVNDAEKY 
cKHSP70-1  469 PAPRGVPQIEVTFDIDANGILNVSAVDKSTGKENKITITNDKGRLSKDDIDRMVQEAEKY 
hHSP70-1   466 PAPRGVPQIEVTFDIDANGILNVTATDKSTGKANKITITNDKGRLSKEEIERMVQEAEKY 
               **** ******************:*.:***** *:***********:::*:***::**** 
 
 
PfHSP70-1  539 KAEDEENRKRIEARNSLENYCYGVKSSLEDQKIKEKLQPAEIETCMKTITTILEWLEKNQ 
cKHSP70-1  529 KAEDEANRDRVGAKNSLESYTYNMKQTVEDEKLKGKISDQDKQKVLDKCQEVISWLDRNQ 
hHSP70-1   526 KAEDEVQRERVSAKNALESYAFNMKSAVEDEGLKGKISEADKKKVLDKCQEVISWLDANT 





β-Subdomain (Peptide substrate binding) 
Connect 2 region 
α-Helicalsubdomain (Lid and hinge region) 
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PfHSP70-1  599 LAGKDEYEAKQKEAESVCAPIMSKIYQDAAGAAGGMPGGMPGGMPGGMPSGMPGGMNFPG 
cKHSP70-1  589 MAEKEEYEHKQKELEKLCNPIVTKLYQGAGGAGAGGSG---------------------- 
hHSP70-1   586 LAEKDEFEHKRKELEQVCNPIISGLYQGAGGPGPGGFGAQ-------------------- 
               :* *:*:* *:** *.:* **:: :**.*.* . *  *                       
 
PfHSP70-1  661 GMPGAGMPGNAPAGSGPTVEEVD 
cKHSP70-1  626 ---------------GPTIEEVD 
hHSP70-1   625 -----G--PKGGSGSGPTIEEVD 
                              ***:**** 
  
Figure 4.9 The positions of the predicted phosphorylation sites on the PfHSP70-1 sequence aligned with 
chicken (Gallus Gallus) cKHSP70-1 and human (Homosapien) hHSP70-1 using Kinasephos. The light blue 
colour (with letter S, Y, T) show the positions of predicted potential serine, tyrosine and threonine phosphorylation 
sites by Kinasephos in the PfHSP70-1 sequence. Dark green phosphate 1 binding region, red phosphate 2 
binding region, yellow connect 1 region, light green connect 2 region, light blue the adenosine binding region, 
purple β-subdomain for peptide substrate binding, grey α-helical subdomain for hinge and lid region, greenish is 
the EEVD mortif. Within the α-subdomain the blue, green and pink show the position of the three immunogenic 
peptide sequences predicted by Predict7™. 
  
Figure 4.7 shows that PfLDH has three possible phosphorylation sites on serine residues and 
one on a tyrosine residue and PfHSP70-1 has seven possible phosphorylation sites on serine 
residues, six on threonine and two on tyrosine residues. The position of the predicted 
phosphorylation sites are shown in Figure 4.8 and Figure 4.9 on the aligned sequences of PfLDH 
and PfHSP 70-1 respectively. The position of the predicted potential serine, tyrosine and 
threonine phosphorylation sites relative to the important amino acid residues in the active sites of 
each protein can be seen on Figure 4.8 and 4.9.  
Human LDH-A was found to be directly phosphorylated by the oncogenic receptor tyrosine 
kinase FGFR1. Phosphorylation at tyrosine 10 (Y10) and tyrosine 83 (Y83) enhances LDH-A 
activity by enhancing the formation of active, tetrameric LDH-A and the binding of LDH-A 
substrate NADH, respectively (Fan et al., 2011). The Y10 in PfLDH is not present, but the Y83 
amino acid is present. If Y83 in PfLDH is phosphorylated, it may increase the activity of PfLDH 
like in human LDH-A. Most of the predicted potential phosphorylation sites are located far away 
from the essential catalytic amino acid residues. The numbering of amino acid residues in LDH is 
based on the standard N numbering system (Evenhoff et al., 1977; Gomez et al., 1997). The Y10 
and Y 83 are conserved in the LDH sequence analysed except PfLDH. 
Muller et al., 2011 identified a C-terminal phosphorylation of human HSP70 and HSP90 
as a switch for regulating co-chaperone binding and indicated that cancer cells possess an 
elevated protein folding environment by the concerted action of co-chaperone expression and 
chaperone modification. S574 in the β-subdomain (peptide substrate binding domain) is a 
predicted phosphorylation site that is conserve in P. falciparum, chicken and human LDH, but 
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may not be phosphorylated because of its location. The remaining phosphorylation sites are 
located far from the essential catalytic amino acids. 
Both LDH and HSP70 are conserved proteins in humans and malaria parasites, and it would be 
important to see if native PfLDH and PfHSP70-1 phosphorylation has an effect on the activity of 
these proteins in malaria parasites. It would be interesting also to find out if native PfLDH and 




Glycosylation is post-translational modification by the conjugation of a sugar moiety to 
proteins. Glycosylation is important in a wide range of biological processes, including cell 
attachment to the extracellular matrix, protein-ligand interactions in the cell, monitoring the status 
of protein folding, quality control mechanisms to ensure that only properly folded proteins are 
trafficked to the Golgi, used in export of proteins to proper destination and can alter the solubility 
of a protein because sugars are soluble. N-Glycosylation in P. falciparum may have a role in 
protein targeting and both N- and O- glycosylation occur in P. falciparum (De Macedo et al., 
2010). Parasite proteins were found to bind concanavalin A (Con A) which suggested the 
presence of mannosylated glycans (Kilejian and Olson, 1979). Later, Kilejian and Olson, (1980) 
demonstrated the presence of glycoproteins in the late trophozoite stage by radioactive labelling 
with glucosamine.  Gowda and Davidson, (1999) also discussed, in their review, that N- and O- 
glycosylation were present in P. falciparum and glycosylation may influence activation of a signal 
pathway in host cells, and thereby induce expression of cytokines, adhesion molecules and 
induced nitric oxide synthase (Gowda et al., 1997). Cova et al., (2015) suggests that P. 
falciparum protein glycosylation is important for parasite survival. Types of glycosylation include 
N-, O-, C-, glypiation and phosphoglycoslation. 
O-Glycosylation of PfLDH and PfHSP70-1 predictions were done according to Gupta et al., 1999 
using a predicting program known as DictyOGlyc (www.cbs.dtu.dk/services/DictyOGlyc/). 
 
A 
Name:  PfLDH  Length:  316 
MAPKAKIVLVGSGMIGGVMATLIVQKNLGDVVLFDIVKNMPHGKALDTSHTNVMAYSNCKVSGSNTYDDLAGADVVIVTA      80 
GFTKAPGKSDKEWNRDDLLPLNNKIMIEIGGHIKKNCPNAFIIVVTNPVDVMVQLLHQHSGVPKNKIIGLGGVLDTSRLK     160 
YYISQKLNVCPRDVNAHIVGAHGNKMVLLKRYITVGGIPLQEFINNKLISDAELEAIFDRTVNTALEIVNLHASPYVAPA     240 
AAIIEMAESYLKDLKKVLICSTLLEGQYGHSDIFGGTPVVLGANGVEQVIELQLNSEEKAKFDEAIAETKRMKALA 
................................................................................      80 
........G.......................................................................     160 







Name    Residue   Number   Potential Threshold   Assignment 
PfLDH     Ser     0012    0.0683     0.7863       .   
PfLDH     Thr     0021    0.0140     0.8543       .   
PfLDH     Thr     0048    0.0191     0.5915       .   
PfLDH     Ser     0049    0.0193     0.5845       .   
PfLDH     Thr     0051    0.0139     0.6325       .   
PfLDH     Ser     0057    0.0160     0.6764       .   
PfLDH     Ser     0062    0.0133     0.5496       .   
PfLDH     Ser     0064    0.0314     0.5636       .   
PfLDH     Thr     0066    0.0173     0.5366       .   
PfLDH     Thr     0079    0.0152     0.7823       .   
PfLDH     Thr     0083    0.2749     0.5795       .   
PfLDH     Ser     0089    0.4551     0.3807       G   
PfLDH     Thr     0126    0.0419     0.7733       .   
PfLDH     Ser     0140    0.1257     0.5745       .   
PfLDH     Thr     0156    0.0109     0.6744       .   
PfLDH     Ser     0157    0.0309     0.6175       .   
PfLDH     Ser     0164    0.0749     0.6714       .   
PfLDH     Thr     0194    0.0214     0.7084       .   
PfLDH     Ser     0210    0.0211     0.6055       .   
PfLDH     Thr     0221    0.0660     0.6185       .   
PfLDH     Thr     0224    0.0118     0.6684       .   
PfLDH     Ser     0234    0.1610     0.6585       .   
PfLDH     Ser     0249    0.0515     0.6555       .   
PfLDH     Ser     0261    0.1525     0.7843       .   
PfLDH     Thr     0262    0.0130     0.7314       .   
PfLDH     Ser     0271    0.3547     0.6575       .   
PfLDH     Thr     0277    0.6417     0.6754       .   
PfLDH     Ser     0296    0.0256     0.4796       .   







Name:  PfHsp70-1  Length:  677 
MASAKGSKPNLPESNIAIGIDLGTTYSCVGVWRNENVDIIANDQGNRTTPSYVAFTDTERLIGDAAKNQVARNPENTVFD      80 
AKRLIGRKFTESSVQSDMKHWPFTVKSGVDEKPMIEVTYQGEKKLFHPEEISSMVLQKMKENAEAFLGKSIKNAVITVPA     160 
YFNDSQRQATKDAGTIAGLNVMRIINEPTAAAIAYGLHKKGKGEKNILIFDLGGGTFDVSLLTIEDGIFEVKATAGDTHL     240 
GGEDFDNRLVNFCVEDFKRKNRGKDLSKNSRALRRLRTQCERAKRTLSSSTQATIEIDSLFEGIDYSVTVSRARFEELCI     320 
DYFRDTLIPVEKVLKDAMMDKKSVHEVVLVGGSTRIPKIQTLIKEFFNGKEACRSINPDEAVAYGAAVQAAILSGDQSNA     400 
VQDLLLLDVCSLSLGLETAGGVMTKLIERNTTIPAKKSQIFTTYADNQPGVLIQVYEGERALTKDNNLLGKFHLDGIPPA     480 
PRKVPQIEVTFDIDANGILNVTAVEKSTGKQNHITITNDKGRLSQDEIDRMVNDAEKYKAEDEENRKRIEARNSLENYCY     560 
GVKSSLEDQKIKEKLQPAEIETCMKTITTILEWLEKNQLAGKDEYEAKQKEAESVCAPIMSKIYQDAAGAAGGMPGGMPG     640 
GMPGGMPGGMNFPGGMPGAGMPGNAPAGSGPTVEEVD 
................................................................................      80 
................................................................................     160 
................................................................................     240 
................................................................................     320 
................................................................................     400 
................................................................................     480 
................................................................................     560 





Name     Residue     Number    Potential  Threshold   Assignment 
PfHsp70-1     Ser     0003    0.0427     0.5406       .   
PfHsp70-1     Ser     0007    0.0516     0.4966       .   
PfHsp70-1     Ser     0014    0.0212     0.6984       .   
PfHsp70-1     Thr     0024    0.0120     0.7424       .   
PfHsp70-1     Thr     0025    0.0604     0.7833       .   
PfHsp70-1     Ser     0027    0.1140     0.7823       .   
PfHsp70-1     Thr     0048    0.0214     0.5785       .   
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PfHsp70-1     Thr     0049    0.0273     0.6155       .   
PfHsp70-1     Ser     0051    0.4669     0.7024       .   
PfHsp70-1     Thr     0056    0.0174     0.7474       .   
PfHsp70-1     Thr     0058    0.0293     0.7114       .   
PfHsp70-1     Thr     0077    0.0265     0.6645       .   
PfHsp70-1     Thr     0090    0.0146     0.6525       .   
PfHsp70-1     Ser     0092    0.1980     0.6964       .   
PfHsp70-1     Ser     0093    0.0347     0.6635       .   
PfHsp70-1     Ser     0096    0.0297     0.6595       .   
PfHsp70-1     Thr     0104    0.0156     0.7164       .   
PfHsp70-1     Ser     0107    0.0425     0.6575       .   
PfHsp70-1     Thr     0118    0.0356     0.7394       .   
PfHsp70-1     Ser     0132    0.0407     0.7713       .   
PfHsp70-1     Ser     0133    0.4580     0.8183       .   
PfHsp70-1     Ser     0150    0.1532     0.6535       .   
PfHsp70-1     Thr     0157    0.0809     0.8233       .   
PfHsp70-1     Ser     0165    0.0175     0.6085       .   
PfHsp70-1     Thr     0170    0.0101     0.5426       .   
PfHsp70-1     Thr     0175    0.0154     0.6984       .   
PfHsp70-1     Thr     0189    0.0210     0.6894       .   
PfHsp70-1     Thr     0216    0.0748     0.7304       .   
PfHsp70-1     Ser     0220    0.0149     0.8283       .   
PfHsp70-1     Thr     0223    0.0155     0.7853       .   
PfHsp70-1     Thr     0234    0.0105     0.6784       .   
PfHsp70-1     Thr     0238    0.0235     0.6625       .   
PfHsp70-1     Ser     0267    0.0161     0.5646       .   
PfHsp70-1     Ser     0270    0.0179     0.6305       .   
PfHsp70-1     Thr     0278    0.0344     0.6575       .   
PfHsp70-1     Thr     0286    0.0151     0.6005       .   
PfHsp70-1     Ser     0288    0.0434     0.6335       .   
PfHsp70-1     Ser     0289    0.0485     0.6445       .   
PfHsp70-1     Ser     0290    0.0223     0.6645       .   
PfHsp70-1     Thr     0291    0.0119     0.6555       .   
PfHsp70-1     Thr     0294    0.0109     0.7264       .   
PfHsp70-1     Ser     0299    0.1401     0.7484       .   
PfHsp70-1     Ser     0307    0.2203     0.7853       .   
PfHsp70-1     Thr     0309    0.0449     0.7683       .   
PfHsp70-1     Ser     0311    0.1890     0.7444       .   
PfHsp70-1     Thr     0326    0.0876     0.7384       .   
PfHsp70-1     Ser     0343    0.0423     0.6355       .   
PfHsp70-1     Ser     0353    0.0897     0.7264       .   
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PfHsp70-1     Thr     0354    0.2519     0.6974       .   
PfHsp70-1     Thr     0361    0.0344     0.7244       .   
PfHsp70-1     Ser     0375    0.2277     0.6575       .   
PfHsp70-1     Ser     0394    0.1559     0.7064       .     
PfHsp70-1     Ser     0398    0.0143     0.6425       .   
PfHsp70-1     Ser     0411    0.0179     0.8013       .   
PfHsp70-1     Ser     0413    0.0117     0.7923       .   
PfHsp70-1     Thr     0418    0.0116     0.7044       .   
PfHsp70-1     Thr     0424    0.0160     0.7813       .   
PfHsp70-1     Thr     0431    0.1538     0.6305       .   
PfHsp70-1     Thr     0432    0.0155     0.6395       .   
PfHsp70-1     Ser     0438    0.0332     0.6435       .   
PfHsp70-1     Thr     0442    0.0245     0.7494       .   
PfHsp70-1     Thr     0443    0.0304     0.7454       .   
PfHsp70-1     Thr     0463    0.0128     0.6085       .   
PfHsp70-1     Thr     0490    0.0570     0.7923       .   
PfHsp70-1     Thr     0502    0.0139     0.7713       .   
PfHsp70-1     Ser     0507    0.0123     0.5755       .   
PfHsp70-1     Thr     0508    0.0179     0.5396       .   
PfHsp70-1     Thr     0515    0.0162     0.7284       .   
PfHsp70-1     Thr     0517    0.0219     0.6804       .   
PfHsp70-1     Ser     0524    0.0137     0.6265       .   
PfHsp70-1     Ser     0554    0.0130     0.6704       .   
PfHsp70-1     Ser     0564    0.0246     0.6665       .   
PfHsp70-1     Ser     0565    0.0187     0.6505       .   
PfHsp70-1     Thr     0582    0.1213     0.7104       .   
PfHsp70-1     Thr     0586    0.0291     0.7364       .   
PfHsp70-1     Thr     0588    0.0558     0.7574       .   
PfHsp70-1     Thr     0589    0.1031     0.7753       .   
PfHsp70-1     Ser     0614    0.0259     0.7014       .   
PfHsp70-1     Ser     0621    0.2921     0.7494       .   
PfHsp70-1     Ser     0669    0.1299     0.5636       .   






Figure 4.10 The predicted O-glycoslation sites on the PfLDH and PfHSP70-1 amino acid sequences using 
DictyOGlyc. A and D are sequences of PfLDH and PfHSP70-1, respectively with the possible gycosylation sites. 
B and E shows the threshold and the predicted values. C and F is a graphical representation of B and E. 
 
 The program predicted 1 glycosylation site for PfLDH and 1 for PfHSP70-1 as shown in figure 
4.10 A where a G (where the green arrow is pointing), in B where a G is written on serine 0089 
and in C (where the green arrow is pointing) and figure 4.10 D where a G (where the green arrow 
is poiting), threonine 0672 in E and F (where the green arrow is pointing). 
 
N-Glycosylation of PfLDH and PfHSP70-1 was done according to Gupta et al., 2002 
using a predicting program known as NetNGlyc 1.0 (www.cbs.dtu.dk/services/NetNGlyc/). 
A 
Name: PfLDH  Length:  316 
MAPKAKIVLVGSGMIGGVMATLIVQKNLGDVVLFDIVKNMPHGKALDTSHTNVMAYSNCKVSGSNTYDDLAGADV      80  
VIVTAGFTKAPGKSDKEWNRDDLLPLNNKIMIEIGGHIKKNCPNAFIIVVTNPVDVMVQLLHQHSGVPKNKIIGLGGVLD     160  
TSRLKYYISQKLNVCPRDVNAHIVGAHGNKMVLLKRYITVGGIPLQEFINNKLISDAELEAIFDRTVNTALEIVNLHASP     240  
YVAPAAAIIEMAESYLKDLKKVLICSTLLEGQYGHSDIFGGTPVVLGANGVEQVIELQLNSEEKAKFDEAIAETKRMKAL     320  
A 
................................................................................      80 
................................................................................     160 
................................................................................     240 
................................................................................     320 
.                                                                                    400 
(Threshold=0.5) 
B 






Name: PfHSP70-1  Length:  677 
MASAKGSKPNLPESNIAIGIDLGTTYSCVGVWRNENVDIIANDQGNRTTPSYVAFTDTERLIGDAAKNQVARNPENT      80  
VFDAKRLIGRKFTESSVQSDMKHWPFTVKSGVDEKPMIEVTYQGEKKLFHPEEISSMVLQKMKENAEAFLGKSIKNAVIT     160  
VPAYFNDSQRQATKDAGTIAGLNVMRIINEPTAAAIAYGLHKKGKGEKNILIFDLGGGTFDVSLLTIEDGIFEVKATAGD     240  
THLGGEDFDNRLVNFCVEDFKRKNRGKDLSKNSRALRRLRTQCERAKRTLSSSTQATIEIDSLFEGIDYSVTVSRARFEE     320  
LCIDYFRDTLIPVEKVLKDAMMDKKSVHEVVLVGGSTRIPKIQTLIKEFFNGKEACRSINPDEAVAYGAAVQAAILSGDQ     400  
SNVQDLLLLDVCSLSLGLETAGGVMTKLIERNTTIPAKKSQIFTTYADNQPGVLIQVYEGERALTKDNNLLGKFHLDGIP     480  
PAPRKVPQIEVTFDIDANGILNVTAVEKSTGKQNHITITNDKGRLSQDEIDRMVNDAEKYKAEDEENRKRIEARNSLENY     560  
CYGVKSSLEDQKIKEKLQPAEIETCMKTITTILEWLEKNQLAGKDEYEAKQKEAESVCAPIMSKIYQDAAGAAGGMPGGM     640  
PGGMPGGMPGGMNFPGGMPGAGMPGNAPAGSGPTVEEVD 
................................................N...............................      80 
................................................................................     160 
.....N..........................................................................     240 
................................................................................     320 
................................................................................     400 
...............................N................................................     480 
.....................N..........................................................     560 
................................................................................     640 




SeqName      Position  Potential   Jury    N-Glyc 
     agreement result 
---------------------------------------------------------------------- 
Sequence      49 NRTT   0.6357     (8/9)   +      
Sequence     166 NDSQ   0.5906     (8/9)   +      
Sequence     432 NTTI   0.5696     (7/9)   +      








Figure 4.11 Predicted N-glycosylation sites on PfLDH and PfHSP70-1 amino acid sequences using 
NetNGlyc. A and D are sequences of PfLDH and PfHSP70-1, respectively with the possible gycosylation sites. B 




PfHSP70-1    1 MASAKGSKPNLPESNIAIGIDLGTTYSCVGVWRNENVDIIANDQGNRTTPSYVAFTDTER 
cKHSP70-1    1 ----------MSGKGPAIGIDLGTTYSCVGVFQHGKVEIIANDQGNRTTPSYVAFTDTER 
hHSP70-1     1 -----------MAKAAAIGIDLGTTYSCVGVFQHGKVEIIANDQGNRTTPSYVAFTDTER 
                            .  ***************::: :*:********************** 
 
PfHSP70-1   61 LIGDAAKNQVARNPENTVFDAKRLIGRKFTESSVQSDMKHWPFTVKSGVDEKPMIEVTYQ 
cKHSP70-1   51 LIGDAAKNQVAMNPTNTIFDAKRLIGRKYDDPTVQSDMKHWPFRVVNE-GGKPKVQVEYK 
hHSP70-1    50 LIGDAAKNQVALNPQNTVFDAKRLIGRKFGDPVVQSDMKHWPFQVIND-GDKPKVQVSYK 
               *********** ** **:**********: :  ********** * .  . ** ::* *: 
 
PfHSP70-1  121 GEKKLFHPEEISSMVLQKMKENAEAFLGKSIKNAVITVPAYFNDSQRQATKDAGTIAGLN 
cKHSP70-1  110 GEMKTFFPEEISSMVLTKMKEIAEAYLGKKVQNAVITVPAYFNDSQRQATKDAGTITGLN 
hHSP70-1   109 GDTKAFYPEEISSMVLTKMKEIAEAYLGYPVTNAVITVPAYFNDSQRQATKDAGVIAGLN 
               *: * *.********* **** ***:**  : **********************.*:*** 
 
 
PfHSP70-1  181 VMRIINEPTAAAIAYGLHKKG--KGEKNILIFDLGGGTFDVSLLTIEDGIFEVKATAGDT 
cKHSP70-1  170 VMRIINEPTAAAIAYGLDKKGTRAGEKNVLIFDLGGGTFDVSILTIEDGIFEVKSTAGDT 
PO4
-1 Binding domain 
Connect 1 region PO4
-2 Binding domain 
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hHSP70-1   169 VLRIINEPTAAAIAYGLDRTG--KGERNVLIFDLGGGTFDVSILTIDDGIFEVKATAGDT 
               *:***************.:.*   **:*:*************:***:*******:***** 
 
PfHSP70-1  239 HLGGEDFDNRLVNFCVEDFKRKNRGKDLSKNSRALRRLRTQCERAKRTLSSSTQATIEID 
cKHSP70-1  230 HLGGEDFDNRMVNHFVEEFKRKHK-RDIAGNKRAVRRLRTACERAKRTLSSSTQASIEID 
hHSP70-1   227 HLGGEDFDNRLVNHFVEEFKRKHK-KDISQNKRAVRRLRTACERAKRTLSSSTQASLEID 
               **********:**. **:****:: :*:: *.**:***** **************::*** 
 
 
PfHSP70-1  299 SLFEGIDYSVTVSRARFEELCIDYFRDTLIPVEKVLKDAMMDKKSVHEVVLVGGSTRIPK 
cKHSP70-1  289 SLFEGIDFYTSITRARFEELNADLFRGTLEPVEKALRDAKLDKGQIQEIVLVGGSTRIPK 
hHSP70-1   286 SLFEGIDFYTSITRARFEELCSDLFRSTLEPVEKALRDAKLDKAQIHDLVLVGGSTRIPK 
               *******: .:::*******  * **.** ****.*:** :** .::::*********** 
 
 
PfHSP70-1  359 IQTLIKEFFNGKEACRSINPDEAVAYGAAVQAAILSGDQSNAVQDLLLLDVCSLSLGLET 
cKHSP70-1  349 IQKLLQDFFNGKELNKSINPDEAVAYGAAVQAAILMGDKSENVQDLLLLDVTPLSLGIET 
hHSP70-1   346 VQKLLQDFFNGRDLNKSINPDEAVAYGAAVQAAILMGDKSENVQDLLLLDVAPLSLGLET 




PfHSP70-1  419 AGGVMTKLIERNTTIPAKKSQIFTTYADNQPGVLIQVYEGERALTKDNNLLGKFHLDGIP 
cKHSP70-1  409 AGGVMTALIKRNTTIPTKQTQTFTTYSDNQSSVLVQVYEGERAMTKDNNLLGKFDLTGIP 
hHSP70-1   406 AGGVMTALIKRNSTIPTKQTQIFTTYSDNQPGVLIQVYEGERAMTKDNNLLGRFELSGIP 
               ****** **:**:***:*::* ****:*** .**:********:********:*.* *** 
 
PfHSP70-1  479 PAPRKVPQIEVTFDIDANGILNVTAVEKSTGKQNHITITNDKGRLSQDEIDRMVNDAEKY 
cKHSP70-1  469 PAPRGVPQIEVTFDIDANGILNVSAVDKSTGKENKITITNDKGRLSKDDIDRMVQEAEKY 
hHSP70-1   466 PAPRGVPQIEVTFDIDANGILNVTATDKSTGKANKITITNDKGRLSKEEIERMVQEAEKY 
               **** ******************:*.:***** *:***********:::*:***::**** 
 
 
PfHSP70-1  539 KAEDEENRKRIEARNSLENYCYGVKSSLEDQKIKEKLQPAEIETCMKTITTILEWLEKNQ 
cKHSP70-1  529 KAEDEANRDRVGAKNSLESYTYNMKQTVEDEKLKGKISDQDKQKVLDKCQEVISWLDRNQ 
hHSP70-1   526 KAEDEVQRERVSAKNALESYAFNMKSAVEDEGLKGKISEADKKKVLDKCQEVISWLDANT 
               ***** :*.*: *:*:**.* :.:*.::**: :* *:.  : :. :..   ::.**: *  
 
 
PfHSP70-1  599 LAGKDEYEAKQKEAESVCAPIMSKIYQDAAGAAGGMPGGMPGGMPGGMPSGMPGGMNFPG 
cKHSP70-1  589 MAEKEEYEHKQKELEKLCNPIVTKLYQGAGGAGAGGSG---------------------- 
Adenosine 
Binding region 
β-Subdomain (Peptide substrate binding) 
Connect 2 region 
α-Helicalsubdomain (Lid and hinge region) 
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hHSP70-1   586 LAEKDEFEHKRKELEQVCNPIISGLYQGAGGPGPGGFGAQ-------------------- 
               :* *:*:* *:** *.:* **:: :**.*.* . *  *                       
 
PfHSP70-1  661 GMPGAGMPGNAPAGSGPTVEEVD 
cKHSP70-1  626 ---------------GPTIEEVD 
hHSP70-1   625 -----G--PKGGSGSGPTIEEVD 
                              ***:**** 
 Figure 4.12 Predicted N-glycosylation sites on the PfHSP70-1 sequence aligned with chicken (Gallus 
Gallus) cKHSP70-1) and human (Homo sapien) hHSP70-1) using NetNGlyc. The light blue colour (with letter 
N) show the positions of predicted potential asparagine glycosylation sites by NetNGlyc in the PfHSP70-1 
sequence. Dark colour phosphate 1 binding region, red phosphate 2 binding region, yellow connect 1 region, light 
green connect 2 region, light blue the adenosine binding region, purple β-subdomain for peptide substrate 
binding, grey α-helical subdomain for hinge and lid region, greenish is the EEVD mortif. Within the α-subdomain 
the blue, green and pink show the position of the 3 immunogenic peptide sequences predicted by Predict7™.  
 
The program predicted no glycosylation sites for PfLDH and four potential glycosylation 
sites for PfHSP70-1 (Figure 4.11 A-D and E where the blue arrows point). The position of the 
predicted N-glycosylation sites in the sequence are shown in Figure 4.12 on the aligned 
sequences of PfHSP 70-1 with chicken and human PfHSP70-1 sequences. The position of the 
predicted potential N-glycosylation sites relative to the important amino acid residues in the 
active site of PfHSP70-1 can be seen in Figure 4.12. The predicted potential glycosylation sites 
N432 and N502 are located in the β-subdomain (the peptide substrate domain) and may not be 
phosphorylated. The other two, N46 and N166 are located far away from the essential catalytic 
residues. The recombinant PfLDH and PfHSP70-1 produced in E. coli are non-glycosylated, but 
the native proteins may be glycosylated leading to differences in their activity compared to the 
recombinant proteins. Glycosylation can be examined in the native protein by digesting with 
neuraminidase, then running an SDS-PAGE gel of the digested and undigested native protein 
and compare the size of the bands. Alternatively, a zymogram of these proteins can be done 
using neuraminidase to cleave off the glucose moiety (Mensah-Brown et al., 2014). 
 
4.3.4 Proteolytic cleavage 
Although recombinant proteins produced in E.coli are not subject to proteolytic digest 
because the host cells lack proteases, native proteins may be cleaved by various proteases. The 
recombinant protein can be subject to protease digestion and probed with antibodies against the 
protein to determine which portion of the protein the antibody binds to. Netcchop 
www.cbs.dtu.dk/services/NetChop/ (Kesmir et al., 2002; Nielsen et al., 2003; Nielsen et al., 2005) 
was used to predict the cleavage sites of PfLDH and PfHSP70-1. The program predicted 92 
cleavage sites for PfLDH and 204 for PfHSP70-1. There are so many predicted sites that the 
data is not shown. Recombinant protein lysate can be immunoprecipitated and an in-gel 
protease digestion can be done ((Dinglasan et al., 2007; Ghosh et al., 2009; Chaerkady et 
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al., 2011), after which immunoprecipitated digested peptides can be analysed on a high 
resolution mass spectrometer (Cha et al., 2016).  
Three peptides were identified in the structure of PfHSP70-1 as potential 
immunogenic peptides by Predict7™ and were found to be located on the α-helical 
subdomain close to the C-terminus of the protein. All the 3 peptides were found to be located 
on the surface of the 3D crystal structure model of PfHSP70-1. 
Potential lysine acetylation sites were identified on both PfLDH and PfHSP70-1. K5 
lysine acetylation on PfLDH is implicated in enzyme activity. The amino acid has been 
shown to be important in human LDH-A as it reduced the activity of human LDH-A. K563, 
K574 and K602 lysine acetylation of PfHSP70-1 may affect activity of the native protein as it 
was found to affect activity of human HSP70-1. Only amino acid residues on the surface of 
the proteins can affect activity of the native proteins because they can interact with 
antibodies. 
Potential phosphorylation sites were identified on both PfLDH and PfHSP70-1. Y83 
of PfLDH may enhance activity of the enzyme as Y83 of human LDH-A was found to 
enhance activity of human LDH-A. The predicted S574 of PfHSP70-1 is found on the β-
subdomain which is less likely to be located on the surface and is far from essential catalytic 
amino acids, and may not affect the activity of PfHSP70-1. 
Potential O-glycosylation sites for both PfLDH and PfHSP70-1 were found. No 
potential N-glycosylation site was found for PfLDH. Four N-glycosylation sites were found on 
PfHSP70-1. N432 and N502 are located in the β-subdomain which is not likely to be on the 
surface and may not be phosphorylated. N46 and N166 are located far away from essential 
catalytic residues, therefore will not affect the activity of the native protein. 92 potential 
cleavage sites for PfLDH and 204 for PfHSP70-1 were identified. Recombinant proteins can 















                                                               Chapter 5 
 
5.1 Brief overview 
Malaria is a global heath burden and an estimated 3.3 billion people are at risk of 
being infected with malaria and 1.2 billion are at high risk (WHO 2014). An estimated 198 
million cases of malaria occurred globally in 2013 and 584 000 deaths were recorded (WHO 
2014). Although malaria control programs in many countries include vector control, treatment 
with artemisinin combination therapy, diagnosis in most remote settings is still problematic 
(Moody, 2002; Kappe et al., 2010; Shiff, 2002). RTS, S/AS01 Vaccine development is in the 
advanced stages of clinical trials (Schwartz et al., 2012). Malaria affects mostly developing 
countries in the tropics, especially sub-Saharan Africa, where there is a lack of infrastructure 
and funding to control the disease (Hay et al., 2009).  
Microscopy is the gold standard for the diagnosis of malaria, but most field clinics 
lack infrastructure, electricity and the experienced manpower needed to use a microscope 
(Moody, 2002; Suh et al., 2004).  Field clinics, therefore, require diagnostic methods that are 
fast, easy to perform and interpret and do not need electricity (Perkins & Bell., 2008; Moody, 
2002; Makler et al., 1998). Various methods have been developed in an attempt to improve 
diagnosis including PCR, flow cytometry, LAMP, DNA aptamers (Gupta et al., 2015; 
Echeverry et al., 2016; Godonoga et al., 2016; Woodrow et al., 2015). Most of the methods 
mentioned require expensive equipment, reagents and skills (Mouatcho & Goldring, 2013).  
Malaria immunochromatographic or rapid diagnostic tests (RDTs) were developed to 
simplify malaria diagnosis as they are fast, easy to use, easy to interpret and do not require 
the use of electricity. RDTs in current use detect Plasmodium falciparum histidine rich 
protein II (PfHRPII), Plasmodium lactate dehydrogenase (LDH) and Plasmodium aldolase 
(Murray et al., 2008; Ashley et al., 2009; Khairnar et al., 2009; Wongrichanalai et al., 2007; 
Leow et al., 2014; Verma et al., 2014; Ho et al., 2014; Shin et al., 2013; Otsuki et al., 2013; 
Miao et al., 2013). The limit of detection is about 200 parasites/µl and takes an average of 5-
20 min to perform (Makler et al., 1998; Murray et al., 2008; Perkins & Bell, 2008; Ashley et 
al., 2009). To detect asymptomatic malaria RDTs require to have a limit of detection of less 
than 100 parasites/µl (Suh et al., 2011). Other short comings among RDTs in current use 
include cross reaction with rheumatoid factor, loss of reactivity due to exposure to high 
temperatures when stored, single nucleotide polymorphism in DNA of parasite genes leading 
to changes in the proteins and failure of the test to differentiate co-infections with different 





5.2 Aims and objectives of the current study 
The main aim of the study was to optimise the expression and purification of 
recombinant PfLDH and PfHSP70-1 to produce recombinant protein for use in raising 
polyclonal antibodies in chickens, antibody-antigen interaction studies and screening of 
ScFvs in Nkuku® library for scFvs. The second aim was to identify immunogenic peptides 
using an epitope prediction algorithm Predict7™. The peptide could be used to raise anti-
peptide antibodies in chickens for comparison with polyclonal antibodies in the detection of 
each protein. The last aim was to identify possible post-translational modifications that may 
interfere with detection of PfLDH and PfHSP70-1 by antibodies.  
 
5.3 Main findings 
PfLDH showed better expression in TB media (Li et al., 2011) (Figure 3.1 and Figure 
3.2) and the expression of PfHSP70-1 was better in TB than LB media (Figure 3.17). TB 
media was found to be a good choice of media by Li et al., (2011) using GFP, gluatathione-
S-transferase tagged GFP and human basic fibroblast growth factor recombinant proteins, 
as cells grow faster in this media and do not require induction.  Growing cells in TB media 
were chosen. Induction in LB media was done using IPTG (a very expensive reagent) 
although IPTG can be substituted by cheaper substances such as lactose and glucose. The 
growth, following bacterial cells, showed that the E. coli host cells grew faster in TB media 
reaching the stationary phase at about 4 hrs and 5 hrs for PfLDH and PfHSP70-1, 
respectively (Figure 3.3 and Figure 3.16). The use of a single colony as starting material for 
expression of recombinant proteins yielded better results than dilution of an overnight culture 
1:100 in fresh growth medium. Induction of cultures at stationary phase was compared with 
induction at mid-log phase or exponential phase. The results showed that inducing the 
culture at stationary phase yields higher amounts of recombinant protein than inducing at 
mid-log phase. This result was similar to that obtained by Flick et al., (2004) with 
recombinant GST-PfEMP1. Expression speed and folding processes appear to influence 
protein folding, and these appear to be slowed when induction is done at stationary phase. 
At stationary phase, there is a low bacterial growth rate, which implicates a slow 
biosynthesis process that results in a low speed of synthesising recombinant proteins. This 
slow process allows the protein processing machinery to efficiently assemble the freshly 
synthesised proteins into correctly folded structures. Correctly folded proteins are more likely 
to remain in the soluble form provided the molecules do not have large numbers of 
hydrophobic amino acid residues (Flick et al., 2004). Expression of recombinant PfLDH 
protein at 25°C was compared to expression at 37°C. Expression at 25°C produced more 
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soluble proteins than at 37°C (Figure 3.6) which has been observed by Tsai et al., 2016 for 
recombinant Mani 1 and Flick et al., for GST-PfEMP1. Low temperature, before and after 
induction, improves the amount of soluble protein obtained and activity but reduces the 
overall final yield (Figure 3.9) (Flick et al., 2004).  
The optimal condition for lysing of E. coli cells was investigated using lysozyme 
digestion, freezing and thawing, and sonication methods. Lysozymes (muramidase) digest 
the peptidoglycan layer of the bacterial cell wall. Gram-negative bacteria such as E. coli 
have an outer membrane external to the cell wall and, therefore, require to be permeabilised 
to expose the peptidoglycan layer to lysozyme digestion. This is achieved by Tris and EDTA 
added in the buffer. During lysozyme mediated cell lysis, a lot of genomic DNA is released 
and makes the solution viscous, and addition of DNase can reduce the viscosity. This 
method is expensive. Freezing and thawing results in the damage of the inner membrane, 
which leaks the T7 lysozyme in E. coli BL21 (DE3) and cytoplasm contents. The resulting 
solution is a bit viscous and this can be sonicated to break down the genomic DNA. 
Sonication lyses cells by using shear force and cavitation. The genomic DNA released in the 
process is sheared. Freezing and thawing followed by sonication done twice was found to be 
optimal for lysing of E. coli cells. Although the combination of all the methods produced more 
proteins in solution, it contained a lot of contaminants, most likely nucleic acids which were 
not completely removed by sonication (Figure 3.5 and Figure 3.20). This perhaps was due to 
the high level of E. coli expression in TB media resulting in a lot of genomic DNA released in 
the solution. 
Purifying at 4°C appeared to be better than at room temperature (25°C) (Figure 
3.10), a result similar to what was observed by Tsai et al., (2016) with recombinant Mani 
1.Goto et al., (2016) also observed the same trend with swine LDH. Higher yields of purified 
PfLDH were observed than PfHSP70-1 throughout the study.  
Western blots of the purified recombinant PfLDH and PfHSP70-1 showed high yields 
of recombinant PfLDH (figure 3.12) and low yields of PfHSP70-1 (Figure 3.22). Preliminary 
enzyme kinetic studies showed that PfLDH was active. It would be interesting to know if the 
activity of the recombinant PfLDH was more or less compared to the native protein. The 
recombinant PfLDH produced could be used in the production of antibodies in chickens, 
study protein activity, antibody-antigen interaction in vitro, screen the Nkuku® scFv library 
(van Wyngaardt et al., 2004) for scFvs. The recombinant proteins could be used to test for 
competition between polyclonal or anti-peptide antibodies produced, with the substrate to 
see if the antibodies inhibits, increases or does nothing to the activity of the recombinant 
protein. Poor expression of PfHSP70-1 appeared to be caused by either low copy number or 
loss of the PfHSP70-1 insert in the plasmid. Because the method used in section 3.2.14 is 
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less sensitive, primers of the PfHSP70-1 gene can be designed and the gene amplified by 
PCR to conclusively know if low copy number or loss of insert is the cause of poor 
expression. The PCR product can be cloned and transformed into E. coli for the expression 
of PfHSP70-1. Alternatively, using specific primers, PfHSP70-1 gene can amplified by PCR 
from genomic DNA, then transcribed into mRNA of PfHSP70-1. The mRNA can be reverse 
transcribed into cDNA and then cloned and transformed as mentioned earlier. 
Three peptides with high surface probability and hydrophilicity values were identified 
from the amino acid sequence of PfHSP70-1 using the Predict 7™ program. These peptides 
were found to be on the surface of PfLDH crystal structure. Production of polyclonal and 
anti-peptide antibodies against PfHSP70-1 in chicken and isolating lgY from the egg yolk. 
Testing of these antibodies with the recombinant and native protein would be required. This 
information would be used to assess the effectiveness in predicting immunogenic epitopes 
by the algorithm Predict7™ used in the current study to predict the epitopes for PfHSP70-1. 
There would be need to study the activity of ATPase and substrate binding domains of 
recombinant PfHSP70-1 and compare this to previous data as proof that the expressed 
recombinant protein in PfHSP70-1. This study may include studying the ATPase activity of 
PfHSP70-1 and determine the ATP hydrolysis of PfHSP70-1 in the presence or absence of 
co-chaperones such as Plasmodium falciparum Dnaj 1-4 and Plasmodium falciparum 
HSP90. Potential acetylation, phosphorylation, glycosylation and proteolytic cleavage sites 
were found in both PfLDH and PfHSP70-1. Polyclonal and anti-peptide antibodies raised 
from these recombinant proteins would be characterized by comparing their affinity for 
acetylated, phosphorylated or glycosylated and non-acetylated, non-phosphorylated and 
non-glycosylated peptides using ELISA formats. 
 
5.4 Conclusion 
Recombinant expression and purification of PfLDH and PfHSP70-1 was achieved. 
PfLDH was expressed and purified in high amounts of 144.77 mg of recombinant protein 
from 200 ml culture volume compared to 18 mg of recombinant PfLDH per liter of culture 
volume obtained by Berwal et al., 2008. Preliminary studies showed activity of PfLDH. 
PfHSP70-1 was poorly expressed and purified. The data observed suggests possible low 
plasmid copy number or loss of PfHSP70-1 insert in the plasmid, and hence poor yields. 
Purification of recombinant proteins at 4°C is better than at room temperature (25°C). The 
purified proteins were identified by anti-His-tag antibodies. Potential acetylation, 
phosphorylation, glycosylation and proteolytic cleavage sites were identified.  
The PfLDH plasmid was sequenced, and the sequence was confirmed to be of 
PfLDH. Probing the recombinant PfLDH protein with anti-peptide antibodies against epitopes 
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of PfLDH or anti-PfLDH antibodies would further confirm the identity of recombinant PfLDH. 
The recombinant PfLDH protein amino acid residues can also be sequenced.   
A basal ATPase and steady state ATPase activity of recombinant PfHSP70-1 can be 
done to confirm the identity of recombinant PfHSP70-1. Probing the recombinant PfHSP70-1 
with anti-PfHSP70-1 antibodies can confirm the identity of PfHSP70-1. Furthermore, 
recombinant PfHSP70-1 plasmid can be isolated and sequenced or amino acid residues of 
recombinant PfHSP70-1 can be sequenced to confirm the identity of PfHSP70-1. 
Future work will involve cloning of the PfHSP70-1 gene with a His6-tag at the N-
terminal into a pQE30 or another appropriate plasmid vector. Express the recombinant 
PfHSP70-1 protein, purify and use the purified recombinant protein to raise anti-peptide and 
whole protein poly clonal antibodies against PfHSP70-1 in chickens. Screening of scFv 
against PfLDH and PfHSP70-1 recombinant proteins in the Nkuku® library will be done. The 
antibodies will be tested in ELISA, western blots, enhanced chemiluminescence and dip 
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